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CHAPTER I   
 
 
Total Synthesis of a Novel Bicyclobutane Fatty Acid 
 
 Background Information 
A Unique Fatty Acid Metabolite from Cyanobacteria 
Fatty acid metabolites are known to have important functions in controlling 
biological processes of many organisms. Since their initial discovery, the biosynthesis of 
prostaglandins has been the focus of significant research due to their role as secondary 
signaling molecules governing pain and inflammation in mammals. 1  When it was 
discovered that these fatty acid metabolites were also produced in the Caribbean sea whip 
coral Plexaura homomalla, further study was initiated to determine the biosynthetic 
pathway leading to such molecules in lower organisms. In mammals, prostaglandin 
biosynthesis is initiated by the reaction of arachadonic acid with cyclooxygenases. It was 
hypothesized that in Plexaura homomalla these natural products were produced, not by 
homologous cyclooxygenase enzymes, but by a pathway similar to that used by plants for 
the conversion of linolenic acid to the jasmonic acid involving lipoxygenase and allene 
oxide synthase enzymes (Scheme I-1). 2  While searching the genome of Plexaura 
homomalla for lipoxygenases involved in this proposed pathway, Brash and co-workers 
identified a gene encoding a novel peroxidase-lipoxygenase fusion protein. 3  The 
peroxidase domain of this fusion protein functions similarly to an allene oxide synthase 
(AOS), converting hydroperoxy-fatty acids to an allene oxide. In the plant pathway, the 
  2 
hemo-proteins that catalyze this reaction are members of the cytochrome P450 
superfamily. The AOS domain of the coral fusion protein contains no sequence 
homology to cytochrome P450 proteins and, instead, contains a modified catalase active 
site. Unlike typical catalase domains, the coral protein’s active site is able to accept 
hydroperoxy-fatty acids instead of only hydrogen peroxide. While it has now been 
determined that coral species contain COX isoforms that are used for the biosynthesis of 
prostaglandins,4 the search for a lipoxygenase pathway resulted in the identification of 
this novel class of fusion protein involved in fatty acid metabolism.  
 
Scheme I-1: Allene oxide biosynthesis 
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Intrigued by this new class of catalase enzyme, Brash and coworkers next 
performed BLAST searches on other known genomes to identify similar genes in other 
species. High sequence homology was found in a gene of the cyanobacterium Anabaena 
sp. strain PCC 7120. Characterization and expression of this gene’s product revealed a 
fusion protein containing a catalase-related domain and a lipoxygenase domain, similar to 
that of the coral protein. Studies on the lipoxygenase revealed that it was an active 
lipoxygenase that converted C18 polyunsaturated fatty acids into the corresponding 9R-
hydroperoxides. The catalase-related domain was found to convert the 9R-
hydroperoxylinolenic acid product of the lipoxgyenase domain into a variety of products 
including triols, diols, and epoxides. It was hypothesized that many of these products 
arrived from the decomposition of a single unstable product.5 
To determine the structure of this hypothetical unstable intermediate, the gene 
encoding the fusion-protein was cloned, expressed in E. coli and purified using a 
histidine tag. The purified protein was treated with the product of the lipoxygenase 
domain, 9R-hydroperoxylinolenic acid. The products of this reaction were then 
immediately extracted with cold hexanes and converted to the methyl ester by immediate 
treatment with diazomethane. Two products were isolated from this process and spectral 
characterization revealed both to incorporate a vinyl epoxide functional group. Further 
analysis determined the minor product to be a triene epoxide 1.2, while the major product 
was found to incorporate a unique strained bicyclo[1.1.0]butane ring 1.1 (Figure I-1).5 
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Figure I-1: Bicyclo[1.1.0]butane product 1.1 and leukotriene like product 1.2 
 
The structure of the bicyclobutane containing product was solved using data from 
several NMR spectroscopy experiments. The 1H NMR and COSY spectra show that the 
major product contains only one double bond. HRMS data show that the compound has 
an identical mass to the known triene epoxide product 1.2, and therefore must contain 
two carbon rings to account for the unsaturation. After determining the general 
connectivity of the molecule through HSQC and HMBC experiments, DEPT experiments 
were key in determining the location of the rings and establishing them as a 
bicyclo[1.1.0]butane. Four consecutive carbons (C-13–C-16) were determined to each be 
bound to a single proton and three carbons based on the chemical shifts and DEPT 
experiments. Strong coupling was observed in the COSY experiments between H-14, H-
15 and H-16 but H-13 was found to only couple to H-12, suggesting a dihedral angle near 
90° between the pair. H-13 is therefore on the endo face. Finally, NOESY through space 
correlations confirmed the structure of the product to be methyl 9-R-10-R-trans-
epoxyoctadeca-11-trans-(13,14,15,16-bicyclo[1.1.0]butyl)-enoate 1.1.5   
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Figure I-2: Oxylipins with interesting biological functions 
 
 Because fatty acids play many important roles in all living cells, both their 
biological functions and biosynthesis have been the focus of much study. Apart from 
being the major component of cellular and organelle membranes and storage lipids, many 
fatty acids and their derivatives act as important signaling molecules (Figure I-2). One of 
the primary reactions that takes place in fatty acid metabolism is the oxidation of 
polyunsaturated fatty acids (PUFAs) to a general class of secondary metabolites called 
oxylipins.6 While many of the known oxidations are initiated by lipoxygenase enzymes 
(LOX), a few noteworthy examples exist of PUFA oxidation by cycloxygenases (COX), 
also known as prostaglandin H synthases (PGHS). COX enzymes catalyze the conversion 
of arachidonic acid to prostaglandin H2 (PGH2, 1.3). In mammals, depending on the 
tissue in which PGH2 is generated, PGH2 is further metabolized to diverse secondary 
signaling molecules. In platelets, PGH2 is converted to thromboxane A2 1.4, which acts 
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as a vasoconstrictor and promotes platelet aggregation. In other tissues, PGH2 is 
converted to one of several prostaglandins that mediate many systemic responses 
including pain, inflammation and fever generation.1 In plants, LOXs initiate the first step 
in the synthesis of jasmonic acid 1.5, an oxylipin that serves as a phytohormone by 
regulating plant development and acting as a transcription factor generated locally in 
response to physical damage.7 In fungi, LOX have been reported to generate oxylipins 
that play roles in growth and development, 8  quorum sensing, 9  pathogenesis, 10  and 
regulation of sexual and asexual spore development.11 In algae, oxylipins have been 
implicated in signaling responses to pathogenic or mechanical attack.12 Compared to 
eukaryotes, relatively little is known about oxylipin biosynthesis and function in 
prokaryotes.13 Indeed, the first prokaryotic LOX enzymes were not identified until 
2001.14 Characterization of these enzymes has revealed products common to other life 
forms as well as novel products such as the bicyclobutane fatty acid 1.13, but little is 
known about the biological function of these molecules in bacteria. One exception is 
mycangimycin 1.6, an oxylipin isolated from an actinomycete that lives in symbiosis with 
the fungus Entomocorticium sp. A. 15  This fungus is part of a second symbiotic 
relationship with the southern pine beetle, Dendroctonus frontalis, which carries the 
fungus as a nutrient source for its larvae. Mycangimycin’s selective antifungal activity 
against the competing fungus, O. minus, protects the host beetle from this competing 
pathogenic fungus. With such diverse biological roles ascribed to oxylipin natural 
products, it is intriguing to wonder what function the unique bicyclobutane fatty acid 1.13 
could have either directly or as an intermediate in further oxylipin biosynthesis.  
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Scheme I-2: Proposed biosynthetic mechanism 
 
While the biosynthetic pathways for the production of many oxylipins are well 
characterized, the bicyclo[1.1.0]butane 1.13 isolated from cyanobacterium represents a 
novel structure for any natural molecule. Brash et al proposed a mechanism for its 
formation involving a series of carbocation rearrangements that represents an unusual 
productive pathway in the chemistry of carbocations (Scheme I-2).5 By the proposed 
route, the 9R-LOX domain of the fusion protein converts linolenic acid 1.7 into 9R-
hydroperoxylenolenic acid 1.8 through a standard mechanism. The modified catalase 
domain then catalyzes the conversion of 1.8 into an epoxy allyl cation 1.9. Deprotonation 
at this step leads to the minor triene epoxide product 1.10. Alternatively, as it is also 
homoallylic, 1.9 can rearrange to form the cyclopropyl carbinyl cation 1.11. Sigma 
HO
O
9R-Lipoxygenase
HO
O OOH
O O O
HO2C O HO2C O
HH
H
H
77
H+ H+
Linolenic Acid1.7
1.8
1.9
1.10
1.11 1.12
1.13
  8 
hyperconjungation of the C-14–C-15 bond of the cylcopropane results in the formation of 
the nonclassical bicyclobutonium cation 1.12. Deprotonation at C14 leads to the 
bicyclobutane product 1.13. Typically, rearrangements of homoallylic carbocations result 
in the formation of cyclopropyl, cyclobutyl and homoallyl products. This mechanism, if 
correct, represents a novel pathway from such carbocations to bicyclobutane products. It 
is suspected that a high degree of control in the enzyme active site results in the 
stabilization of the proposed bicyclobutonium ion to promote deprotonation by a basic 
site on the protein. Evidence for such a constrained active site is supported by the fact 
that no cyclopropane products arriving from the deprotonation of 1.11 are observed.5 
While we were intrigued to learn why evolution would have selected for an 
enzyme to produce this unusual, highly strained structure, the small quantities of 1.13 
available from in vitro enzymatic production prevented such investigations. The 
important roles of many oxidized fatty acid natural products in biology, the unique 
structure and the synthetic challenges that the molecule presented attracted our lab to 
design a synthesis of this bicyclobutane oxylipin natural product. 
 Chemistry of Bicyclo[1.1.0]butanes 
 
 
Table I-1: Strain energies of select cyclic hydrocarbons16 
 
Structure
Strain Energy 
(kcal/mol) 27 26 64 51
  9 
The challenge in designing a synthesis of this unique fatty acid metabolite lies 
primarily in the formation of the highly strained bicyclo[1.1.0]butane ring. As the 
smallest possible bicyclic ring system, bicyclo[1.1.0]butanes are expected to have a large 
amount of ring strain. The strain energies of a few small cyclic hydrocarbons are shown 
in Table I-1. A comparison to the next largest bicyclic ring system, bicyclo[2.1.0]pentane 
reveals that the ring strain of the bicyclo[1.1.0]butane is even larger than would be 
predicted. The ring strain of bicyclo[2.1.0]pentane is essentially the sum of its constituent 
rings, while that of bicyclo[1.1.0]butane is significantly more than double that of 
cyclopropane. This instability is attributed to a very high amount of torsional strain 
necessary to form the highly compact structure. IR and Raman spectral data have led to 
the assignment of the structure of bicyclobutane as essentially two equilateral triangles 
fused with a 126° interplanar angle and the C-C-H bond angle centered at the bridgehead 
carbon is estimated to be 163°.17 While the side bond angles are similar to those of 
cyclopropane, the bridging bond is greatly distorted from the ideal 109.5° bond angle of 
an sp3 carbon. The thermal instability of these molecules resulting from this great 
torsional strain has been observed in reactions and even exploited in ring expansion 
methodologies.18 
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Scheme I-3: Examples of reactivity of bicyclo[1.1.0]butanes 
 
Molecular orbital calculations have led to an interesting bond model for the 
central carbon-carbon bond of the bicyclo[1.1.0]butane ring that helps to explain its 
reactivity. Bicyclo[1.1.0]butane is known to be reactive towards a variety of reagents 
including acids, bases, carbenes, and halogens.16 Calculations based on 13C-1H coupling 
constants estimate that the C-H bond of the bridgehead carbon is hybridized between sp2 
and sp, giving it a near acetylenic (sp hybrid) character. 19 This estimation is supported by 
ready deprotonation of the bridgehead carbon upon treatment with methyllithium 
(Scheme I-3, A).20 Many degradation pathways of bicyclobutanes involve breaking the 
central C-C bond. Molecular orbital calculations suggest that this bond is likely formed as 
a bent σ bond of unhybridized p-orbitals, giving it electron density above the molecule as 
well as to the sides (Scheme I-3, B).21 This model is supported by the relative ease of 
decarboxylation of exo over endo 2,4-diphenylbicyclo[1.1.0]butane carboxylate (Scheme 
I-3, C).22 The exo face of the bond is sterically inaccessible, while the endo face is 
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readily protonated at the external lobe of the central bond. The p-character of this bond 
also helps to explain the UV-absorbance of 1,3-diphenylbicyclo[1.1.0]butane at 270 nm 
indicative of a conjugated biphenyl system.23 Electrophilic halogens are able to add 
across the central bond giving cis products, suggesting a four centered transition state 
(Scheme I-3, D).16 As these examples illustrate, attempting synthetic transformations on 
a substrate containing a bicyclo[1.1.0]butane moiety poses a significant challenge due to 
the unique bonding and reactivity of the molecule.  
 
 
Scheme I-4: Examples of previous bicyclo[1.1.0]butane syntheses 
 
While no other natural products have been reported to date that contain a 
bicyclo[1.1.0]butane previously, several syntheses of bicylo[1.1.0]butanes have been 
reported. The first confirmed synthesis of a bicyclo[1.1.0]butane was described by 
Wiberg and Ciula in 1959. Wiberg employed a transannular alkylation reaction of methyl 
3-bromocyclobutanecarboxylate to form the key central C-C bond (Scheme I-4, A). 24 
Since this publication, a few other methods have been developed for access to the 
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bicyclo[1.1.0]butane structure with various functional group substitutions. One 
interesting method is the photochemical mediated cyclization of butadiene to provide the 
parent bicyclo[1.1.0]butane hydrocarbon (Scheme I-4, B). 25  The most frequently 
employed method to access the fused ring system is the intramolecular displacement of a 
leaving group by a cyclopropyl anion derived from a lithium-halogen exchange reaction 
(Scheme I-4, C).26 Other methods utilize various methods of cyclopropanation. One such 
example is a double carbene addition to an alkyne using an excess of the carbene reagent 
(Scheme I-4, D).27 Wipf has employed this method in the formation of bridgehead 
substituted bicyclobutanes using the Simmons-Smith reagent (Scheme I-4, E).28 Recently, 
Tilley and co-workers generated a bicyclobutane by the hydrolysis of a cyclobutyl 
sulfonate, employing β-silyl stabilization of the intermediate carbocation (Scheme I-4, 
F).29 
 Synthetic Strategy 
 
 
Figure I-3: Bicyclo[1.1.0]butane fatty acid fragments 
 
In contemplating a synthesis of bicyclo[1.1.0]butane fatty acid 1.13, we identified 
two distinct fragments of the molecule of differing complexity (Figure I-3). The first 
fragment contains the eight carbon alkyl chain and terminal carboxylic acid incorporating 
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no stereogenic centers or other functionality. The carboxylic acid moiety must emerge as 
the methyl ester for spectral comparison with the literature as well as the known 
instability of the parent acid. The second fragment contains the reactive 
bicyclo[1.1.0]butane, two stereogenic centers and a vinyl epoxide. While the isolated 
bicyclo[1.10]butane moiety is achiral due to its symmetry, attention must be paid to the 
exo and endo orientation of the alkenyl and ethyl groups, respectively. To address this 
stereocontrolled assembly of the core bicyclobutane we elected to conduct a simple 
model study to identify an appropriate reaction substrate and conditions.  
 
 
Scheme I-5: Cyclization reactions 
 
 We chose to pursue a cyclization reaction similar to that developed by Bentley, 
that utilized an intermolecular epoxide opening by an in situ formed cyclopropyl anion 
(Scheme I-5, A).30 After investigating several substrates, we arrived at the extension of 
such a reaction to an SN2’ epoxide opening that, if performed on an all cis substituted 
cyclopropane 1.14, would provide us with the requisite relative stereochemistry of the 
bicyclo[1.1.0]butane ring 1.15 (Scheme I-5, B). Furthermore, we proposed that the 
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alcohol group of 1.15 could be used to elaborate this intermediate to the target molecule, 
should the bicyclobutane prove stable to reaction conditions.  
 
 
Scheme I-6: Cyclization/epoxidation cascade 
 
Ultimately, the key to our synthesis was the placement of the bicyclobutane 
forming cyclization as the final step. We hypothesized that if we were to carry out the 
SN2’ epoxide opening cyclization on an substrate such as 1.16 that, under the basic 
reaction conditions, the resulting alkoxide could displace a leaving group strategically 
placed adjacent to the epoxide to form not only the bicyclo[1.1.0]butane ring but also the 
vinyl epoxide in a single step (Scheme I-6). To arrive selectively at the desired trans 
epoxide product of the proposed cascade reaction, we needed only to ensure that the 
leaving group in substrate 1.16 was installed anti to the epoxide. Substrate 1.16 could be 
formed through one of several strategies coupling aldehyde 1.19 with a derivative of 
azelaic acid monomethyl ester 1.18 including a Keto-Darzens reaction, sulfur ylide 
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epoxidations and olefination reactions. Aldehyde 1.19 could be prepared from Z-2-
pentenol 1.20 (Scheme I-7).  
 
 
Scheme I-7: Retrosynthetic analysis 
 
 Synthesis of a Bicyclobutane Fatty Acid 
Model Study 
Our model study investigation began with assembly of cis-dibromocyclopropane 
1.24 starting from cis-2-pentenol 1.20 (Scheme I-8). To this end, protection of the 
primary alcohol of cis-2-pentenol 1.20 as a TBS ether 1.21 followed by dibromocarbene 
addition under phase transfer conditions provided the cyclopropane 1.22 in good yield 
(Scheme I-8). Deprotection of the silyl ether followed by oxidation of the resulting 
primary alcohol under Parikh-Doering conditions31 gave cyclopropyl aldehyde 1.24.  
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Scheme I-8: Cyclopropanation of Z-2-pentenol 1.20 
 
 Having been inspired by the work of Bentley (Scheme I-5, A), we first 
investigated the possibility of bicyclo[1.1.0]butane formation from the intermolecular 
opening of a terminal epoxide (Scheme I-9). However, direct conversion of aldehyde 
1.24 to the epoxide 1.25 by treatment with dimethysulfoxonium ylide32 was unsuccessful. 
Surprisingly, both Wittig olefination and treatment with dimethyl titanocene also failed to 
provide olefin 1.26 for epoxidation to the desired substrate 1.25.  
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Scheme I-9: Failed epoxide forming reactions 
 
 Thinking that perhaps terminal epoxide 1.25 and vinyl cyclopropane 1.26 were 
too unstable for isolation via chromatographic purification, we next turned our attention 
to the preparation of a more substituted epoxide. Gratifyingly, olefination of aldehyde 
1.24 using a Horner-Wadsworth-Emmons olefination proceeded in high yield to afford 
α,ß-unsaturated ester 1.27 (Scheme I-10). Reduction of 1.27 followed by peracid 
epoxidation of the resultant allylic alcohol 1.28 yielded the epoxy alcohol 1.29 as a 
mixture of diastereomers. Protection of the alcohol as the silyl ether 1.30 allowed for 
facile chromatographic separation of the two diastereomers. Unfortunately, treatment of 
either isomer with excess n-BuLi resulted only in lithium/halogen exchange and the 
desired cyclization to bicyclo[1.1.0]butane 1.31 was not observed.  
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Scheme I-10: Failed epoxide opening cyclization 
 
Our failure to affect intramolecular epoxide opening led us to investigate other 
electrophilic substituents. To test our idea of an intermolecular SN2’ cyclization that 
would install the vinyl group, we sought to prepare a substrate for a cuprate cyclization 
utilizing a phenyl carbamate leaving group. To ensure that only the cis cyclopropyl 
cuprate was being generated, we developed reaction conditions to selectively reduce the 
sterically less hindered trans bromo group. While standard Bu3SnH-AIBN (benzene at 
reflux) was effective in non-stereoselective monodebromination, Oshima’s low 
temperature variation (Ph3SnH and Et3B in the presence of molecular oxygen) was found 
to provide the desired stereoselectivity.33 We hypothesize that, while the cyclopropyl 
radical intermediate formed is planar, strong steric repulsion between the cyclopropyl 
substituents of 1.27 and the very bulky triphenyl stanane hydrogen source lead to the 
observed high selectivity, resulting in a 95% isolated yield of the desired all cis 
cyclopropylbromide 1.32 (Scheme I-11). Subsequent reduction followed by treatment of 
the resultant alcohol 1.33 with phenylisocyanate resulted in the formation of the phenyl 
carbamate 1.34. Lithium halogen exchange followed by in situ formation of the organo-
cuprate resulted in consumption of the starting material. In one experiment, LCMS 
O
Br
Br
Br
Br
MeO2C
Br
BrHO
Br
Br
O
TBSO HBr
Br
O
HO H
HO
(EtO)2P(O)CH2CO2CH3
NaH
THF
-78°C
DCM
-78°C
(87%) (82%)
DIBAl-H
m-CPBA
DCM
(90%)
TBSOTf
2,6-lutidine
DMF
(86%)
2.2 EQ n-BuLi
OTBS
THF
-78°C
1.24 1.27 1.28
1.29 1.30 1.31
  19 
analysis of the reaction mixture showed an ion corresponding to the desired product 1.35. 
However, NMR analysis of the crude reaction mixture as well as multiple attempts at 
chromatographic purification never revealed further evidence of bicyclo[1.1.0]butane 
formation. The low molecular weight and compact structure of the predicted product 1.35 
made us suspect that the compound could be highly volatile and consequently evaporate 
during the reaction work-up. Attempts at direct distillation of the reaction mixture were 
also unsuccessful in delivering the desired product.  
 
 
Scheme I-11: Phenyl carbamate model cuprate cyclization 
 
 In order to avoid product volatility, we combined our previous strategies by 
generating a cuprate for for an SN2’ epoxide opening. To that end, allylic alcohol 1.32 
was oxidized in high yield to aldehyde 1.19 using MnO2 (Scheme I-12). Isolation of the 
desired terminal epoxide 1.36 was unsuccessful under a variety of conditions using sulfur 
ylide additions to the aldehyde. The instability of terminal vinyl epoxides to SiO2 
chromatography had been previously observed by Matteson, who developed a two-step 
procedure for converting aldehydes to epoxides.34 With this method, lithium/iodine 
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exchange of chloroiodomethane generated chloromethyllithiate in situ. The resultant 
addition provided chlorohydrin 1.37 in modest yield, which was easily purified on SiO2. 
Treatment of 1.37 with sodium hydride followed by aqueous work-up revealed the 
epoxide 1.36 in good yield as an inconsequential mixture of diastereomers without 
further purification.  
 
 
Scheme I-12: Preparation of vinyl epoxide 1.36 
 
 Gratifyingly, treatment of this mixture of epoxides 1.36 with n-BuLi followed by 
transmetallation to the organocuprate produced the desired bicyclo[1.1.0]butane alcohol 
1.15 (Scheme I-13). 1H, 13C, and 13C DEPT NMR analysis of the reaction mixture after 
aqueous workup showed a surprisingly clean spectrum of the desired 
bicyclo[1.1.0]butane. Indicative NMR shifts in the natural product and the model 
bicyclo[1.1.0]butane are shown in Table I-2. Attempts to purify the product using flash 
chromatography or chilled normal or reversed phase HPLC resulted in rapid 
decomposition of the bicyclo[1.1.0]butane; no desired product was isolated from these 
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experiments. This observed instability led us to pursue the cascade cyclization that places 
the bicyclo[1.1.0]butane forming cyclization as the final step of the synthesis. 
 
 
Scheme I-13: Model cyclization 
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C# δ 1H(model) δ 13C(model) δ 1H(lit) δ 13C(lit) 
2 5.67 (ddd, J= 15.2, 5.6, 5.2 Hz) 129.3 5.34(dd, J= 15.4, 8.1 Hz) 128 
3 5.27 (dd, J= 15.6, 9.2 Hz) 129.4 5.39(dd, J= 15.5, 8.2 Hz) 133 
4 2.44 (d, 8.8 Hz) 44.8 2.36 (d, 8.2 Hz) 44.73 
5 1.40 (m) 9.18 1.31/1.34 (m) 9.32/9.23 
6 1.91 (m) 45.9 1.91 (m) 45.8 
Table I-2: NMR shifts comparison of model bicyclo[1.1.0]butane 1.15 with natural 
product 1.1 
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Preparation of a Substrate for the Stereocontrolled Cascade Reaction  
Having identified reaction conditions whereby a bicyclo[1.1.0]butane product 
with the desired substitution could be formed, we turned our attention to the investigation 
of an optimal route to incorporate the remaining alkyl chain in a substrate for the 
proposed bis-cyclization reaction. Initially, aldehyde 1.19 was converted to alkyne 1.38 
in two steps and modest yield (Scheme I-14). Deprotonation of 1.38 at low temperature 
generated an intermediate alkynyllithium, which was added to aldehyde 1.39 (accessed in 
3 steps from cis-cyclooctyne) 35  to form advanced intermediate 1.40. Extensive 
investigation into conditions for the semihydrogenation to dieneol 1.41 resulted in a 44% 
yield of 1.41 with poor reproducibility. Subsequent attempts at sulfonation of 1.41 were 
unsuccessful using a variety of reagents (TsCl, Ts2O, MsCl and Ms2O) and reaction 
conditions. Furthermore, treatment of 1.41 under either metal-catalyzed or peracid 
epoxidation conditions failed to provide the desired epoxide products leading instead to 
either a mixture of products or decomposition. The low yield of this route hindered our 
ability to find acceptable conditions to afford the desired anti-epoxy sulfonates, therefore 
a more efficient route was pursued.  
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Scheme I-14: Alkyne addition route 
 
With the observed difficulty in the preparation and oxidation of substrates such as 
1.41, we next investigated reactions that would not only couple the saturated alkyl 
fragment with our cyclopropane but also simultaneously install the elusive epoxide. 
Variations of the Corey-Chaykovsky reaction have been developed by Aggarwal utilizing 
sulfur ylide condensation with aldehydes to provide direct access to 2,3 epoxyketones.36 
While such reactions had not been demonstrated to be effective in coupling two aliphatic 
substrates, we prepared the substrates to investigate this as a route to our target molecule. 
Azelaic acid monomethylester 1.18 was converted to the acid chloride, then treated with 
diazomethane to provide a separable mixture of α-chloro ketone 1.43 and α-diazoketone 
1.44 (Scheme I-15). First, α-chloroketone 1.43 was converted to the sulfonium salt 1.45  
 
H
BrO
H
Br
7
H
O
MeO
O
H
Br
OH
MeO
O
7
H
Br
OHMeO
O
H
Br
OMsMeO
O
O
1. (Ph3CH2Br)+Br-, t-BuOK, THF
2. t-BuOK, t-BuOH, 50°C n-BuLi
THF
-78°C
H2
Lindlar Catalyst
EtOH
44%
50% over 2 steps
63%
Epoxidation/Sulfonation
7
7
1.19 1.38
1.39
1.40 1.41
1.42
  24 
 
Scheme I-15: Alkylation of azeleic acid monomethylester 1.18 
 
by treatment with methyl sulfide (Scheme I-16). Attempts at condensation of aldehyde 
1.19 with an in situ generated ylide under Aggarwal’s conditions failed to affect the 
desired condensation to epoxy ketone 1.47.37 Ylide generation was also attempted by the 
formation of a rhodium carbene from diazoketone 1.44 followed by treatment with 
dimethyl sulfide.38 These conditions were also unsuccessful at producing the desired 
epoxyketone 1.48. In both of these reactions, the strong change in color reported to 
accompany ylide formation was not observed under the conditions examined.  
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Scheme I-16: Sulfur ylide couplings 
 
 Next, we investigated the use of a keto-Darzens39 reaction to couple aldehyde 
1.19 with α-chloroketone 1.43 to provide the epoxy alcohol 1.47 (Scheme I-17). 
Unfortunately, under a variety of conditions, only decomposition of α-chloroketone 1.43 
was observed, accompanied by recovery of aldehyde 1.19.  
 
 
Scheme I-17: Keto-Darzens reaction 
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 Knowing from previous experiments that aldehyde 1.19 was reactive to 
olefination with phosphorous ylides, we next pursued a Horner-Wadsworth-Emmons 
strategy (Scheme I-18). Azeleic acid monomethylester 1.18 was coupled to 2-
mercaptothiazole 1.48 to give amide 1.49. Treatment of this amide with the lithiate of 
methyl dimethylphosphonate afforded the β-ketophosphonate ester 1.50 in good yield.40 
Condensation of this product with 1.19 afforded dieneone 1.51 in 91% yield.  
 
 
Scheme I-18: Horner-Wadsworth-Emmons coupling 
 
 From dienone 1.51 we could investigate multiple methods for conversion to the 
desired anti-epoxysulfonate. First, we attempted basic epoxidation of the vicinal olefin to 
give epoxy ketone 1.46 (Scheme I-19). Using Zn(BH4)2, such a ketone could be 
selectively reduced to the required anti-epoxy alcohol. 41  However, 1.51 proved 
unreactive to all combinations of base and peroxide assayed. While basic epoxidations 
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are common with α,β-unsaturated ketones, very few examples exist with α,β-γ,δ-
unsaturated ketones. Extensive delocalization of π-electrons within both the diene and the 
cyclopropane likely contributes to the poor reactivity of 1.51 to basic epoxidation. Luche 
reduction42 of 1.51 afforded dieneol 1.52, which was subjected to various hydroxyl 
directed epoxidation methods (Scheme I-20). Treatment with peroxyacid epoxidation 
conditions resulted in no reaction. Metal catalyzed hydroxyl directed epoxidations using 
either VO(acac)2 or Ti(i-PrO)4 were unreactive at low temperature and provided a 
complex mixture of products upon warming.  
 
 
Scheme I-19: Basic epoxidations 
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Scheme I-20: Hydroxyl directed epoxidations 
 
 Having had no success with hydroxyl-directed epoxidations, we next investigated 
dimethyl dioxirane (DMDO), a reagent occasionally reported to be hydroxyl directed.43-44 
Treatment of alcohol 1.52 with DMDO at 0°C resulted in the regio-selective epoxidation 
of the vicinal double bond (Scheme I-21).  
 
 
Scheme I-21: Dimethyl dioxirane epoxidation 
 
 Separation of the four diastereomeric epoxide products of 1.47 on NP-HPLC 
allowed for a tentative assignment of the relative stereochemistry of the epoxyalcohols 
based upon 1H-1H coupling constants (Scheme I-22).45,46 The reaction showed a slight 
(~2:1) selectivity for the undesired threo or syn epoxyalcohol products. The desired anti 
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epoxy alcohol products could be separated from the syn diastereomers by flash 
chromatography. As the proposed cascade cyclization was diastereo-convergent by 
design, the anti epoxy alcohol products were taken forward as a mixture of diastereomers. 
Using the Mitsunobu reaction, the syn epoxy alcohol products could be easily converted 
to the anti in 75% yield over two steps. Treatment of 1.47 with MsCl provided mesylate 
1.54 in modest yield (Scheme I-23). With this compound in hand, we could finally 
investigate the proposed cascade reaction.  
 
 
Scheme I-22: Stereochemical analysis of epoxidy alcohol products 1.47  
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Scheme I-23: Mesylate formation 
 
Cascade Cyclization Investigation and Completion of the Synthesis 
Initially, we attempted to apply the conditions that had been successful for the 
cyclization reaction in our model system. However, low temperature treatment of 1.53 
with n-BuLi to affect a lithium/halogen exchange followed by transfer to a cold solution 
of CuI•2LiCl afforded neither the desired product nor any recoverable starting material as 
determined by 1H NMR analysis of the crude reaction mixture and attempts at 
chromatographic purification (Scheme I-24). To determine if the lithium/halogen 
exchange was successful and selective, we next treated 1.53 with n-BuLi alone. After 
aqueous workup of this reaction mixture, we expected to observe debromination of 1.53. 
However, we were intrigued to discover that the resultant cyclopropyllithiate 
intermediate had subsequently cyclized to a bicyclo[1.1.0]butane-containing product, as 
indicated by 1H NMR analysis. While purification of this product was unsuccessful, it 
was also clear from the 1H NMR data that the n-BuLi had also reacted with the methyl 
ester moiety. Furthermore it was unclear if the desired epoxide forming displacement had 
occurred.  
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Scheme I-24: Application of model cyclization conditions 
 
 We recognized the possibility of n-BuLi acting as a nucleophile on the 
electrophilic methyl ester group and next surveyed other reagents capable of 
metal/halogen exchange that would be less nucleophilic (Scheme I-25). Sterically 
hindered Grignard reagents have shown success in metal/halogen exchange for 
previously reported cyclizations, however treatment of 1.53 with such reagents lead only 
to decomposition. Certain lithium/halogen exchange reactions have been successful and 
selective using high surface area lithium metal sources such as lithium sand, however 
treatment of 1.53 with this reagent afforded no reaction at low temperatures and rapid 
decomposition upon warming. Similar results were obtained using various non-
nucelophilic zinc sources including activated Zinc dust or Rieke Zinc. We next turned 
back to alkyl lithium reagents, and treated 1.53 with excess t-BuLi. Gratifyingly, 1H 
NMR analysis of this reaction mixture indicated a very clean conversion to a single 
bicyclobutane product. Furthermore, 1D TOCSY analysis of this mixture indicated the 
successful formation of the desired epoxide moiety confirming the success of the cascade 
reaction. However, it was again evident that the methyl ester was no longer present and 
13C NMR data indicated that instead, the t-butylketone 1.54 had been formed.  
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Scheme I-25: Reducing nucleophilicity 
 
 Having failed in our attempts to attenuate the nucleophilicity of the lithiating 
reagent, we sought a strategy that would instead alter the substrate to remove the 
electrophilic site. To this end, ester 1.53 was hydrolyzed by treatment with LiOH to 
provide the carboxylic acid 1.55 (Scheme I-26). Rapid isolation of this compound 
followed by treatment with an excess of t-BuLi resulted first in deprotonation of the acid 
followed by lithium/halogen exchange. The resulting dianion then cyclized to the 
bicyclo[1.1.0]butane and formed the desired epoxide intercepting the natural product 1.13. 
After warming to -20°C, the reaction mixture was treated with diazomethane to afford 
methyl ester 1.1 in a clean conversion. HPLC purification under conditions identical to 
those used in the original isolation resulted in a 20% yield of 1.1. Spectral data was in 
agreement with that reported in the literature, confirming our success in synthesizing the 
product.47 The acid 1.13 proved unstable and all attempts at its isolation from the reaction 
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mixture were unsuccessful. Indeed, NMR analysis of the crude reaction mixture revealed 
no evidence of a bicyclo[1.1.0]butane when treatment with diazomethane was forgone.  
 
 
Scheme I-26: Cyclization cascade to complete the synthesis of 1.1 
 
 A route to this unique fatty acid natural product was developed that employs a 
cyclization/epoxidation cascade reaction as the key step to deliver the product in 3.06% 
yield over 13 linear steps as a racemate. Studies aimed at determining the biological role 
of this unusual metabolite can now be investigated with this synthetic material. Brash 
reported that the enzymatic production of this compound leads to the isolation of a 
variety of downsteam products. With a pure source of 1.1, it is now possible to determine 
which of these products arise from its degradation as opposed to those from triene 
epoxide 1.2. Furthermore, we hypothesize that the vinyl oxirane and bicyclobutane may 
act as an electrophile, perhaps used to modify macromolecules. Preparation of a labeled 
derivative of 1.1 could allow this hypothesis to be tested.  
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Experimental Methods 
General procedure: All non-aqueous reactions were performed in flame-dried or oven 
dried round-bottomed flasks under an atmosphere of argon. Where necessary (so noted) 
solutions were deoxygenated by alternate freeze (liquid nitrogen)/evacuation/argon-
flush/thaw cycles (FPT, three iterations) or degassed by purging with argon for several 
minutes. Stainless steel syringes or cannulae were used to transfer air- and moisture-
sensitive liquids. Reaction temperatures were controlled using a thermocouple 
thermometer and analog hotplate stirrer. Reactions were conducted at room temperature 
(rt, approximately 23 °C) unless otherwise noted. Flash column chromatography was 
conducted as described Still et. al. using silica gel 230-400 mesh.48 Where necessary, 
silica gel was neutralized by treatment of the silica gel prior to chromatography with the 
eluent containing 1% triethylamine. Analytical thin-layer chromatography (TLC) was 
performed on E. Merck silica gel 60 F254 plates and visualized using UV, ceric 
ammonium molybdate, potassium permanganate, and anisaldehyde stains. Yields were 
reported as isolated, spectroscopically pure compounds. 
Materials. Solvents were obtained from either a MBraun MB-SPS solvent system or 
freshly distilled (tetrahydrofuran was distilled from sodium-benzophenone; toluene was 
distilled from calcium hydride and used immediately; dimethyl sulfoxide was distilled 
from calcium hydride and stored over 4Å molecular sieves). Commercial reagents were 
used as received with the following exceptions. The molarity of n-butyllithium and tert-
butyllithium solutions were determined by titration using diphenylacetic acid as an 
indicator (average of three determinations).  
  35 
Instrumentation. Reverse phase HPLC was conducted on a Varian ProStar HPLC 
system using a Phenomenex Luna 5u C18(2) 100A Axia 50 x 30.00 mm column unless 
otherwise noted. Infrared spectra were obtained as thin films on NaCl plates using a 
Thermo Electron IR100 series instrument and are reported in terms of frequency of 
absorption (cm-1). 1H NMR spectra were recorded on Bruker 300, 400, 500, or 600 MHz 
spectrometers and are reported relative to deuterated solvent signals. Data for 1H NMR 
spectra are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, m = multiplet, br = broad, app = apparent), 
coupling constants (Hz), and integration. 13C NMR spectra were recorded on Bruker 75, 
100, 125, or 150 MHz spectrometers and are reported relative to deuterated solvent 
signals. LC/MS was conducted and recorded on an Agilent Technologies 6130 
Quadrupole instrument. High-resolution mass spectra were obtained from the Department 
of Chemistry and Biochemistry, University of Notre Dame using either a JEOL 
AX505HA or JEOL LMS-GCmate mass spectrometer.  
 
Compound Preparation 
 Silyl ether 1.21 To a solution of cis-2-penten-1-ol (1.20) (1.0 mL, 
9.75 mmol) in dichloromethane (19.5 mL) at 0 °C was added 
triethylamine (2.04 mL, 14.63 mmol) and the resulting solution was maintained at 0 °C 
for 10 min, tert-butyldimethylchlorosilane (TBSCl) (1.76g, 11.70 mmol) in DMF (4.0 
mL) was added. The resulting solution was warmed to rt and maintained at that 
temperature for 4 h. Water (20 mL) was added to the reaction mixture and the aqueous 
TBSO
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layer was extracted with dichloromethane (3 × 20 mL). The combined organic extracts 
were dried (MgSO4) and concentrated in vacuo. The resulting residue was purified by 
flash chromatography (20:1 hexane-EtOAc) to afford 1.84 g (94%) of 1.21 as a colorless 
oil: Rf = 0.63 (10:1 hexane-EtOAc)); IR (neat) 2958, 1463 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 5.49-5.41 (m, 2H), 4.23 (d, J = 6.0 Hz, 2H), 2.06-2.03 (m, 2H), 0.97 (t, J = 7.5 
Hz, 3H), 0.90 (s, 9H), 0.07 (s, 6H); 13C NMR (125 MHz, CDCl3) δ; 132.7, 129.1, 59.6, 
26.3, 21.1, 18.6, 14.4, -4.9; MS (ESI) m/z  199.1512 (M +H)+ (199.1513 calcd for 
C11H23OSi]. 
Dibromide 1.22 To a solution of silyl ether 1.21 (1.0 g, 5.0 mmol) 
and benzyltriethylammonium chloride (BnNEt3Cl) (20.0 mg, 0.1 
mmol) in bromoform (2.85 mL, 17.5 mmol) was added a solution of 
NaOH (1.42 g, 35.4 mmol) in water (1.42 mL) over 1 h. The reaction mixture was stirred 
for 16 h. The mixture was diluted with water (50 mL) and filtered through a plug of 
Celite, washed with dichloromethane (150 mL). The aqueous layer was extracted with 
dichloromethane (3 x 30 mL). The combined organic extracts were dried (MgSO4) and 
concentrated in vacuo. The resulting residue was purified by flash chromatography 
(hexane) to afford 1.49 g (80%) of 1.22 as a colorless oil: Rf = 0.48 (20:1 hexane-
EtOAc)); IR (neat) 2957, 1463, 1255cm-1; 1H NMR (500 MHz CDCl3) δ 3.80 (dd, J = 
11.15, 6.55 Hz, 1H), 3.58 (dd, J = 115, 7.24 Hz, 1H), 1.88 (dt, J = 11.00, 6.85 Hz, 1H), 
1.63 (dt, J = 11.00, 7.30 Hz, 1H), 1.52-1.40 (m, 2H), 1.08 (t, J = 7.35 Hz, 3H), 0.91 (s, 
9H), 0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (125 MHz, CDCl3) δ; 61.4, 35.6, 35.0, 34.3, 
26.1, 20.8, 18.5, 13.1, -5.0, -5.1; MS (ESI) m/z 392.9858 (M + Na)+ (392.9855 calcd for 
C12H24Br2NaOSi). 
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 Alcohol 1.23 To a solution of dibromide 1.22 (2.18 g, 5.8 mmol) in 
THF (58.0 mL) was added a solution of tetrabutylammonium (TBAF) 
(8.2 mL, 1.0 M in THF, 8.2 mmol). After 30 min, the solution was 
diluted with ethyl acetate (30 mL) and washed with 1 M aqueous HCl (50 mL). The 
aqueous layer was extracted with ethyl acetate (3 × 30 mL) and the combined organic 
extracts were dried (MgSO4) and concentrated in vacuo. The resulting residue was 
purified by flash chromatography (8:1 hexane-EtOAc) to afford 1.42 g (95%) of 1.23 as a 
light yellow oil: Rf = 0.27 (4:1 hexane-EtOAc); IR (neat) 3351, 2967, 2931, 1460, cm-1; 
1H NMR (500 MHz CDCl3) δ 3.75-3.66 (m, 2H), 1.96-1.91 (m, 2H), 1.69-1.64 (m, 1H), 
1.56-1.40 (m, 2H), 1.06 (t, J = 7.38 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 61.2, 36.0, 
34.9, 34.2, 20.9, 13.1; MS (EI) m/z 255.9080 (M +H)+ (255.9098 calcd for C6H10Br2O). 
 Aldehyde 1.24 To a solution of alcohol 1.23 (2.48 g, 9.63 mmol) in 
dichloromethane (40 mL) and DMSO (10 mL) at -15 °C was added N,N,-
diisopropylethylamine (5.02 mL, 28.84 mmol). The resulting solution 
was maintained for 10 min at -15 °C and SO3⋅Pyr (4.59 g, 28.84 mmol) in DMSO (10 
mL) was added dropwise. The resulting solution was maintained at -15 °C for 1 h and 
warmed to rt. After dilution with Et2O (75 mL) the solution was washed sequentially with 
water (2 x 30 mL), brine (1 x 30 mL), 15% NaHCO3 (1 x 30 mL) and saturated aqueous 
CuSO4 (2 x 30 mL). The organic layer was then dried (MgSO4) and concentrated in 
vacuo. The residue was purified by flash chromatography (8:1 hexane-EtOAc) to afford 
1.94 g (79%) of 1.24 as a light yellow oil: Rf = 0.58 (4:1 hexane-EtOAc); IR (neat) 2969, 
2874, 1707 cm-1; 1H NMR (500 MHz CDCl3) δ 9.31 (d, J = 5.55 Hz, 1H), 2.40 (dd, J = 
10.90, 5.55 Hz, 1H), 2.14-2.08 (m, 1H), 1.97-1.89 (m, 1H), 1.80-1.71 (m, 1H), 1.12 (t, J 
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= 7.35 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 198.3, 41.6, 40.2, 29.1, 21.5, 13.0; MS 
(ESI) m/z 255.0, (M + H) (254.90 calcd for C6H9Br2O). 
 Enoate 1.27 To a solution of methyl 2-
(diethoxyphosphoryl)acetate (3.18 g, 18.17 mmol) in THF (90 
mL) at 0 °C was added NaH (392 mg, 16.35 mmol) in 5 portions 
over 2 min. The resulting solution was maintained at 0 °C for 10 min then warmed to rt. 
Neat aldehyde 1.24 was added to the solution dropwise. The resulting reaction mixture 
was stored for 4 h then diluted with Et2O (100 mL). The ethereal solution was then 
washed with 1 M NaOH (50 mL). The organic layer was separated and the aqueous layer 
was extracted with Et2O (3 x 75 mL). The combined organic extracts were dried 
(MgSO4) and concentrated in vacuo. The residue was purified by flash chromatography 
(10:1 hexane-EtOAc) to afford 2.45 g (87%) of 1.27 as a light yellow oil: Rf = 0.58 (4:1 
hexane-EtOAc); IR (neat) 2968, 2933, 2875, 1708, cm-1; 1H NMR (400 MHz, CDCl3) δ 
6.60 (dd, J = 15.6, 10.0 Hz, 1H), 6.13 (d, J = 15.6 Hz, 1H), 3.75 (s, 3H), 2.42 (t, J = 10.4 
Hz, 1H), 1.93 (ddd, J= 10.7, 7.5, 7.5 Hz, 1H), 1.72-1.63 (m, 1H), 1.54-1.47 (m, 1H), 1.06 
(t, J = 7.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ166.0, 143.3, 125.1, 51.7, 39.9, 35.7, 
35.1, 21.7, 12.5; MS (ESI) m/z 332.9114 (M +Na)+ (332.9096 calcd for C9H12Br2NaO2). 
 Cyclopropylbromide 1.32 To a solution of enoate 1.27 (6.45 g, 
19.73 mmol) in toluene (79 mL) at -78 °C was added 
triphenylstannane (6.93 mL, 19.73 mmol) and a solution of 
triethylborane (5.92 mL, 1 M in hexanes, 5.92 mmol). The reaction flask was fitted with a 
drying tube and the solution was maintained at -78 °C for 4 h. The reaction mixture was 
warmed to room temperature and poured into a saturated solution of potassium fluoride 
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(100 mL) and the resulting mixture was stirred for an additional 3 h. The solution was 
then passed through a plug of Celite and washed with Et2O (150 mL). The resulting 
solution was extracted with Et2O (3 x 75mL) The combined organics were dried 
(MgSO4) and concentrated to ~80 mL in vacuo (toluene not removed). The resulting 
solution was filtered through a long plug of silica gel first with hexanes (500 mL) then 
with Et2O (500 mL). The ethereal fractions were combined and concentrated in vacuo. 
The residue was purified by flash chromatography (10:1 hexane-Et2O) to afford 4.37 g 
(95%) of 1.32 as a light yellow oil: Rf = 0.50 (4:1 hexane-EtOAc); IR (neat) 2968, 1732, 
1645, 1435 cm-1; 1H NMR (400 MHz CDCl3) δ 6.82 (dd, J = 15.6, 10.4 Hz, 1H), 6.05 (d, 
J = 15.6 Hz, 1H), 3.74 (s, 3H), 3.47 (t, J = 7.6 Hz, 1H), 1.86 (ddd, J = 9.9, 9.9, 7.3 Hz), 
1.57-1.66 (m, 2H), 1.24-1.36 (m, 1H) 1.02 (t, J = 7.4 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ166.3, 146.2, 123.2, 51.5, 30.9, 26.5, 22.6, 19.8, 13.1; MS (ESI) m/z 254.9991 
(M +Na)+ (254.9991 calcd for C9H13BrNaO2). 
 Allylic alcohol 1.33 To a solution of cyclopropylbromide 1.32 
(4.96 g, 17.84 mmol) in dichloromethane (200 mL) at -78 °C was 
added neat diisobutylaluminum hydride (DIBAL-H) (7.57 mL, 
42.46 mmol, 2.0 equiv) dropwise. The resulting solution was maintained at -78 °C for 45 
min. The reaction mixture was warmed to rt, quenched with a saturated solution of 
Rochelle’s salt (150 mL) and stirred for 2 h. The aqueous layer was extracted with Et2O 
(3 × 100 mL). The combined organic extracts were dried (MgSO4) and concentrated in 
vacuo. The residue was purified by flash chromatography (4:1 hexane-EtOAc) to afford 
3.85 g (95%) of 1.33 as a yellow oil: Rf = 0.30 (hexane-EtoAc, 4:1); IR (neat) 3309, 2964 
cm-1; 1H NMR (500 MHz CDCl3) δ 5.88 (dt, J = 15.35, 6.00 Hz, 1H), 5.51 (dd, J = 15.35, 
H
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9.30 Hz, 1H), 4.12 (d, J = 6.00 Hz, 2H), 3.34 (t, J = 7.45 Hz, 1H), 1.76-1.70 (m, 1H), 
1.51-1.47 (m, 2H), 1.13-1.07 (m, 1H), 0.99 (t, J = 7.35 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 132.7, 128.4, 63.8, 31.1, 23.9, 22.0, 19.7, 13.2; MS (ESI) m/z 187.0088 (M + H 
–H2O)+ (187.01 calcd for C8H12Br). 
 Phenyl carbamate 1.34 To a solution of alcohol 1.33 
(194 mg, 0.94 mmol) in DCM (18.8 ml) was added phenyl 
isocyanate (0.206 ml, 1.89 mmol) and triethyl amine 
(0.263 mL, 1.89 mmol) with stirring. The resulting solution was maintained for 45 
minutes, diluted with hexanes (50 mL) and filtered. The resulting solution was 
concentrated and purified by flash column chromatography (10:1 hexane:Et2O) to yield 
1.34 as a pale yellow oil (202 mg, 0.62 mmol, 66%). 1H NMR (400 MHz, CDCl3): δ 7.28 
(d, J = 8.0 Hz., 2H), 7.31 (dd, J = 7.6, 8.4 Hz, 2H), 7.064 (dd, J = 7.2, 7.6 Hz, 1H), 6.61 
(br s, 1H), 5.89 (ddd, J = 15.2, 6.8, 6.4 Hz, 1H), 5.66 (dd, J = 15.2, 9.2 Hz, 1H), 4.66 (d, 
J = 6.8 Hz, 2H), 3.37 (dd, J = 7.2, 7.2 Hz, 1H), 1.77 (ddd, J = 9.6, 9.2, 7.6 Hz, 1H) 1.56-
1.49 (m, 2H), 1.18-1.10 (m, 1H), 1.01 (t, J = 7.2 Hz, 3H). 
 Enal 1.19 To a solution of allylic alcohol 1.34 (1.0 g, 4.88 mmol) 
in dichloromethane (50 mL) was added manganese(IV) oxide (4.24 
g, 48.76 mmol). The reaction mixture was stirred for 16 h and 
filtered through a plug of Celite. The filtrate was concentrated in vacuo. The residue was 
purified by flash chromatography (8:1 hexane-Et2O) to afford 0.983 g (99%) of 1.19 as a 
colorless oil: Rf = 0.38 (4:1 hexane-EtOAc); IR (neat) 2965, 2862, 1683 cm-1; 1H NMR 
(500 MHz CDCl3) δ 9.49 (d, J = 7.95 Hz, 1H), 6.67 (dd, J = 15.45, 10.15 Hz, 1H), 6.34 
(dd, J = 15.50, 7.95 Hz, 1H), 3.56 (t, J = 7.25 Hz, 1H), 1.98 (dt, J = 9.93, 7.15 Hz, 1H), 
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1.65-1.58 (m, 2H), 1.47-1.42 (m, 1H), 1.01 (t, J = 7.35 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 193.0, 155.8, 135.2, 31.6, 27.7, 23.3, 20.0, 13.1; MS (ESI) m/z 224.9879 (M 
+Na)+ (224.9885 calcd for C8H11BrNaO). 
 Epoxide 1.36 To a solution of aldehyde 1.19 (500 mg, 2.446 
mmol) and ICH2Cl (0.179 mL, 2.46 mmol) in THF (5 mL) at -
78 °C was added a solution of n-BuLi (1.16 mL, 2.13 M in hexane, 
2.46 mmol) dropwise. The resulting solution was maintained for 30 min at -78 °C and 
quenched with saturated NH4Cl (10 mL). The reaction mixture was warmed to rt, diluted 
with water (3 mL) and extracted with Et2O (3 x 10 mL). Combined ethereal extracts were 
dried (MgSO4) and concentrated. Flash column chromatography of the resulting residue 
(4:1 hexane-Et2O 4:1) yielded 318 mg (51%) of a mixture of chlorohydrins 1.37 as a light 
yellow oil: 1H NMR (400 MHz, CDCl3): δ 5.77 (dd, J = 15.6, 6.4 Hz, 1H), 5.65 (dd, J = 
15.2, 8.8 Hz, 1H), 4.36 (m, 1H), 3.60 (dd, J = 11.2, 4.0 Hz, 1H), 3.52 (dd, J = 10.4, 6.8 
Hz, 1H), 3.62 (dd, J = 7.6, 7.6 Hz, 1H), 1.73 (ddd, J = 16.8, 9.2, 7.6 Hz, 1H), 1.53-1.46 
(m, 2H), 1.15-1.11 (m, 1H), 0.99 (t, J = 7.6 Hz, 3H).  
To a solution of chlorohydrins 1.37 (50 mg, 0.20 mmol) in THF (2 mL) was added NaH 
(9.5 mg, 0.39 mmol). The resulting mixture was stirred for 1 h and quenched with 10% 
NaHCO3 (3 mL) and water (3 mL) and separated. The aqueous was extracted with Et2O 
(5 x 5 mL) and the combined organic extracts were dried (MgSO4) and concentrated. The 
resulting residue was purified by flash column chromatography (10:1 hexane-Et2O-1% 
Et3N) to yield 36.3 mg (84%) of epoxide 1.36 as a light yellow oil and as a mixture of 
diastereomers: IR (neat) 2965, 2929, 2873, 1248 cm-1; 1H NMR (400 MHz, C6D6): δ 5.75 
(ddd, J = 15.2, 9.6, 9.2), 5.22 (dd, J = 15.2, 8.0 Hz, 1H), 3.05-3.01 (m, 1H), 2.88 (dd, J = 
H
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7.6, 7.6 Hz, 1H), 2.50-2.46 (m, 1H), 2.26 (dd, J = 5.6, 2.4 Hz, 1H), 1.42-1.32 (m, 3H), 
1.23-1.17 (m, 1H), 0.87(t, J = 7.6 Hz, 3H). 13C NMR (150 MHz, C6D6): δ 132.3, 132.1, 
131.9, 131.4, 131.1, 128.5, 128.4, 128.1, 128.0, 52.0, 51.9, 48.5, 48.4, 31.0(4), 31.0(1), 
24.3, 24.2, 22.4, 22.3, 19.9, 19.8, 13.1, MS (EI) m/z 216.0167 (M +H)+ (216.0150 calcd 
for C9H14BrO). 
 Bicyclobutane 1.15 To a solution of epoxide 1.36 (50 mg, 0.23 
mmol) in THF (2.3 mL) at -78 °C was added 0.325 mL n-BuLi 
(2.13 M in hexanes, 0.325 mL, 0.69 mmol) slowly. The solution was maintained at -
78 °C for 30 min.  In a separate flask CuI (88 mg, 0.46 mmol) and LiCl (39 mg, 0.92 
mmol) were weighed and the flask flame dried under vacuum, purged with argon and 
cooled to rt. The salts were dissolved in THF (1.15 mL) and stirred for 10 min. The 
resulting yellow solution was cooled to -78 °C. The prepared solution of 
cylopropyllithium was added to the yellow solution of CuI-LiCl dropwise via cannula. 
The resulting solution was stirred for 2 h, warmed to -15 °C and quenched with a 9:1 
aqueous solution of saturated NH4Cl and NH4OH (3 mL). After warming to room 
temperature, the aqueous layer was extracted with Et2O (4 x 7 mL). Organic extracts were 
dried (MgSO4) and concentrated to yield bicyclobutane 1.15 as a light yellow oil: 1H 
NMR (400 MHz, C6D6): δ 5.67 (ddd, J = 15.2, 5.6, 5.2 Hz, 1H), 5.27 (dd, J = 15.6, 9.2 
Hz, 1H), 3.89 (d, J =3.6 Hz, 2H), 2.44 (d, J = 8.8 Hz, 1H), 2.04 (m, 1H), 1.45-1.35 (m, 
2H), 1.29-1.23 (m, 2H), 0.97 (t, J = 7.2 Hz, 1H). 13C NMR (100 MHz, C6D6): δ 129.4 
(CH), 129.3 (CH), 63.1(CH2), 45.9 (CH), 44.8 (CH), 17.2 (CH2), 13.6 (CH3), 9.18 (CH). 
HO
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 Alkyne 1.38 To a solution of (bromomethyl)triphenylphosphonium 
bromide (2.36 g, 5.42 mmol) in THF (25 mL) at -78°C was added t-
BuOK (552 mg, 4.92 mmol). Solution was stirred at -78°C for 20 
minutes and became bright yellow. Aldehyde 1.19 (500 mg, 2.46 mmol) was added to the 
solution dropwise as a solution in THF (1 mL). The reaction mixture was stirred for 2 
hours at -78°C, warmed to room temperature, diluted in EtOAc (30 mL) and washed with 
H2O (10 mL). The aqueous layer was extracted with EtOAc (3 x 30 mL). Combined 
organics were dried (MgSO4) and concentrated. The resulting residue was diluted in 
hexane (100 mL) and filtered through a plug of silica and concentrated to yield a pale 
yellow oil (452 mg). Without further purification, the resulting oil was dissolved in t-
BuOH (10 mL). t-BuOK (544 mg, 4.84 mmol) was added to the solution at room 
temperature with stirring. The reaction mixture was warmed to 45oC and stirred for 2 
hours. After cooling to room temperature, the mixture was washed with H2O (10 mL). 
The aqueous layer was extracted with Et2O (3 x 35 mL). Combined organics were dried 
(MgSO4) and concentrated. Flash column chromatography (hexane) of the resulting 
residue yielded 242.3 mg of alkyne 1.38 (50% over 2 steps) as a pale yellow oil. IR (film) 
νmax 3293, 2965, 2932, 2874, 1249, 951, 641. 1H NMR (400 MHz, CDCl3): δ 6.09 (dd, J 
= 15.8, 9.7 Hz, 1 H), 5.68 (dd, J = 16.8, 2.2 Hz, 1H), 3.39 (dd, J = 7.4, 7.4 Hz, 1H), 2.88 
(d, J = 2.2 Hz, 1 H), (ddd, J = 9.7, 7.4, 7.4 Hz, 1H), 2.54 (m, 2H), 1.22 (m, 1H), 1.01 (t, J 
= 7.4 Hz, 3H) 13C NMR (100 MHz, CDCl3): δ 142.4, 111.02, 82.44, 76.88, 30.94, 25.40, 
23.06, 19.81, 13.13. 
Propargylic alcohol 1.40 To a solution of 1.38 (283 
mg, 1.42 mmol) in THF (14 mL) at -78°C was added 
H
Br
H
Br
OH
MeO
O
7
  44 
n-BuLi as a 2.35 M solution in hexane (0.67 mL, 1.56 mmol). The resulting mixture was 
stirred at -78°C for 30 minutes. The resulting golden lithiate solution was added dropwise 
via canula to a stirred solution of methyl 9-oxononanoate 1.39 (344 mg, 1.85 mmol) as a 
solution in THF (18 mL). The reaction mixture was stirred for 2.5 hours at -78°C. The 
cold bath was removed and the reaction mixture was diluted in Et2O (30 mL) then 
washed with H2O (10 mL). The aqueous layer was extracted with Et2O (3 x 30 mL). 
Combined organics were dried (MgSO4) and concentrated. Flash column chromatography 
of the residue (3:1 Hexanes:EtOAc) yielded 338 mg of 1.40 (67%) as a light yellow oil. 
1H NMR (400 MHz, CDCl3): δ 5.97 (dd, J = 16.0, 9.6 Hz, 1H) 5.71 (d, J = 16Hz, 1H), 
4.47 (dd, J = 12.0, 6.4 Hz, 1H), 3.66 (s, 3H), 3.39 (dd, J=7.6, 7.6 Hz, 1H), 2.30 (t, J = 7.2 
Hz, 2H), 1.78 (ddd, J = 7.4, 7.4, 9.6 Hz, 1 H), 1.75-1.50 (m, 7H), 1.33 (s(br), 6H), 1.26–
1.16 (m, 1H), 1.01 (t J= 7.2 Hz, 3H). 
Dieneol 1.41 To a solution of 1.40 (100 mg, 0.26 mmol) 
in EtOAc (2.6 mL) at room temperature was added 
Lindlar’s catalyst. Solution was stirred at room 
temperature for 4 hours under H2 (1 atm). The resulting suspension was filtered through a 
pad of celite with ethyl acetate and concentrated. Flash column chromatography (3:1 
hexane-EtOAc) yielded 44.0 mg of 1.41 (44%) as a light yellow oil. 1H NMR (400 MHz, 
CDCl3): δ 6.57 (dd, J = 17.2, 11.2 Hz, 1H), 6.09 (dd, J = 11.2, 11.2 Hz, 1H), 5.58 (dd, J = 
15.2, 9.2 Hz, 1H), 5.31 (dd, J = 10.0, 10.0 Hz, 1H), 5.57 (dd, J = 14.8, 6.4 Hz, 1H)3.66 (s, 
3H), 3.40 (dd, J = 7.2, 7.2 Hz, 1H), 2.30 (t, J = 7.2 Hz, 2H), 1.78 (ddd, J = 9.2, 8.4, 7.6 
Hz, 1H), 1.56-1.44 (m, 9H), 1.37-1.27 (s (br), 6 H), 1.26-1.13 (m, 1H), 1.00 (t, J = 7.6 Hz, 
3H). 
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α-chloro ketone 1.43 To a flask charged with azeleic acid 
monomethyl ester 1.18 (2.0 g, 9.89 mmol) in EtOAc was added 
oxalyl chloride (2.59 mL, 12.93 mmol) dropwise. Mixture was stirred at room 
temperature for 45 minutes. The remaining oxalyl chloride was removed by evaporation 
to yield the crude acid chloride. The acid chloride was dissolved in Et2O (15 mL) and 
added to a freshly prepared solution of diazomethane (~19.5 mmol in 70 mL Et2O). After 
30 mintutes, solvent was removed concentrated to yield a yellow residue. Flash column 
chromatography (4:1 Hexanes:EtOAc) yielded 823.7 mg of α-chloro ketone 1.43 (37%) 
as a clear oil. IR (film) νmax 2935, 2857, 1738, 1732, 1435, 1175; 1H NMR (400 MHz, 
CDCl3): δ 4.02 (s, 2H), 3.59 (s, 3H), 2.51 (t, J = 7.36, 2H), 2.22 (t, J = 7.5 Hz, 2H), 1.58-
1.48 (m, 4H), 1.24 (s (br), 6H); 13C NMR (100 MHz, CDCl3): 202.5, 174.1, 60.1, 51.3, 
48.2, 39.5, 34.2, 33.9, 24.8, 23.4. 
This procedure also yielded 1.04 g of α-diazo ketone 1.44 (45%) as 
a pale yellow oil. IR (film) νmax 2933, 2857, 2103, 1738, 1651, 
1372; 1H NMR (400 MHz, CDCl3): δ 5.23 (s(br), 1H), 3.66 (s, 3H), 2.29 (t, J = 7.5 Hz, 
4H), 1.66-1.56 (m, 4H), 1.31 (s(br), 6H); 13C NMR (100 MHz, CDCl3): δ 195.1, 173.9, 
51.10, 40.61, 33.7, 33.6, 28.6, 24.8, 24.6, 24.5. 
 Amide 1.49 Azelaic acid monomethyl ester 1.18 (404 mg, 2.0 
mmol), 2-mercaptothiazole 1.49 (240 mg, 2.0 mmol), N,N-
dimethylaminopyridine (48 mg, 0.4 mmol), N,N-dimethylpyridin-
4-aminium chloride (64 mg, 0.4 mmol), and dicyclohexylcarbodiimide were combined in 
a microwave reaction vessel and dissolved in THF (20 mL). Resulting solution was 
subjected to microwave irradiation at 85°C for 7.5 minutes. The resulting slurry was 
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filtered through a plug of silica (3:1 Hexanes:DCM 2% Et3N). The resulting solution was 
concentrated, diluted in EtOAc (150 mL) and washed with 2M HCl (2x 30 mL) and 
saturated NaHCO3 (1 x 30 mL). The organic layer was dried (MgSO4) and concentrated 
to a yellow oil. Flash column chromatography (5:1 Hexanes:EtOAc) of the resulting 
residue yielded 589 mg (94%) of amide 1.49 as a a yellow oil that solidified upon storage 
at 4°C . 1H NMR (400 MHz, CDCl3): δ 4.57 (t, J = 7.5 Hz, 2H), 3.66 (s, 3H), 3.28 (t, J = 
7.5 Hz, 2H), 3.23 (t, J = 7.5 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 1.71-1.58 (m, 4H), 1.32 
(s(br), 6H). Spectral data matched that reported in the literature.40 
 β-ketophoshonate ester 1.50 To a stirred solution of methyl 
dimethyl phosphonate (2.09 g, 16.8 mmol) at -65°C 
(CHCl3/dry ice) in THF (100 mL) was added n-BuLi as a 2.27 M solution in hexanes (7.4 
mL, 16.8 mmol). The resulting mixture was stirred for 30 minutes at -65°C then cooled to 
-90°C (Hexanes/N2(liq)). The lithiate solution was then transferred via canula to a solution 
of amide 1.49 (2.55 g, 8.4 mmol) in THF (30 mL) at -90oC over ~30 minutes. The 
resulting solution was maintained at -90°C for an additional 1.5 hours. Oxalic acid (2.27 
g, 25.2 mmol) was added to the reaction vessel as a solution in THF (12 mL) at -90oC. 
After stirring for an additional 30 minutes at that temperature, the vessel was removed 
from the bath and warmed to room temperature. The resulting slurry was filtered through 
a pad of celite (EtOAc) and concentrated. Flash column chromatography (EtOAc) of the 
residue yielded 1.85 g (71%) of β-ketophoshonate ester 1.50 as a clear oil. 1H NMR (400 
MHz, CDCl3): δ 3.80 (s, 3H), 3.77 (s, 3H), 3.66 (s, 3H), 3.08, (d, J = 22.7 Hz, 2H), 2.60 
(t, J = 7.3, 2H), 2.30 (t, J = 7.5 Hz, 2H), 1.66-1.54 (m, 4H), 1.30 (s(br), 6H). Spectral data 
matched that reported in the literature.40 
O
MeO
O
7
P OMe
OMeO
  47 
Dieneone 1.51 To a solution of β-ketophosphonate 
ester 1.50 (1.32g, 16.8 mmol) in THF at -78°C was 
added KHMDS (812 mg, 4.07 mmol). The resulting 
solution was allowed to stir at -78°C for 30 min then warmed to room temperature. 
Aldehyde 1.19 (435 mg, 2.14 mmol) was added neat drop-wise and the resulting solution 
was stirred 16 h. The reaction mixture was quenched with water (10 mL) and extracted 
with Et2O (3 x 30 mL). Combined organic extracts were dried (MgSO4) and concentrated. 
Flash column chromatography of the residue (8:1 hexane-EtOAc) yielded 762.2 mg 
(92%) of dienone 1.51 as a pale yellow oil: IR (neat) 2932, 2858, 1737, 1685, 1660, 1628, 
1595cm-1; 1H NMR (400 MHz, CDCl3): δ 7.17 (dd, J = 15.5, 10.9 Hz, 1H), 6.42 (dd, J = 
15.1, 10.9, 1H), 6.09 (d, J = 15.5 Hz, 1H), 6.02 (dd, J = 15.1, 9.8 Hz), 3.66 (s, 3H), 3.45 
(dd, J = 7.4, 7.4 Hz, 1H), 2.55 (t, J = 7.5 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 1.85 (ddd, J = 
9.7, 7.4, 7.4 Hz, 1H), 1.65-1.50 (m, 6H), 1.32 (br s, 6H), 1.31-1.23 (m, 1H), 1.01 (t, J = 
7.4 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 201.1, 174.3, 142.2, 141.1, 131.6, 128.0, 
51.5, 40.4, 34.1, 31.6, 29.2, 29.1, 29.0, 26.1, 25.0, 24.4, 23.4, 19.8, 13.1; MS (ESI) m/z 
385.1379 (M +H)+ (385.1373 calcd for C19H30BrO3). 
 Alcohol 1.52 To a stirred solution of dieneone 1.51 
(762 mg, 1.98 mmol) in methanol (15 mL) was added 
CeCl3.7H2O (2.2 g, 6.0 mmol). The resulting mixture 
was stirred for 30 min and NaBH4 (150 mg, 3.95 mmol) was then added in 3 portions. 
The resulting solution was stirred for 10 min, quenched with water (10 mL), 2 M HCl (10 
drops) and extracted with EtOAc (4 x 30 mL). Combined organic extracts were dried 
(MgSO4) and concentrated. Flash column chromatography of the residue (4:1 hexane-
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EtOAc) yielded 754 mg (98%) of alcohol 1.52 as a colorless oil and as a mixture of 
diastereomers: IR (neat) 3455 (br), 2931, 2856, 1737 cm-1; 1H NMR (400 MHz, CDCl3): 
δ 6.33–6.23 (m, 2H), 5.65–5.51 (m, 2H), 3.66 (s, 3H), 3.38 (dd,t, J = 7.49, 7.49 Hz, 1H), 
2.29 (t, J = 7.5 Hz, 2H), 1.75 (ddd, J = 9.6, 7.5, 7.5 Hz, 1H), 1.66–1.45 (m, 9H), 1.31 ( s 
(br), 6H), 1.15 (dddd, J = 9.66, 7.36, 7.36, 7.28 Hz, 1H), 1.00 (t, J = 7.5 Hz, 3H) 13C 
NMR (125 MHz, CDCl3): δ 174.4, 134.4, 134.3, 132.7, 130.5, 130.4, 130.1, 72.7, 72.5, 
51.5, 37.3, 37.3, 34.1, 31.5, 29.4, 29.2, 29.1, 25.4, 25.0, 24.5(3), 24.5(1), 22.6, 19.7, 13.1; 
MS (ESI) m/z 369.1414, (M+H−H2O)+ (369.1424 calcd for C19H30BrO2). 
Epoxy alcohols 1.47 To a stirred solution of alcohol 
5.52 (150 mg, 0.39 mmol) at 0 oC in dichloromethane 
(15 mL) was added dimethyl dioxirane as a 0.05 M 
solution in acetone (7.75 mL, 0.39 mmol). The resulting solution was stirred for 10 min 
at 0 oC and concentrated to yielded a colorless oil. Flash column chromatography (3:1-
1% Et3N hexane-EtOAc) yielded a mixture of syn-1.47 and anti-1.47 epoxy alcohols. 
The syn isomers (Rf= 0.22; syn-1.47, 99.5 mg, 64%) proved to be the slower eluting 
mixture and the faster eluting isomers (Rf= 0.31; anti-1.47, 49.0 mg, 31%) anti. 
Diastereomers were separated by HPLC using a Varian Dynamax 8 µm Si column (2.14 x 
25 cm) eluted at a flow rate of 10 mL/min with Hexane/i-propanol gradient (1%-->3% 
IPA) with UV light detection at 205 nm using a Varian 230 detector. Diastereomers syn-
1.47a/b and anti-1.47a/b were not assigned.  
syn-1.47a: 33.2 min; 1H NMR (400 MHz, CDCl3): δ 5.79 (dd, J = 15.5, 9.4 Hz, 1H), 5.45 
(dd, J = 15.5, 8.4 Hz, 1H), 3.84 (m, 1H), 3.66 (s, 3H), 3.49 (dd, J = 8.36, 2.28, 1H), 3.37 
(dd, J = 7.4, 7.4 Hz, 1H), 2.96 (dd, J = 2.7, 2.7 Hz, 1H), 2.30 (t, J = 7.5 Hz, 2H), 1.77 
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(ddd, J = 9.6, 7.6, 7.6 Hz, 1H), 1.65–1.46 (m, 8H), 1.32 (s(br), 6H), 1.16 (dddd, J = 9.8, 
9.6, 7.4, 7.4 Hz, 1H), 1.02 (t, J = 7.4 Hz, 1H); 13C NMR (150 MHz, CDCl3): 174.5, 133.0, 
130.0, 68.6, 62.8, 55.1, 51.6, 34.2, 33.4, 30.9, 29.9, 29.6, 29.3, 29.2, 25.3, 25.0, 24.4, 22.3, 
19.7, 13.2.  
syn-1.47b: 34.1 min; 1H NMR (400 MHz, CDCl3): δ 5.78 (dd, J = 15.4, 9.4 Hz, 1H), 5.47 
(dd, J = 15.4, 8.1 Hz, 1H), 3.85 (m, 1H), 3.66, (s, 3H), 3.48 (dd, J = 8.2, 2.1 Hz, 1H), 
3.37 (dd, J = 7.42, 7.42 Hz, 1H), 2.95 (dd, J = 2.64, 2.64 Hz, 1H), 2.30 (t, J = 7.5 Hz, 2H), 
1.77 (ddd, J = 9.2, 7.6. 7.6 Hz, 1H), 1.65–1.45 (m 8H), 1.32 (s(br), 6H), 1.53 (m, 1H), 
1.01 (t, J = 7.4 Hz, 3H). 13C NMR (150 MHz, CDCl3): 174.5, 132.8, 129.9, 68.5, 62.9, 
55.0, 51.6, 34.2, 33.4, 30.9, 29.9, 29.6, 29.3, 29.2, 25.3, 25.0, 24.4, 19.8, 13.1. 
anti-1.47a: 41.0 min; 1H NMR (400 MHz, CDCl3): δ 5.77( dd, J = 15.4, 9.5 Hz, 1H), 
5.43 (dd, J = 15.5, 8.3 Hz, 1H) 3.66 (s, 3H), 3.52 (m, 1H), 3.39 (dd, J = 8.4, 2.2 Hz, 1H0, 
3.36 (dd, J = 7.5, 7.5 Hz, 1H), 2.91 (dd, J = 4.8, 2.3 Hz, 1H), 2.30 (t, J = 7.5 Hz, 2H), 
1.77 (ddd, J = 9.6, 7.4, 7.4 Hz, 1H), 1.65–1.51 (m, 8H), 1.31 (s(br), 6H), 1.21–1.12 (m, 
1H), 1.02 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3): 174.4, 132.9, 129.9, 71.0 
63.4 56.9, 51.6, 34.5, 34.2, 30.9, 29.5, 29.3, 29.2, 25.3, 25.0, 24.4, 22.2, 19.7, 13.2.  
anti-1.47b: 41.9 min; 1H NMR (400 MHz, CDCl3): δ 5.78 (dd, J = 15.5, 9.4 Hz, 1H), 
5.46 (dd, J = 15.5, 8.1 Hz, 1H), 3.66 (s, 3H), 3.53 (m, 1H), 3.39 (dd, J = 8.1, 2.3 Hz, 1H), 
3.37 (dd, J = 7.4, 7.4 Hz, 1H), 2.91 (dd, J = 4.7, 2.3 Hz, 1H), 2.30 (t, J = 7.5 Hz, 2H), 
1.76 (ddd, J = 9.4, 7.4, 7.4 Hz, 1H), 1.65–1.48 (m, 8H), 1.31 (s(br), 6H), 1.19–1.10 (m, 
1H), 1.00 (t, J = 7.4 Hz, 1H). 13C NMR (125 MHz, CDCl3): 174.4, 132.8, 129.8, 71.0 
63.5 56.8, 51.6, 34.6, 34.2, 30.9, 29.5, 29.3, 29.2, 25.4, 25.0, 24.4, 22.2, 19.7, 13.1.  
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 p-Nitro benzoate 1.57 To a solution of syn-epoxy 
alcohols syn-1.47a/b (182 mg, 0.45 mmol) in THF 
(4.5 mL) was added PPh3 (237 mg, 0.90 mmol) and p-
nitrobenzoic acid (151 mg, 0.90 mmol). The solution was maintained for 10 min and 
diisopropylazadicarboxylate (DIAD) was added dropwise. The resulting solution was 
maintained for 16 h, concentrated in vacuo and the residue purified by flash column 
chromatography (5:1-1% Et3N hexane-EtOAc) to yield 215 mg (86%) of 1.57 as a 
colorless oil and as a mixture of diastereomers: IR (neat) 2933, 2860, 1729, 1529, 1271 
cm-1; 1H NMR (400 MHz CDCl3) δ 8.27 (d, J = 8.8 Hz, 2H), 8.18 (d, J = 8.8 Hz, 2H), 
5.71-5.80 (m, 1H), 5.35-5.46 (m, 1H), 5.06-5.13 (m, 1H), 3.63 (s, 3H), 3.42-3.46 (m, 1H), 
3.33 (t, J = 7.6 Hz, 1H), 3.01-3.05 (m, 1H), 2.26 (t, J = 7.6 Hz, 2H), 1.76-1.83 (m, 2H), 
1.68-1.75 (m, 1H), 1.57-1.63 (m, 2H), 1.33-1.56 (m, 4H), 1.20-1.30 (m, 6H), 1.04-1.18 
(m, 1H), 0.92-1.0 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 193.0, 155.8, 135.2, 31.6, 27.7, 
23.3, 20.0, 13.1; MS (ESI) 574.1368 m/z,  [(M +Na)+, calcd for C26H34BrNNaO7, 
574.14]. 
Methanolysis of 1.57 To a solution of p-nitrobenzoate ester 1.57 (44 mg, 0.08 mmol) in 
MeOH (0.7 mL) was added K2CO3 (11 mg, 0.08 mmol). The resulting solution was 
stirred for 30 minutes, quenched with saturated ammonium chloride (1 mL) and the 
aqueous layer extracted with dichloromethane (3 x 5 mL). Combined organic extracts 
were dried over Na2SO4, filtered and concentrated in vacuo. Flash column 
chromatography (4:1-1% Et3N hexane:EtOAc) yielded 28 mg (86%) of anti-epoxy 
alcohol anti-1.47a/b as a mixture of diastereomers.  
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Mesylate 1.53 To a solution of anti-epoxy alcohol 
anti-1.47a/b (248 mg, 0.61 mmol) in 
dichloromethane (20 mL) over activated 4 Å 
molecular sieves at 0 °C was added MsCl (0.142 mL, 1.84 mmol). The resulting solution 
was stirred at that temperature for 5 min and Et3N (0.257 mL, 1.84 mmol) was added 
dropwise. One crystal of 4,4-Dimethylaminopyridine was added and the solution was 
warmed to room temperature and stirred for 16 h. The resulting solution was diluted with 
EtOAc (30 mL), washed with 15% NaHCO3 (15 mL) and extracted EtOAc (3 x 30 mL). 
Combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. 
Flash column chromatography (3:1-1% Et3N hexane-EtOAc) to yield mesylate 1.53 as a 
light yellow oil and as a mixture of diastereomers (165.1 mg, 0.34 mmol, 56%): IR (neat) 
2934, 1736, 1359, 1175, 925 cm-1; 1H NMR (400 MHz CDCl3) δ 5.80 (dd, J = 15.2, 9.2 
Hz, 1H), 5.40 (dd, J = 15.2, 8.4 Hz, 1H), 4.63-4.57 (m, 1H), 3.65 (s, 3H), 3.60-3.45 (m, 
1H), 3.38-3.33 (m, 1H), 3.10-3.00 (m, 3H), 2.99-2.96 (m, 1H), 2.28 (t, J = 7.6 Hz, 2H), 
1.71-1.78 (m, 3H), 1.39-1.63 (m, 6H), 1.21-1.35 (m, 6H), 1.10-1.20 (m, 1H), 0.96-1.03 
(m, 3H); 13C NMR (125 MHz, CDCl3) δ174.3, 133.8, 133.6, 129.0, 128.8, 80.3, 60.0, 
59.9, 56.6, 51.6, 38.9, 38.8, 34.1, 32.2, 30.8, 29.1(1), 29.0(5), 24.9, 24.7, 24.5, 24.4, 22.2, 
19.7, 13.1; MS (ESI) 521.1176 m/z, [(M+Na+H2O)+, calcd for C20H35BrNaO7S, 521.12]. 
 Bicyclobutane 1.1 To a solution of mesylate 1.53 
(53.7 mg, 0.11 mmol) in THF (2.0 mL) and water 
(2.79 mL) was added LiOH (117 mg, 2.79 mmol) at 
room temperature. The resulting solution was warmed to 60 °C, stirred for 2.5 h, cooled 
to room temperature, diluted with EtOAc (20 mL), and washed with saturated NH4Cl (5 
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mL). The aqueous layer was extracted with EtOAc (4x 20 mL). Combined organic 
extracts were dried (Na2SO4) and concentrated in vacuo. Resulting oil was concentrated 
from benzene (3 x 5 mL) in vacuo, the residue dissolved in THF (14 mL) and the cooled 
to -78 °C. A solution of t-BuLi (1.50 M in pentane, 0.297 mL, 0.45 mmol) was added 
dropwise to the solution of crude carboxylic acid. The reaction mixture was stirred at -
78 °C for 2 h, warmed to -20 °C and stirred an additional 30 min. The mixture was 
warmed to 0 °C and quenched with saturated NH4Cl (0.2 mL). An ethereal solution of 
diazomethane (7 mL, ~0.25 M) was added and the mixture was stirred an additional 5 
min, diluted with H2O (10 mL) and extracted with EtOAc (4 x 20 mL). The combined 
organic extracts were dried over Na2SO4, filtered and concentrated in vacuo to yield a 
faint yellow oil (38 mg crude yield). The crude material was purified on RP-HPLC using 
a Varian microsorb-mv 4.6 x 250 mm column eluting with 85:15 (MeOH:H2O) + 20 mM 
Et3N at pH=8 at 0.5 mL/min with a UV detector at 205 nm. Aqueous fractions containing 
product were extracted with freshly distilled n-pentane (5 x 5 mL) and concentrated to 
yield 6.87 mg (20.3%) of 1.1 as a colorless oil: Retention time 27 min; 1H NMR (400 
MHz, C6D6) δ 5.41 (dd, J = 8.0, 15.6 Hz, 1H), 5.34 (dd, J = 7.2, 15.6 Hz,1H), 3.37 (s, 
3H), 2.93 (dd, J = 2.0, 6.8 Hz, 1H), 2.64 (dt, J = 2, 5.6 Hz, 1H), 2.34 (d, J = 8.0 Hz,1H), 
2.11 (t, J = 7.6 Hz, 2H), 1.92 (m, 1H), 1.49-1.58 (m, 2H), 1.23-1.42 (m, 6H), 1.06-1.19 
(m,8H), 0.87( t, J = 7.6 Hz, 3H); 13C NMR (150 MHz, C6D6) δ 173.4, 132.8, 128.6, 
60.4, 58.0, 51.0,45.7, 44.6, 34.1, 32.4, 29.5(3), 29.4(8), 26.2, 25.2, 17.1, 13.6, 9.4, 9.3 
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Spectra Relevant to Chapter 1 
 
 
 
 
Spectra I-1: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.21 in CDCl3. 
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Spectra I-2: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.22 in CDCl3. 
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Spectra I-3: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.23 in CDCl3. 
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Spectra I-4: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.24 in CDCl3. 
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Spectra I-5: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.27 in CDCl3. 
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Spectra I-6: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.32 in CDCl3. 
H
Br
MeO2C
1.32
  63 
 
 
 
 
 
 
 
Spectra I-7: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.33 in CDCl3. 
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Spectra I-8: The 400 MHz 1H spectra of 1.34 in CDCl3. 
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Spectra I-9: The 400 MHz 1H and 100 MHz 13C NMR spectra of 1.19 in CDCl3. 
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Spectra I-10: The 600 MHz 1H and 150 MHz 13C NMR spectra of 1.36 in C6D6. 
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Spectra I-11: The 400 MHz 1H and 100 MHz 13C DEPT135 NMR spectra of 1.15 in 
C6D6. 
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Spectra I-12: The 400 MHz 1H and 100 MHz 13C NMR spectra of 1.38 in CDCl3. 
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Spectra I-13: The 400 MHz 1H and 100 MHz 13C NMR spectra of 1.40 in CDCl3. 
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Spectra I-14: The 400 MHz 1H and 100 MHz 13C NMR spectra of 1.41 in CDCl3. 
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Spectra I-15: The 400 MHz 1H and 100 MHz 13C NMR spectra of 1.43 in CDCl3. 
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Spectra I-16: The 400 MHz 1H and 100 MHz 13C NMR spectra of 1.44 in CDCl3. 
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Spectra I-17: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.51 in CDCl3. 
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Spectra I-18: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.46 in CDCl3. 
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Spectra I-19: The 500 MHz 1H and 125 MHz 13C NMR spectra of syn-1.47a in CDCl3. 
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Spectra I-20: The 500 MHz 1H and 125 MHz 13C NMR spectra of syn-1.47b in CDCl3. 
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Spectra I-21: The 400 MHz 1H and 150 MHz 13C NMR spectra of anti-1.47a in CDCl3. 
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Spectra I-22: The 400 MHz 1H and 150 MHz 13C NMR spectra of anti-1.47b in CDCl3. 
H
Br
OH
MeO
O
7
O
anti-1.47b
  79 
 
 
 
 
Spectra I-23: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.57 in CDCl3. 
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Spectra I-24: The 400 MHz 1H and 125 MHz 13C NMR spectra of 1.53 in CDCl3. 
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Spectra I-25: The 600 MHz 1H and 150 MHz 13C NMR spectra of 1.1 in C6D6. 
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CHAPTER II  
 
 
Structural Diversification of Apoptolidins Through Mutasynthesis 
 
Background Information  
Isolation of Apoptolidin 
Apoptolidin 2.1 was isolated from the actinomycete Nocardiopsis sp. FU40 while 
screening bacterial extracts for selective inducers of apoptosis.1 This novel polyketide 
natural product was reported to induce apoptosis selectively in E1A transformed rat glia 
cells (IC50 = 11 ng/mL) relative to untransformed glia cells (IC50 > 10 µg/mL). Apoptosis 
induction in these cells was characterized by the observation of condensed chromatin and 
fragmented nuclei as visualized by staining with Hoechst Dye 333258 and significant 
DNA laddering. Subsequent NMR analysis revealed apoptolidin to consist of a 20 
membered macrolactone, a highly substituted pyran ring and two sugar residues, located 
at C9 and C27.2   
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Figure II-1: Structure of natural apoptolidins 
 
Since this initial report, several more apoptolidin natural products have been 
isolated from Nocardiopsis sp. FU40 as minor metabolites, now designated apoptolidins 
B–G (Figure II-1). Apoptolidin B 2.2 and C 2.3 are deoxygenated at C16 and both C16 
and C18, respectively, but are otherwise identical to the primary metabolite, apoptolidin 
A 2.1.3 Apoptolidins E 2.5 and F 2.6 are also deoxygenated at C16 and C18 but differ in 
the nature of the deoxy sugar at C9 and C27.4 Apoptolidin D 2.4 lacks a C6 methyl group 
relative to other apoptolidins.5 Also, apoptolidin was first reported to undergo a ring 
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expansion to give a 21 membered isomeric macrolactone named isoapoptolidin A, 2.8.6,7 
Similar isomeric forms have subsequently been identified for apoptolidins B and D as 
well. Finally, Apoptolidin G 2.7 was isolated from a fermentation extract and assigned 
the C2-C3 configurational isomer of apoptolidin A. We hypothesized that this compound 
was not being directly synthesized but was the result of a light-induced isomerization of 
apoptolidin A. To test this, a solution of apoptolidin A 2.1 in acetone was irradiated with 
a 275 W sunlamp for 16 hours and indeed produced apoptolidin G as a 5:1 mixture with 
apoptolidin A.8  
In order to design and access apoptolidin derived chemical probes to support 
mechanism of action studies, a high yielding source of apoptolidin was required. 
Fortunately, using a fermentation protocol of Nocardiopsis sp. FU40 optimized for the 
production of apoptolidin A 2.1, we were able to obtain >100 mg per liter of culture broth. 
To aid in identification and confirmation of the mechanism of action and more 
specifically the molecular target of apoptolidin, it is advantageous to also have access to a 
diverse library of structural analogues of the parent compound. For example, a good 
indicator that the mechanism and target are correctly identified is the parallel nature of 
phenotypic (cytotoxicity) and mechanistic (biochemical activity) responses to structural 
modifications. Furthermore, compound analogues of variable activity can be 
advantageous in the development of probes that explore the importance of specific 
structural features in regulating biological activity and identification of a minimum 
pharmacophore. The minor apoptolidin shunt metabolites (B-G) afford access to only a 
limited number of structural homologues in trace quantity. Alternatively, novel 
apoptolidin congeners can be produced either by de novo synthesis, synthetic 
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transformation of natural apoptolidin isolated from bacterial fermentation or by 
modification of the producing organism’s biosynthetic machinery to provide access to 
large quantities of apoptolidin congeners. 
Synthesis of Apoptolidins 
The reported potent, selective cytotoxicity of apoptolidin as well as its complex 
structural features have prompted multiple research groups to pursue its total synthesis.9 
More significantly, various routes aimed at total syntheses have also produced novel 
apoptolidin analogues. The first total synthesis of apoptolidin A was reported by 
Nicolaou and co-workers in 2003. 10  Utilizing late stage glycosylations and 
macrolactonization in their strategy, they were also able to prepare three novel 
apoptolidin analogues (Figure II-2) including C27-hydroxy apoptolidin A 2.11 and two 
macrolactones missing the pyran fragment (2.12 and 2.13). Previous work in the 
Sulikowski laboratory planned to implement a bioglycosylation of synthetic apoptolidin 
agylcones (apoptolidinones) for the synthesis of apoptolidin A and D and potentially 
novel apoptolidin congeners. To this end, our group developed routes to three apoptolidin 
agylcones (Figure II-3).11,12 Successful whole cell glycosylation of apoptolidinone D 
was realized at C27 only, providing access to the apoptolidin D disaccharide 2.17.13 
While the low yield of apoptolidin compounds from time and labor intensive total 
synthesis makes it an inefficient method to access the natural compounds, relative to 
fermentation, studies towards this end have provided access to novel apoptolidins for 
early biological testing (vida infra). 
To further investigate SAR of apoptolidin natural products, several groups have 
successfully modified apoptolidin isolated from bacterial fermentation culture (Figure 
  86 
II-4). Salomon and coworkers generated a truncated apoptolidin 2.18 by acid hydrolysis 
of the C27 disaccharide accompanied by elimination of water in the pyran moiety.14 In 
the Sulikowski laboratory, nonselective acetylation of apoptolidin A provided 
hexaacetylated apoptolidin A 2.19, which allowed for deglycosytion at C27 by treatment 
with methanolic hydrochloric acid to provide acylated apoptolidin monosaccharide 2.20.7 
Wender and coworkers were able to generate a variety of apoptolidin analogues by 
functionalizing the various hydroxyl groups of apoptolidin using careful protecting group 
manipulation15 or peptide catalysis, a single example (2.21) is shown.16 Wender and co-
workers also prepared a few analogues of macrocycle 2.12 and δ-lactone apoptolidin 
fragment 2.22 by way of oxidative cleavage of apoptolidin A 2.1.17  
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Figure II-2: Nicolaou's apoptolidin analogues 
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Figure II-3: Sulikowski's apoptolidin analogues 
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Figure II-4: Semisynthetic apoptolidin analogues 
 
 Together, total synthesis and semisynthesis have afforded a small group of 
structural analogues of apoptolidin that aid investigations of the mechanism of its 
observed selective cytotoxicity. However, the preparation of apoptolidins by total 
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low yields. For example, our group’s optimized, high yielding synthesis of 
apoptolidinone 2.14 resulted in the isolation of only 2-5 mg of material over 14 linear 
steps in a total of 2.6% yield.11 Furthermore, minor structural changes to target analogues 
on complex polyketides such as apoptolidin frequently require a significant change in 
synthetic strategy, limiting rapid diversification. Preparation of new apoptolidin 
congeners through semisynthesis is limited by the relatively poorly selective reactivity of 
apoptolidin with reagents and its tendency to undergo decomposition under either acidic 
or basic reaction conditions. To avoid these limitations and create low cost, high yielding 
sources of apoptolidin congeners for use in studying apoptolidin cytotoxicity, we sought 
to instead employ a strategy taking full advantage of the high yielding apoptolidin 
fermentation protocol. Specifically, we aimed to efficiently produce analogues of 
apoptolidin by genetic manipulation of the apoptolidin producing machinery followed by 
fermentation of the transformed microbe. 
Biosynthesis of Apoptolidin: Type 1 PKS 
To identify parts of the biosynthesis of apoptolidin that might be modified to 
produce interesting apoptolidin congeners from fermentation of mutant producers, it is 
important to first understand the biogenesis of apoptolidin. Apoptolidin is the product of 
a type I polyketide synthase (PKS). Type 1 PKS’s are multi-domain megasynthases that 
construct the core of many polyketide natural products. Chain elongation is achieved 
through a non-iterative series of decarboxylative Claisen condensations and β-reductions. 
Briefly, acyltransferase (AT) domains transfer the elongation units (various C2 
substituted malonate derivatives) from a molecule of coenzyme A (CoA) to a 
phosphopantathienylated acyl carrier protein domain (ACP) for activation. Ketosynthase 
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(KS) domains then transfer this activated malonate unit to a cysteine residue and 
catalyzes the decarboxylative Claisen condensation onto the downstream malonyl ACP 
(Scheme II-1). The β-ketoacyl moiety is then variably transformed to the appropriate 
oxidation state by the action of ketoreductase (KR), dehydratase (DH) and enoylreductase 
(ER) domains. When chain elongation is complete, a thioesterase (TE) domain then 
catalyzes the cleavage and/or macrolactonization to the polyketide product.18 
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Scheme II-1: Biosynthesis of polyketides 
 
In type 1 PKS, the ordering of genes enconding the catalytic domains in each 
module typically corresponds to the order of reactions in the biosynthesis, making it 
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possible to predict the structure of the polyketide chain from the genetic sequence of the 
PKS. Given this mechanism and the structure of apoptolidin, we expect the PKS to be 
encoded by a 14-module domain sequence. Several more transformations must occur in 
the biosynthesis of apoptolidin after completion of the polyketide core (post-PKS 
modifications). The variable oxidation at C16 and C20 of apoptolidins B and C suggest 
that these positions are oxidized by one or more P450 oxidases. Gylcosylation at C9 and 
C27 will also require up to three gylcosyltransferases as well as enzymes involved in 
biosynthesis of the unusual deoxysugars L-olivomycose and D-oleandrose. While the 
order of events in the post-PKS modification are unknown, the failure of apoptolidinones 
2.14 and 2.16 to be bioglycosylated at C9 in studies in our lab12 suggest that apoptolidin 
is glycosylated at C9 at an earlier stage of biosynthesis, perhaps even during chain 
elongation process.  
 
Genetic Manipulation of Apoptolidin Biosynthesis 
Identifying the Apoptolidin Biosynthetic Gene Cluster 
In order to increase the understanding of apoptolidin biosynthesis as well as to 
identify genes to target for disruption to afford access to structural analogues, our 
collaborators in the Bachmann lab sequenced the genome of Nocardiopsis sp. FU40 with 
a goal of identifying the biosynthetic gene cluster.20 The organism’s genomic DNA was 
isolated, sequenced and assembled yielding an estimated 9,433,896 bp genome, in 
agreement with actinomycete genomes previously sequenced. BLAST-based algorithms19 
were used to identify two gene clusters within the genome that putatively encoded type 1 
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PKS.20 While one of these only possessed eight intact PKS modules, the second ~ 116 kb 
region contained, as expected, 14 PKS modules and appeared to also contain genes 
necessary for all post-PKS elaboration to apoptolidin.  
The identified gene cluster apo is 115.74 kb and contains 39 individual open 
reading frames (ORFs). By sequence homology, these genes were identified as shown in 
Figure II-5 and include nine type 1 PKS genes, six oxidoreductase genes, four 
methyltransferase genes, three glycosyltransferases and other genes responsible for sugar 
and starter unit biosynthesis. The PKS genes ApoS1–S8 encode the synthases responsible 
for the biosynthesis of the polyketide backbone of apoptolidin. The protein product of 
ApoS1 contains the KSQ domain that is responsible for initiating the polyketide synthesis. 
From this point, domains are organized as predicted based upon the structure of 
apoptolidin in ApoS1–S7 and terminate with a thioesterase domain in ApoS8 required for 
release from the megasynthase. Of the two remaining PKS genes ApoS9 and ApoS10, 
ApoS10 is proposed to be responsible for macrocylization and ApoS9 appears to be an 
incomplete module sequence with no obvious function. Upon cyclization, it is expected 
that the compound is further modified by glycosylation, oxidation and O-methylation but 
the exact order of these events and the specific genes responsible for each of these 
reactions cannot be predicted from the genetic sequence alone (Figure II-6). 
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Figure II-5: Genetic organisation of the apoptolidin gene cluster in Nocardiopsis sp. 
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Figure II-6: Overview of the proposed biosynthetic pathway for apoptolidin 
 
Genetic Knockouts  
  In order to both confirm the identification of the apoptolidin gene cluster, as well 
as to create mutant producers, a method for selective gene knockout of the apoptolidin 
gene cluster was developed by Du et al.20 Briefly, a cosmid library was created in E. coli 
from the genomic DNA of Nocardiopsis sp. FU40. Oligonucleotides of ApoM2, ApoGT1 
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and ApoM1 were generated and used as hybridization probes to screen the library to 
identify 3 cosmids containing the gene cluster apo. Sequencing of these cosmids 
confirmed that they covered the apo gene cluster of interest in its entirety. Genetic 
knockouts were then introduced by replacing targeted genes with apramycin resistance 
gene makers by double homologous recombination in E. coli. The resulting cosmids were 
introduced into nocardiopsis using either interspecies conjugation or electroporation.20 
 To validate the identification of apo as the biosynthetic gene cluster responsible 
for the apoptolidin biogenesis, a gene was targeted for disruption that would ideally 
eliminate the ability of Nocardiopsis sp. FU40 to produce apoptolidin. To this effect, 
ApoS8 was disrupted. Fermentation and subsequent extraction of this mutant producer 
(FU40∆ApoS8) with ethyl acetate resulted in the production of no apoptolidin 
compounds as indicated by HPLC/MS analysis (Figure II-8: Mass selective (858.5 m/z) 
LCMS trace of FU40∆ApoGT2Figure II-7). Furthermore, pulse feeding of 
FU40∆ApoS8 with apoptolidin monosaccharide 2.11 restored production of apoptolidin 
A. These results confirmed the disruption of the apoptolidin polyketide synthase without 
disruption of other genes involved in biosyntheses.  
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Figure II-7: Mass selective (1146.5 m/z) LCMS trace of FU40 wt and FU40∆ApoS8 
 
 Equipped with a method for selective gene disruption in Nocardiopsis sp. FU40, 
disruption of genes that would produce novel apoptolidins was next pursued. Since the 
disruption of ApoS8, our collaborators in the Bachmann laboratory have been able to 
successfully produce several knockout strains. Genes successfully targeted for disruption 
include the oxygenase genes ApoP and ApoD2, the methyl transferase ApoM2, genes 
responsible for the synthesis of the initiating methoxymalonyl ACP starting subunit 
ApoJ/K, as well as glycosyl transferase knockouts ApoGT1/2. These mutant producers are 
beginning to shed light on the specifics of the post-PKS modifications of apoptolidin by 
various tailoring enzymes. For use in our studies of the biological activity of apoptolidin, 
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we have selected to pursue structure activity relationships of variable apoptolidin 
glycosylation. A few mutant Nocardiopsis were generated that produced novel 
apoptolidin compounds with reduced glycosylation of the polyketide core. 
 First, a selective knockout of ApoGT2 was produced. The resulting mutant 
Nocardiopsis was cultured and extracted. Analysis of the crude extracts revealed that 
production of apoptolidins A-G had been eliminated. Instead, the organism produced two 
compounds with the signature UV absorbance of apoptolidin (λmax= 232, 333), with a 
product ion mass of 858.5 m/z. This ion corresponds to the ammonium adduct of the 
apoptolidin polketide core, glycosylated at C9 only, confirming the role of ApoGT2 in the 
installation of the disaccharide moiety at the C27 hydroxyl group. One compound was 
tentatively assigned the name apoptolidin H and the second compound was suspected to 
be the ring expanded isomer, isoapoptolidin H.  
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Figure II-8: Mass selective (858.5 m/z) LCMS trace of FU40∆ApoGT2 
 
 To confirm the structure of these products, FU40∆GT2 was cultured on large 
scale. Extraction and purification conditions were optimized leading to the isolation of 
>60 mg of apoptolidin H and 45 mg of isoapoptolidin H per liter of media. Subsequent 
NMR characterization verified the identity of apoptolidin H as 27-hydroxyapoptolidin A 
2.11 as previously synthesized by Nicolaou et al.10 Furthermore, the structure of 
isoapoptolidin H 2.23 was solved through extensive NMR experiments. 1H and 13C shifts 
of the two compounds are shown in Table II-1.  
 While knockout strains of ApoGT1 have not resulted in new congener isolation 
and knockouts of ApoGT3 have yet to be realized, an additional apoptolidin congener was 
identified from a knockout of ApoM3 with apparent reduced glycosylation. Although 
analysis of the extracts of this mutant producer still revealed a high level of apoptolidin A 
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production, a minor metabolite was identified with the characteristic UV signature of 
apoptolidin natural products and a product ion of 1002.6 m/z. This mass corresponds to 
an apoptolidin ammonium adduct of apoptolidin that is missing the D-oleandrose sugar of 
the disaccharide at C27. Scale-up fermentation of this mutant followed by extraction and 
careful chromatographic purification resulted in the isolation of a very small amount of 
this compound (>>1 mg) as confirmed by MALDI-MS. The low yield and challenge of 
purification of this minor metabolite in the presence of large amounts of apoptolidin A 
have prohibited NMR characterization and limit the utility of this strain in probe 
development.  
 
 
Figure II-9: Mass selective (1002.6 and 1146.5 m/z) LCMS trace FU40∆ApoM3 
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 While new mutant producers are currently being pursued in the Bachmann lab, 
our lab has been investigating the biological activity of apoptolidin using the parent 
compound apoptolidin A produced from wild type Nocardiopsis sp. FU40 and 
apoptolidin H from the mutant producer FU40∆ApoGT1. These efforts have involved 
experiments aimed at characterizing and quantifying the reported selective cytotoxicity 
and the semisynthesis of molecular probes for understanding apoptolidin SAR and 
identifying any molecular targets.  
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 δC  δC  δC  δC 
C# 2.11 2.23 C# 2.11 2.23 C# 2.11 2.23 C# 2.11 2.23 
1 172.5 170.3 12 134.8 134.2 23 73.7 73.3 22-Me 12.2 12.0 
2 123.9 124.9 13 133.3 133.6 24 40.7 40.7 24-Me 5.3 5.3 
3 149.0 147.1 14 24.6 25.4 25 69.1 69.0 17-OMe 61.4 60.0 
4 133.4 132.7 15 36.5 33.7 26 38.4 38.0 28-OMe 59.4 59.4 
5 147.1 143.5 16 74.5 68.1 27 68.1 74.1 1’ 96.0 96.2 
6 133.2 132.8 17 83.8 82.2 28 78.6 78.4 2’ 73.9 73.7 
7 142.9 136.9 18 38.5 36.0 2-Me 14.0 13.4 3’ 74.9 74.9 
8 38.9 39.4 19 72.3 67.8 4-Me 17.8 17.9 4’ 87.5 87.5 
9 84.1 84.0 20 75.4 75.3 6-Me 16.5 17.6 5’ 68.2 68.2 
10 126.4 125.8 21 101.2 102.9 8-Me 18.2 18.4 6’ 18.3 18.3 
11 141.2 141.0 22 36.3 36.6 12-Me 12.0 12.1 4’-OMe 61.0 61.0 
 δH  δH  δH  δH 
C#  2.11 2.23 C#. 2.11 2.23 C# 2.11 2.23 C# 2.11 2.23 
1 -- -- 12 -- -- 23 2.04 3.76 22-Me 1.03 1.05 
2 -- -- 13 5.68 5.47 24 1.76 1.78 24-Me 0.88 0.86 
3 7.36 7.34 14 2.47,2.05 2.49,1.94 25 4.09 4.28 17-OMe 3.36 3.50 
4 -- -- 15 1.53,1.41 1.39 26 1.58,1.29 1.78,1.41 28-OMe 3.29 3.38 
5 6.19 5.97 16 3.44 3.86 27 3.55 3.47 1’ 4.82 4.80 
6 -- -- 17 2.72 3.36 28 3.21,3.17 3.38 2’ 3.39 3.39 
7 5.23 5.08 18 2.15,1.72 1.68,1.39 2-Me 2.11 2.06 3’ 3.72 3.73 
8 2.75 2.75 19 5.31 4.45 4-Me 2.19 2.09 4’ 2.71 2.72 
9 3.83 3.78 20 3.54 4.94 6-Me 1.93 1.73 5’ 3.74 3.75 
10 5.22 5.26 21 -- -- 8-Me 1.26 1.16 6’ 1.36 1.25 
11 6.18 6.05 22 2.04 1.78 12-Me 1.68 1.71 4’-OMe 3.58 3.58 
Table II-1: 13C (150 MHz) and 1H (600 MHz) NMR shifts for apoptolidin H 2.11 and 
isoapoptolidin H 2.23 
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Experimental Methods 
Light-induced isomerization of apoptolidin A: To a 6 mg (0.005mmol) sample of 
apoptolidin A in a borosilicate glass NMR tube was added deuterated acetone (0.6 mL). 
Additionally. The solution was exposed to a 275 watt sunlamp. The solution was 
removed from irradiation and monitored by 1H NMR for the appearance of the new 
isomer. After 16 hours, the solution was concentrated and the resulting photoisomerized 
product was purified from the mixture using flash chromatography (silica gel, 2.5% 
methanol in dichloromethane then 10-15% methanol in dichloromethane) to give 2.3 mg 
(0.002 mmol) of apoptolidin G isomer as a white solid. 1H NMR (600 MHz, CD3OD): δ 
6.21 (d, J = 15.7 Hz, 1H), 6.09 (s, 1H), 5.88 (s, 1H), 5.69 (dd, J = 7.8, 7.8 Hz, 1H), 5.34 
(dd, J = 9.0, 15.7 Hz, 1H), 5.21 (dd, J = 5.0, 11.7 Hz, 1H), 5.03 (d, J = 4.2 Hz, 1H), 4.94 
(d, J = 10.0 Hz, 1H), 4.83 (dd, J = 1.7, 9.8 Hz, 1H), 4.80 (d, J = 3.84 Hz, 1H), 4.07 (d, J 
= 9.8 Hz, 1H), 3.91 (m, 1H), 3.68–3.82 (m, 5H), 3.57 (s, 3H), 3.54 (s, 3H), 3.43 (s, 3H), 
3.38 (m, 1H), 3.37 (m, 1H), 3.33 (s, 3H), 3.33–3.30 (m, 2H), 3.22 (dd, J = 7.2, 14.5 Hz, 
1H), 3.22–3.15 (m, 2H), 2.97 (dd, J = 9.0, 9.0 Hz, 1H), 2.81 (m, 1H), 2.71 (dd, J = 9.3, 
9.3 Hz, 1H), 2.36–2.46 (m, 3H), 2.18 (m, 1H), 2.11 (m, 1H), 2.01 (s, 3H), 1.98 (d, J = 
13.4, 1H), 1.79 (m, 2H), 1.73 (s, 3H), 1.71 (s, 3H), 1.73–1.69 (m, 4H), 1.60 (s, 3H), 1.40–
1.48 (m, 2H), 1.34 (s, 3H), 1.2–1.3 (m, 9H), 1.09 (d, J = 6.5 Hz, 3H), 1.5 (d, J = 6.7 Hz, 
3H), 0.89 (d, J = 6.9 Hz, 3H); 13C NMR (150 MHz, CD3OD): δ 172.1, 141.4, 139.2, 
138.4, 135.1, 133.6, 133.5, 133.0, 132.9, 128.7, 126.4, 101.9, 101.4, 99.5, 95.5, 87.6, 86.0, 
86.0, 82.7, 82.0, 77.3, 77.3, 77.0, 76.2, 75.8, 75.8, 75.0, 73.9, 73.2, 73.1, 73.0, 68.6, 68.2, 
67.5, 61.0, 61.0, 59.5, 57.3, 45.2, 40.7, 39.6, 37.8, 37.8, 37.3, 36.8, 36.8, 24.1, 23.0, 22.7, 
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18.4, 18.4, 18.3, 18.0, 17.8, 16.1, 12.4, 12.0, 5.4; HRMS (ESI-TOF MS) m/z 1151.6336 
(M+Na)+ calculated for C58H96NaO21, measured 1151.6372. 
Apoptolidin A fermentation procedure 
Plate Culture: 20 microliters of glycerol stock of Nocardiopsis sp. FU40 was plated 
onto a Petri dish containing Bennett’s medium and incubated upside down at 30 oC for 3 
days. Dishes with spores can then be sealed with parafilm and stored at room temperature 
for up to 1 month for future use. The composition of Bennett’s medium was as follows: 
yeast extract 1.0 g, beef extract 1.0 g, NZ amine A (casein digest) 2.0 g, glucose 10.0 g, 
agar 20.0 g per liter of deionized water. The pH of the medium was adjusted to 7.0 with 1 
M HCl and 1 M NaOH. After autoclaving, the solution was cooled to room temperature 
and poured into sterile Petri dishes (30 mL/dish). 
Seed Culture: The production fermentation was initiated by aseptically inoculating one 
full loop of mycelia grown on Bennett’s agar plate into a sterile 50 mL Falcon tube 
containing 5 mL seed medium. The seed cultures were incubated for 4 days in a rotary 
shaker (170 rpm) at 30 °C. The composition of seed medium was as follows: soluble 
starch 10.0 g, molasses 10.0 g, peptone 10.0 g, beef extract 10.0 g per liter of deionized 
water. The pH of the medium was adjusted to 7.2 with 1 M HCl and 1 M NaOH. After 
autoclaving, the solution was cooled to room temperature and distributed into sterile 50 
mL Falcon tubes (5 mL/tube). Typically, for compound production, 20 tubes of seed 
culture were used.  
Production Culture and Extraction: Each 5 mL seed culture was poured into a 250 mL 
Erlenmeyer flask containing 50 mL production medium. In a typical production, 20 flasks 
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were used to create a total of 1 L of production culture. The flasks were incubated for 6 
days in a rotary shaker (170 rpm) at 30 °C. The composition of production medium was 
as follows: glycerol 20.0 g, molasses 10.0 g, casamino acids 5.0 g, peptone 1.0 g, calcium 
carbonate (CaCO3) 4.0 g per liter of deionized water. Specifically, 200 mg of calcium 
carbonate was first distributed into each 250 mL Erlenmeyer flask. The remaining media 
components were dissolved in an appropriate volume of water and 50 mL of this solution 
was distributed into each Erlenmeyer flask. The pH of each flask was individually 
adjusted to 7.2 with 1 M HCl and 1 M NaOH. The resulting suspensions were autoclaved 
to produce the production media flasks. After 6 days’ incubation, the cell bodies were 
scraped from each flask and transferred into 50 mL Falcon tubes. The resulting 
suspensions were centrifuged at 3750 rpm for 30 minutes. The supernatants were 
decanted and combined into a separatory funnel and extracted with ethyl acetate (3x 750 
mL for 20 flasks). The combined ethyl acetate extracts were dried (Na2SO4) and 
concentrated under reduced pressure at 29 °C.  
Apoptolidin A/isoapoptolidin A Purification: The resulting residue from concentration 
of ethyl acetate extracts were dissolved in 3 mL of DMSO/1L culture and filtered through 
a 0.2 µm filter. The resulting DMSO solution was purified with preparative reverse phase 
HPLC (Gilson) with multiple 300 µL injections using a 4 minute gradient of 35-70% 
acetonitrile in water at a flowrate of 30 mL/min with UV detection at 220 nm and a 
Phenomenex Luna column (100 Å, 50 x 21.20 mm, 5 µm C18). Apoptolidin A r.t.= 2.69 
min/ isoapoptolidin A r.t.=2.69 min. Fractions containing each product were combined 
into a round bottomed flask and concentrated (T < 31°) to remove acetonitrile. Resulting 
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aqueous solution was frozen at -80 °C and water was removed by lyophilization to yield 
white solids. NMR spectral data matched the literature.2,6,7 
 
Figure II-10: HPLC trace of apoptolidin A/isoapotolidin A purification 
 
Apoptolidin H fermentation procedure 
Plate Culture: 20 microliters of glycerol stock of Nocardiopsis sp. FU40∆ApoGT2 (also 
labeled as FU40∆412) was plated onto a Petri dish containing apramycin dosed Bennett’s 
medium and incubated upside down at 30 oC for 3 days. Dishes with spores can then be 
sealed with parafilm and stored at room temperature for up to 1 month for future use. The 
composition of apramycin dosed Bennett’s medium was as follows: yeast extract 1.0 g, 
beef extract 1.0 g, NZ amine A (casein digest) 2.0 g, glucose 10.0 g, agar 20.0 g per liter 
of deionized water. The pH of the medium was adjusted to 7.0 with 1 M HCl and 1 M 
NaOH. After autoclaving, the solution was cooled to near room temperature, 80 mg 
apramycin was added per liter and the resulting solution was poured into sterile Petri 
dishes (30 mL/dish). 
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Seed Culture: The production fermentation was initiated by aseptically inoculating one 
full loop of mycelia grown on Bennett’s agar plate into a sterile 50 mL Falcon tube 
containing 5 mL seed medium. The seed cultures were incubated for 4 days in a rotary 
shaker (170 rpm) at 30 °C. The composition of seed medium was as follows: soluble 
starch 10.0 g, molasses 10.0 g, peptone 10.0 g, beef extract 10.0 g per liter of deionized 
water. The pH of the medium was adjusted to 7.2 with 1 M HCl and 1 M NaOH. After 
autoclaving, the solution was cooled to room temperature, 80 mg apramycin was added 
per liter and the resulting solution was distributed into sterile 50 mL Falcon tubes (5 
mL/tube). Typically, for compound production, 20 tubes of seed culture were used.  
Production Culture and Extraction: Production culture and extraction procedure was 
identical to that used for apoptolidin A. No apramycin is added to the production media.  
Apoptolidin H/isoapoptolidin H Purification: The resulting residue from concentration 
of ethyl acetate extracts were dissolved in 3 mL of DMSO/1L culture and filtered through 
a 0.2 µm filter. The resulting DMSO solution was purified with preparative reverse phase 
HPLC (Gilson) with multiple 300 µL injections using a 4 minute gradient of 30-60% 
acetonitrile in water at a flow-rate of 30 mL/min with UV detection at 220 nm and a 
Phenomenex Luna column (100 Å, 50 x 21.20 mm, 5 µm C18). Apoptolidin A r.t.= 2.63 
min/ isoapoptolidin A r.t.=3.13 min. Fractions containing each product were combined 
into a round bottomed flask and concentrated (T < 31°) to remove acetonitrile. Resulting 
aqueous solution was frozen at -80 °C and water was removed by lyophilization to yield 
white solids.  
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Figure II-11: HPLC trace for apoptolidin H/isoapoptolidin H purification 
Apoptolidin H: 1H NMR (600 MHz, CD3OD): δ 7.36 (s, 1H), 6.19 (s, 1H), 6.18 (d, J = 
15.7 Hz, 1H), 5.69 (dd, J = 2.2, 9.1 Hz, 1H), 5.30 (d, J = 11.4 Hz, 1H), 5.23 (dd, J = 9.1, 
9.1, 1H), 5.21 (d, J = 9.0 Hz, 1H), 4.82 (d, J = 3.8 Hz, 1H), 4.09 (ddd, J = 2.1, 3.1, 7.9 Hz, 
1H), 3.83 (dd, J = 9.2, 9.2 Hz, 1H), 3.75 (ddd, J = 4.8, 6.3, 11.1 Hz, 2H), 3.72 (dd, J = 
9.2, 9.2 Hz, 1H), 3.58 (s, 3H), 3.54 (m, 2H), 3.44 (m, 1H), 3.40 (dd, J = 3.8, 9.8 Hz, 1H), 
3.37 (dd, J = 7.0, 7.0 Hz, 1H), 3.36 (s, 3H), 3.31 (ddd, J = 1.6, 1.6, 3.2, 1H), 3.29 (s, 3H), 
3.21 (dd, J = 4.7, 9.4 Hz, 1H), 3.17 (dd, J = 6.3, 9.4 Hz, 1H), 2.70-2.80 (m, 2H), 2.72 (dd, 
J = 29.1, 9.1, 1H), 2.46 (m, 1H), 2.18 (s, 3H), 2.16 (m, 1H), 2.12 (s, 3H), 2.05 (m, 1H), 
2.04 (m, 1H), 1.93 (s, 3H), 1.76 (m, 1H), 1.74 (m, 1H), 1.71 (m, 1H), 1.68 (s, 3H), 1.58 
(ddd, J = 2.6, 2.7, 5.4, 8.9 Hz, 1H), 1.48-1.55 (m, 1H), 1.37-1.45 (m, 1H), 1.29 (m, 1H), 
1.26 (d, J = 6.3, 3H), 1.03 (d, J = 6.7 Hz, 3H), 0.88 (d, J = 6.9 Hz, 3H); 13C NMR (150 
MHz, CD3OD): δ 172.6, 149.0, 147.1, 142.9, 141.2, 134.8, 133.4, 133.3, 133.2, 126.4, 
123.9, 101.2, 96.0, 87.5, 84.1, 83.8, 78.6,75.4, 74.9, 74.5, 73.7, 73.6, 72.3, 69.1, 68.2, 
68.1, 61.4, 61.0, 59.4, 40.7, 38.9, 38.5, 38.4, 36.5, 36.3, 24.6, 18.3(2), 18.2(6), 17.8, 16.5, 
14.0, 12.2, 12.0, 5.3; HRMS (ESI-TOF MS) m/z 863.4769 (M+Na)+ calculated for 
C44H72NaO15, measured 863.4766. 
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Isoapoptolidin H: 1H NMR (600 MHz, CD3OD): δ 7.34 (s, 1H), 6.04 (d, J = 15.8, 1H), 
5.97 (s, 1H), 5.47 (dd, J = 6.5, 8.8 Hz, 1H), 5.26 (dd, J = 8.8, 15.8 Hz, 1H), 5.07 (d, J = 
10.4 Hz, 1H), 4.94 (d, J = 2.4 Hz, 1H), 4.80 (d, J = 3.8 Hz, 1H) 4.45 (ddd, J = 2.0, 2.0, 
11.3 Hz, 1H), 3.86 (m, 1H), 3.78 (m, 1H), 3.76 (m, 1H),3.75 (m, 1H), 3.73 (m, 1H), 3.58 
(s, 3H), 3.49 (s, 3H), 3.47 (m, 1H), 3.40 (m,1H), 3.38 (s, 3H), 3.37 (m, 1H), 3.35 (m, 1H), 
2.75 (m, 1H), 2.72 (dd, J = 9.2, 9.2 H, 1H), 2..48 (m, 1H), 2.09 (s, 3H), 2.06 (s, 3H), 1.94 
(m, 1H), 1.6-1.8 (m, 4H), 1.73 (s, 3H), 1.71 (s, 3H), 1.42 (m, 1H), 1.39 (m, 3H), 1.25 (d, 
J = 6.2 Hz, 3H), 1.17 (d, J = 6.5 Hz, 3H), 1.05 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.9 Hz, 
3H) ; 13C NMR (150 MHz, CD3OD): δ 170.3, 147.1, 143.5, 141.0, 136.9, 134.2, 133.6, 
132.8, 132.7(9), 125.8, 124.9, 102.9, 96.2, 87.5, 84.0, 82.2, 78.4, 75.3, 74.9, 74.1, 73.7, 
73.3, 69.0, 68.1(6), 68.0(9), 67.8, 61.0, 60.0, 59.4, 40.7, 39.4, 38.0, 36.6, 36.0, 33.7, 25.4, 
18.4, 18.3, 17.9, 17.6, 13.4, 12.1, 12.0, 5.3; HRMS (ESI-TOF MS) m/z 863.4769 
(M+Na)+ calculated for C44H72NaO15, measured 863.4764. 
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 Spectra Relevant to Chapter 2 
 
 
Spectra II-1: The 600 MHz 1H and 150 MHz 13C NMR spectra of 2.7 in CD3OD 
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Spectra II-2: The 600 MHz 1H and 150 MHz 13C NMR spectra of 2.11 in CD3OD. 
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Spectra II-3: The 400 MHz COSY NMR of 2.11 in CD3OD 
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Spectra II-4: The 400 MHz HSQC NMR spectrum of 2.11 CD3OD 
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Spectra II-5: The 400 MHz HMBC NMR spectrum of 2.11 in CD3OD. 
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Spectra II-6: The 400 MHz NOESY NMR spectrum of 2.11 in CD3OD. 
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Spectra II-7: The 600 MHz 1H and 150 MHz 13C NMR of 2.23 in CD3OD. 
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Spectra II-8: The 400 MHz COSY NMR spectrum of 2.23 in CD3OD. 
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Spectra II-9: The 400 MHz HSQC NMR spectrum of 2.23 in CD3OD. 
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Spectra II-10: The 400 MHz HMBC NMR spectrum of 2.23 in CD3OD. 
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Spectra II-11: The 400 MHz NOESY NMR spectrum of 2.23 in CD3OD. 
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CHAPTER III  
 
Apoptolidin Biological Activity Studies 
 
 
Background: Previous Reports on Biological Activity 
A Cell Selective Cytotoxic Polyketide Natural Product 
 Apoptolidin’s reported selective and potent cytotoxicity in E1A transformed 
primary rat glia cells, compared to untransformed cells, has prompted significant study in 
several laboratories.1 Transformation with the E1A adenovirus oncogene is used to create 
a simplified model of cancer. E1A is a transcription regulator that increases expression of 
genes that promote rapid proliferation and inhibit protective apoptotic responses, 
effectively mimicking cancerous phenotypes 2 , 3 Using this model, apoptolidin was 
reported to induce apoptosis as indicated by chromatin condensation and DNA laddering.  
 Apoptolidin was later submitted for testing against the National Cancer Institute’s 
60-cell line panel (NCI-60) to determine if the observed potency and selectivity in rat 
models would track into human models of cancer.4 The resulting data showed a high 
level of cell line selective activity in this assay (Figure III-1). Indeed, apoptolidin was 
cited by Salomon et al to be “ranked in the top 0.1% most selective agents of the 37,000 
compounds screened up to that time” based on these data.5 To properly appreciate these 
results, it is important to understand the basics of the assay employed by the NCI in the 
60-cell line cancer panel.6,7 The NCI 60-cell line assay was developed to rapidly screen 
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compounds under a defined set of cell culture conditions to provide the most information 
possible, recognizing that this single set of conditions might lead to false positives and 
false negatives given the many possible mechanisms of cytotoxicity. This assay 
simultaneously assays for both cytotoxicity (a reduction in cell population after treatment 
compared to a t=0 measurement) and growth rate inhibition (a reduction in cell 
population due to treatment compared to a vehicle control) from a two day treatment at a 
single cell density per cell line. Under the conditions employed by the NCI, apoptolidin 
showed potent growth rate inhibition in select cell lines, but no cytotoxicity was observed 
at concentrations up to 10 µM in any of the lines tested.4  
 The Stanford research group indicated the pattern of activity of apoptolidin 
correlates with a family of highly cell line selective cytotoxic macrocyclic natural 
products (Figure III-2). These complex polyketides were isolated from diverse bacterial 
species, have different selectivity profiles in the NCI-60 and significantly different 
structures but all exert potent cytotoxicity in cancer cells under specific conditions. Some 
of these compounds have known targets that include both FoF1ATPase (oligomycin) and 
vaculoular ATPase (bafilomycin) but knowledge of the exact mechanisms of their 
selectivity and toxicity is poor. The identification of novel biological targets for the 
selective induction of cell death in cancer is highly desired in designing new 
therapeutics.8 While apoptolidin is expected to induce cell death through an apoptotic 
mechanism, mounting evidence suggests the possibility of alternative death pathways. 
Cell death is currently classified into three primary categories based upon biochemical 
and morphological hallmarks: necrosis, apoptosis, and autophagic cell death.9  
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Figure III-1: NCI-60 cell line screening results for apoptolidin A 
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Figure III-2: Cytotoxic macrocycles 
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 Apoptosis was initially described by Kerr et al in 1972 as a morphologically 
distinct form of cell death.10 This death is programmed and highly regulated in all 
eukaryotes. Apoptosis is an evolutionarily conserved pathway that is responsible for 
complex morphological changes ranging from the metamorphosis of insects and 
amphibians to human embryonic development. Apoptosis also occurs normally in mature 
organisms to both maintain cell populations in tissues and as a defense mechanism in 
immune response through the elimination of damaged cells resulting from disease, toxic 
agents or environmental stress. The highly regulated nature of this cytotoxicity and its 
dysregulation in diseases of neurodegeneration and cancer has prompted significant study 
to understand its mechanism.11  
 Apoptosis signaling results from the activation of various executioner caspases (3, 
6, and 7) by way of the activation of initiator caspases (2, 8, 9, and 10). Caspases are 
proteolytic enzymes that are constitutively expressed in the inactive procasepase form. 
The ability of each caspase to proteolytically activate other caspases quickly commits the 
cell to apoptosis upon receipt of a death signal. Upon activation, executioner caspases, 
most significantly caspase 3, begin to activate endonucleases that fragment chromosomal 
DNA and cause chromatin condensation.11 Depolarization of the plasma membrane is 
also observed, resulting in the external presentation of phosphatidylserine on the cell 
surface marking the cell for phagocytosis. Morphological features acompanying 
apoptosis include reduction in cell volume (pyknosis) and plasma membrane blebbing.9  
 A second, morphologically distinct form of cell death is necrosis. Classically, 
necrosis was described as accidental (as opposed to programmed) cell death. Growing 
evidence, however, suggests that necrotic cell death may involve regulated biochemical 
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reactions of its own, leading to the increased popularity of the term ‘necroptosis’ to 
indicate programmed necrosis.12,13 The biochemical reactions involved in necrosis are 
still poorly understood, making it difficult to positively confirm necrosis through a 
biochemical assay. Because of this, necrosis can only be implicated by the absence of 
data to suggest an alternative cell death (e.g. apoptosis or autophagy). While the most 
common causes of necrosis appear to be interference with cellular energy supply or direct 
damage to the plasma membrane, diverse stimuli can also induce necrosis including 
many of the stimuli associated with apoptosis induction. Morphologically, necrosis is 
characterized by cytoplasmic swelling, plasma membrane rupture, swelling of 
cytoplasmic organelles as well as moderate chromatin condensation.9  
 Finally, cell death has also been implicated to be the result of macroautophagy 
called autophagic cell death. 14  Autophagy is a catabolic cellular process whereby 
specialized vesicles are formed, called autophagosomes, which engulf organelles and 
macromolecules to be broken down by lysosomes to regenerate cellular building blocks. 
Not surprisingly, autophagy is known to have a protective role when stimulated by 
nutrient deprivation.15 Autophagic cell death is defined as cell death that is accompanied 
by massive autophagic vacuolization but occurs without chromatic condensation.9  
 The observed cytotoxicity of apoptolidin was initially attributed to apoptosis due 
to observed DNA laddering and chromatin condensation in E1A transformed rat glia 
cells.1 While experiments with human cancer cell lines have shown potent cytotoxicity 
under specific conditions with select cell lines (vida infra) and indicate the central 
importance of mitochondria in this toxicity, little evidence exists to indicate that that the 
toxicity is the result of apoptosis. A careful analysis of what is currently known about the 
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mechanisms of apoptosis, the best characterized of the three principle forms of cell death, 
and specifically those initiated by the mitochondria helps to appreciate the details of these 
results.  
Known Mechanisms of Apoptosis Induction 
 Two pathways for apoptosis initiation have been identified, namely the extrinsic 
(death receptor) and the intrinsic (mitochondrial) pathways. The extrinsic pathway is 
initiated in response to the binding of an extracellular death ligand to one of several death 
receptors (typically members of the tumor necrosis factor TNF family) at the cell surface. 
This binding results in the recruitment and activation of the initiator procaspase 8.11 
Alternatively, the intrinsic pathway is initiated by the release of various proapoptotic 
factors from within the mitochondria, most notably cytochrome C (cyt c). The release of 
cytochrome C and other mitochondrial apoptosis initiator proteins occurs in response to 
many stimuli including but not limited to reactive oxygen species (ROS), DNA damage, 
radiation and viral infections.11 Release of cytochrome c from the mitochondria results in 
the activation of the initiator procaspase 9, beginning the proteolitic cascade that results 
in apoptosis. Initial results of experiments on the activity of apoptolidin by Salomon et al 
confirm that apoptolidin acts upon a mitochondrial target (vida infra).4,16  
 In addition to their ability to initiate programmed cell death through apoptosis, the 
mitochondria are responsible for many vital processes in cell survival and proliferation.17 
One of the primary roles of the mitochondria is energy production through the synthesis 
of ATP by oxidative phosphorylation. The mitochondria also house key enzymes 
involved in the biosynthesis of heme, steroids, fatty acids and Fe/S clusters. Mitochondria 
are involved in the metabolism of some amino acids, contain all enzymes of the Krebs 
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cycle and are responsible for calcium homeostasis in the cell.18 Dysregulation of many of 
these processes or of cytosolic protein concentrations can result in mitochondrial 
membrane permeabilization (MMP) and subsequent apoptosis signaling. MMP results in 
the dissipation of the mitochondrial membrane potential (Δψm) thereby halting ATP 
synthesis, which leads to the release of mitochondrial proteins that trigger apoptosis. 
There are two known mechanisms for MMP19 that result in the induction of apoptosis 
from the mitochondria (Figure III-3). 
 A well-characterized pathway for mitochondrial apoptosis regulation is mediated 
by the Bcl-2 family of proteins. Bcl-2 proteins are divided into three subcategories: Bax-
like (pro-apoptotic), Bcl-2-like (anti-apoptotic) and BH3-only (BH=bcl-2 homology 
domain).20 The Bax-like proteins consist of membrane permeable moieties and with the 
assistance of certain BH3-only proteins can oligomerize and insert into the outer 
mitochondrial membrane (OMM) to form pores (Figure III-3, top).21 These pores allow 
for the release of cyt c from within the mitochondria and thereby initiate the apoptotic 
cascade. The Bcl-2-like proteins can bind to the Bax-like proteins and prevent their 
oligomerization. Therefore, a careful balance in the concentration of these proteins in 
favor of the anti-apoptotic proteins must be maintained in the cytosol in order for cells to 
survive but still be responsive to apoptotic signals that increase pro-apoptotic factors. In 
many cancer cells, the ratio of anti-apoptotic/pro-apoptotic Bcl-2 proteins is 
disproportionally high, making them resistant to apoptosis.22  
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Figure III-3: Known mechanisms for mitochondrial apoptosis initiation 
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mitochondria. Closure of VDAC is thought to lead to the formation of the mitochondrial 
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 Apart from apoptosis initiation, a primary role of the mitochondria is glucose 
metabolism and ATP generation through oxidative phosphorylation. Apoptolidin is 
proposed to initiate cell death in select cancer cell lines by acting upon a mitochondrial 
target. Among the most significant differences between cancerous and healthy cells is a 
common reprogramming of glucose metabolism known as the Warburg effect. To 
understand the cell line selectivity of apoptolidin’s potent cytotoxicity, one must consider 
the metabolic changes commonly associated with cancerous cells. 
Metabolic Reprogramming 
 Among the most common traits of cancer cells is an observed preference for 
aerobic glycolysis commonly referred to as the Warburg effect.26 Typically, per the 
Pasteur hypothesis, mammalian cells prefer to produce ATP primarily through the 
energetically more efficient mitochondrial (oxidative phosphorylation) pathway. Under 
hypoxic (anaerobic) conditions, glycolysis by the less efficient Embden-Meyerhof 
pathway is preferred (Figure III-4). Cancer cells, however, prefer glycolytic 
fermentation of glucose to lactate despite the much greater efficiency of oxidative 
phosphorylation with respect to glucose consumption.27 Aerobic glycolysis yields only 
~4 molecules of ATP per molecule of glucose, whereas oxidative phosphorylation gives 
~36 molecules of ATP per glucose molecule.28 Warburg initially hypothesized that this 
preference was due to mutations that caused a defect in mitochondrial respiration,29 
however it has been shown that most cancer cells do not have impaired mitochondrial 
function.30  
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Figure III-4: Glucose Metabolism Pathways 
 
 The primary reason for this preference for aerobic glycolysis is made apparent by 
the observation that non-cancerous proliferating tissues also display a preference for 
aerobic glycolysis.17 Cells driven to rapid proliferation are understood to generate ATP 
through glycolysis because it allows for more efficient use of glucose in the anabolism of 
other building blocks (amino acids, lipids, etc) required for cellular replication (Figure 
III-4). Regardless of the mode of metabolism, neither ATP generation nor glucose 
availability is typically a limiting factor to drive selection for rapidly proliferating 
mammalian cells. However, due to the constant presence of growth promoting stimuli in 
cancer cells, factors that contribute to rapid proliferation do drive selection. Moreover, a 
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balance of the ratio of ATP/ADP must be maintained within the cell for production of 
NADH and acetyl-CoA (vital for macromolecular biosynthesis). Reliance on oxidative 
phosphorylation for ATP generation would tip this balance to greatly favor ATP in order 
to anabolize a comparable amount of these building blocks and effectively slow 
proliferation. Studies have also shown that lactate waste excreted by cancer cells can be 
reabsorbed and further catabolized in some cases. 31  Furthermore, cancerous cells 
frequently proliferate at a rate that exceeds the rate of angiogenesis, thus decreasing the 
availability of oxygen.  
 There are other factors that make the Warburg effect desirable for cancer cells, 
particularly in protection from the damaging effects of reactive oxygen species (ROS). 
Oxidative phosphorylation is the primary cellular source of ROS. Indeed, it is estimated 
that 2% of molecular oxygen used in respiration is converted into superoxide (O2•-).32 
ROS production can trigger the detachment of cyt c (typically membrane bound by way 
of cardiolipin) from the IMM. Furthermore, ROS can affect the activation of Bax and 
allow for MMP and subsequently apoptosis initiation. The formation of ROS in the 
mitochondria also hazardous to mitochondrial DNA (mtDNA).33 This DNA contains the 
genes of many vital mitochondrial proteins and is, as a result of the highly oxidized 
environment of the mitochondria, easily damaged. Damage to mtDNA can in turn cause 
mitochondrial protein dysfunction and result in further ROS production. Increased ROS 
production can also reduce cell proliferation rates.34 ROS production is known to be 
exacerbated under hypoxic conditions. The drastic reduction in the activity of oxidative 
phosphorylation helps to contribute to the stability of the cell with respect to apoptosis as 
well as protecting the cell from self-damaging ROS production.  
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 In order to study these metabolic pathways, a few key enzymes have been 
identified as “switches” between aerobic glycolysis (Figure 2.5) and mitochondrial 
respiration including lactate dehydrogenase (LDH) and pyruvate kinase (PK). PK 
catalyzes the conversion of phosphoenolpyruvate (PEP) and ADP into pyruvate and ATP. 
Pyruvate kinase is known to exist in two distinct isoforms designated M1 and M2.35 The 
M2 form is expressed in many forms of embryonic cells, but PK-M1 is the isoform most 
commonly expressed in differentiated tissues. All cancer cells express PK-M2, and PK-
M2 expression has long been a biomarker for malignancy.36 Active PK exists as a 
homotetramer and has a known allosteric modulation site with a natural modulator, 
fructose-1,6-bis-phosphate (FBP). However, in cancer cells, PK-M2 exists as a dimer that 
shows greatly reduced activity. This reduced activity is thought to cause a preference for 
glycolysis and a backup in previous steps of glucose metabolism, allowing redirection of 
intermediates into anabolic pathways like the pentose phosphate shunt (Figure III-4).  
 Another indication of the Warburg effect is up-regulation of hypoxia-inducible 
factor 1 subunit alpha (HIF-1α) despite the presence of oxygen (common among many 
cancers).37 HIF-1β is constitutionally expressed in cells, and the α subunit is expressed in 
response to hypoxic conditions. When both subunits are present, they complex to form 
active HIF-1.38 HIF-1 activation causes many cellular signals including the induction of 
genes controlling angiogenesis, glucose metabolism, and cell proliferation and the 
activation of proteins involved in glycolysis.  
 The mitochondria of cancer cells have key differences relative to mitochondria of 
normal differentiated cells, both in metabolic activity and apoptosis regulation. While 
many of the known differences help to contribute to stability and proliferation rates, the 
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existence of such differences may allow for the identification of novel therapeutic targets 
for the treatment of cancer. Apoptolidin A has been stated to induce cell death in multiple 
cancer cell lines. Some preliminary studies have been undertaken to determine the 
mechanism of this activity, but more work remains to be done in order to detail the 
mechanism of cell death and identification of a apoptolidin’s cellular target. 
FoF1ATPase: A Target of Apoptolidin? 
 Initial studies on the mechanism of action of apoptolidin’s selective cytotoxicity 
was undertaken by Salomon et al (Stanford University). These studies ultimately 
concluded that apoptolidin’s activity was associated with its inhibition of F0F1-ATPase. 
Furthermore, the observed cell line selectivity was attributed to metabolic differences 
among cancer cell lines.4,16 A few inconsistencies among data reported for apoptolidin 
suggests a more significant molecular target may exist.  
 The Stanford group’s investigations began with pharmacological experiments to 
determine the mechanism of cell death induction by identifying the dependency of the 
toxicity on specific proteins.16 The first such experiment was on the dependence of cell 
death on p53, a protein responsible for inducing the pro-apoptotic gene bax. To determine 
the dependence on p53 status, HCT116 wild type and p53 null cells were each treated 
with apoptolidin A. Similar growth inhibition was observed for both cell lines, indicating 
that this activity was independent of p53 status. The key role of Bcl-2 proteins in 
mitochondrial apoptosis signaling pathways prompted experiments to determine the 
significance of these proteins in apoptolidin induced toxicity. To this effect, LYas cells 
(wild type do not have bcl-2) were transfected with bcl-2 and the resulting cells were 
compared to wild type for apoptolidin sensitivity. Bcl-2 overexpression was found to 
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make cells completely resistant to apoptolidin induced toxicity, as measured by Annexin 
V. Furthermore, cells were found to become completely resistant to apoptolidin by co-
treatment with a caspase-9 inhibitor, suggesting a mitochondrial apoptosis initiation 
pathway. These experiments show that apoptolidin cytotoxicity is independent of p53 
expression, inhibited by the expression of anti-apoptotic Bcl-2 proteins and caspase-9 
dependent.  
 The Stanford group further suggested structural similarities between apoptolidin, 
oligomycin, and bafilomycin (Figure III-2). Oligomycin is a known inhibitor of F1Fo-
ATPase and bafilomycin is a selective inhibitor of vacuolar ATPase; both have known 
cytotoxicity. Furthermore, they noted some overlap in the cytotoxicity profiles from the 
NCI-60 assay of oligomycin with other macrolactones such as cytovaricin and ossamycin, 
proposed inhibitors of F1Fo-ATPase. Based on this comparison, apoptolidin was tested in 
mitochondrial preparations from yeast and determined to be an inhibitor of FoF1-ATPase 
with a Ki of 5 µM.16  
 To investigate the means by which inhibition of FoF1-ATPase might lead to 
selective cytotoxicity, they further noted similarities in gene expression profiles for 
known F0F1-ATPase inhibitor cytovaricin within the NCI-60.13 Specifically within 
leukemia cell lines in the NCI-60, cytovaricin was found to be most active in lines that 
had increased expression levels of PK and aspartate aminotransferase (AAT) and 
decreased expression of HIF-1α. These expression profiles indicate a preference for 
mitochondrial ATP production, rather than aerobic glycolysis. Based on this fact, he 
hypothesized that inhibitors of F1Fo-ATPase might be inducing apoptosis in cells that rely 
heavily on the mitochondria for glucose metabolism.  
  139 
 To further evaluate this hypothesis, cells were co-treated with apoptolidin and 
glycolysis inhibitors 2-deoxyglucose or oxamate. 2-deoxyglucose is known to inhibit 
glucose transport while oxamate is a known inhibitor of lactate dehydrogenase (LDH) 
preventing lactate formation that results in a shift in preference towards mitochondrial 
respiration. Co-treatment of Jurkat cells with either compound (50 mM) and apoptolidin 
(1 µM) showed a strong increase in sensitivity to apoptolidin induced cell death. 
Furthermore, assays were preformed that showed similar sensitization of nine different 
cell lines to apoptolidin induced apoptosis, including lines that were otherwise resistant. 
While these studies do not confirm the exact mechanism of action of apoptolidin, they do 
provide good evidence that cell death is induced in the mitochondria and show a 
requirement for reliance on mitochondrial respiration over glycolysis in order to observe 
apoptolidin cell sensitivity.  
Structure Activity Relationships of Apoptolidins 
 Many of the apoptolidin analogues that have been either isolated from 
fermentation (apoptolidins A-G) or produced by total synthesis and semisynthesis have 
been evaluated for cytotoxicity. The various research groups involved in these studies 
have produced data from different assays, cell lines, and conditions but have lead to some 
basic definitions of apoptolidin SAR (Table III-1). 
 Apoptolidin A has been tested in cell viability assays against multiple cell lines 
and typically has an EC50 in the low nanomolar range (~10-20 nM). While the Stanford 
group’s initial report on apoptolidin A measured an IC50 of 5 µM for F1FoATPase 
inhibition, subsequent analysis has resulted in reports as low as 0.7 ± 0.5 µM. In cell 
viability assays on H292 human lung cancer cells, apoptolidins B and C show 
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comparable activity to the parent compound. 39  Apoptolidin D, 40  E 41  and the 
photoisomerized apoptolidin G42 all show only moderately reduced activity in cell 
viability assays. Apoptolidin F, which is missing the C27 disaccharide moiety, is notably 
less potent than apoptolidin A.41 The ring expanded isoapoptolidin A showed potent 
activity in cell viability assays on Ad12-3Y1 cells but minimal activity in ATPase 
inhibition. 43  This difference in potency can be attributed to the equilibration of 
isoapoptolidin to apoptolidin during the lengthy cell viability assays (2-4 days) but 
minimal conversion during the short time course (~30 min) of the ATPase inhibition 
assay.  
 Evaluation of synthetic and semisynthetic apoptolidin congeners has added 
significantly to knowledge of the structure-activity relationships (Table III-1). Selective 
modification of the hydroxyl group array at multiple positions by Wender showed a 
minimal effect on activity in both cell based and ATPase assays.43 Conversely, 
peracetylation of apoptolidin A hydroxyl groups resulted in a complete loss in ATPase 
inhibition.44 Evaluation of the C27 deglycosylated apoptolidin A 2.11, prepared by 
Nicolaou and coworkers, in cell viability assays with 1A9 human ovarian carcinoma cells 
showed a significant loss (~48 X) in activity compared to apoptolidin A (IC50 240 µM in 
this cell line).45 While C9 deglycosylated apoptolidin D 2.17 showed minor reduction in 
potency in cell viability assays.46 Synthetic aglycones (apoptolidinones) showed complete 
loss of cytotoxic activity.47 Analysis of macrolide fragments such as 2.13 all showed a 
significant (~215 X) loss in activity from cell based assays accompanied by a relatively 
small loss (~23 X) in ATPase inhibition. Finally, the lactone fragment 2.22 produced by 
oxidative cleavage of apoptolidin A was found to be completely inactive in both assays.43 
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Compound EC50 (nM) Ki (µM) 
Apoptolidin A (2.1) 13* 0.7 
Apoptolidin B (2.2) 7* n/a 
Apoptolidin C (2.3) 24* n/a 
Apoptolidin D (2.4) 110* n/a 
Apoptolidin E (2.5) < 100* n/a 
Apoptolidin F (2.6) > 10x Apo A* n/a 
Apoptolidin G (2.7) 150* n/a 
Isoapoptolidin A (2.8) 9‡ 17 
Selectively Acylated (2.21) 56‡ 0.8 
Peracetylated (2.19) n/a >100 
C27 Hydroxyapoptolidin A (2.11) 11,500† n/a 
Apoptolidin D disaccharide (2.17) 200* n/a 
Apoptolidinone A (2.14) >10,000*  
Macrolide Fragment (2.13)  1,400‡ 16 
Lactone Fragment (2.22) >12,000‡ 190 
Table III-1: Apoptolidin structure activity relationships (*H292 Human Lung Carcinoma, 
†1A9 Human Ovarian Carcinoma, ‡AD12-3Y1) 
 
 These data, taken together, shed some light on the importance of specific 
structural features in biological activity. First, minor modifications to the macrocyclic 
core are tolerated (shunt metabolites and selective hydroxyl group acylation) while more 
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significant modifications are not (peracetylation). Second, the C9 sugar can be either 
modified or removed to retain significant biological activity while the C27 disaccharide 
appears to be requisite for cellular activity. The relatively minor loss in ATPase activity 
of fragments such as 2.13 compared to the loss of toxicity indicates that the C27 
disaccharide moiety might be important for cellular transport and not for target binding.47 
Alternatively, such discrepancies in activity might indicate that the most significant 
biological target may not actually be the F1FoATPase. Structure activity relationships are 
somewhat challenging to analyze due to the multiple cell lines and assays used in these 
experiments.  
 The large difference in the EC50 for cytotoxicity in cell based assays (10-20 nM) 
and the Ki for enzyme inhibition (~1-4 µM) further call to question the validity of the 
F1FoATPase as the most significant biological target of apoptolidin. Furthermore, the 
cytotoxicity of apoptolidin is expected to occur by the same mechanism as oligomycin. 
However, unlike apoptolidin, oligomycin’s activity is not prevented by capsapse 9 
inhibitors.48 This target fails to account for the selectivity of apoptolidin towards cancer 
models over untransformed cells (typically preferring oxidative phosphorylation) as 
originally reported by Seto and Hiyawaka.1 Finally, none of the data to date from human 
models of cancer definitively confirm that apoptotic signaling is responsible for the 
cytotoxicity. Caspase inhibition and Bcl-2 overexpression experiments were performed 
on LYas (mouse) cells. While Salomon et al performed multiple assays using an Annexin 
V readout, any Annexin V staining was always either accompanied by propidium iodide 
staining (indicating necrosis) or data from propidium iodide staining was not reported. 
Such inconsistencies and unanswered questions have prompted our investigations into 
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apoptolidin biological activity to quantify apoptolidin cytotoxicity, understand the 
requirements for this cytotoxicity and identify the mechanism of cell death. 
 
Results: Investigations in the Sulikowski Lab 
Cytotoxicity of Apoptolidins 
 We began our investigations of apoptolidin biological activity with experiments 
aimed to replicate the reported potent cytotoxicity in cancer cell lines. Initially, these 
experiments were carried out by our collaborators in the Marnett lab. Using their standard 
cell viability assay conditions, only growth inhibition was observed in H292 cells 
(Figure III-5, A). In these experiments, cells were treated with various apoptolidin 
concentrations at ~20% confluence for 48 hours then assayed for cell viability compared 
to a vehicle control employing a tetrazole based (MTT or WST) colorimetric assay.49 A 
similar growth inhibition result was observed when cells were treated at very low 
confluence for seven days (Figure III-5, B). In both of these conditions a cytostatic 
effect was observed but there was no apparent cytotoxicity. However, when cells were 
grown to near confluence before treatment with apoptolidin, a cytotoxic effect was 
observed at concentrations similar to those previously reported (Figure III-5, C).39 
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Figure III-5: Preliminary data from apoptolidin testing 
 
 When we started to perform these experiments in our lab, challenges with 
reproducibility were initially encountered. We identified the problem as difficulty in 
objectively measuring cell confluence at the time of treatment. To eliminate variability in 
this measurement, a standard protocol was developed based upon plated cell number. 
Cells were plated in 96-well plates at 10, 15, 20 and 25 thousand cells per well, allowed 
to attach for 16 hours, then treated with apoptolidin A. After four days, cells from each 
condition were assayed for cell viability compared to a vehicle control using the MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay. These 
data indicated that 25,000 cells/well was the optimal plating conditions for reproducibly 
H292 Cell Viability with Apoptolidin A
(Std Assay: 48 hour treatment)
0 2 4 6 8 10
0
20
40
60
80
100
120
Apoptolidin A [!M]
%
 V
ia
b
ili
ty
 C
o
m
p
a
re
d
 t
o
 C
o
n
tr
o
l
H292 Cell Viability with Apoptolidin A
(Low Density Assay: 7-day treatment)
0 2 4 6 8 10
0
20
40
60
80
100
120
 !C
50
 = 65 n"
Apoptolidin A [!M]
%
 V
ia
b
ili
ty
 C
o
m
p
a
re
d
 t
o
 C
o
n
tr
o
l
H292 Cell Viability with Apoptolidin A
(High Density Assay: 4-day treatment)
0 2 4 6 8 10
0
20
40
60
80
100
120
!C
50
 = 35 n"
Apoptolidin A [!M]
%
 V
ia
b
ili
ty
 C
o
m
p
a
re
d
 t
o
 C
o
n
tr
o
l
A  B 
C 
  145 
observing apoptolidin induced cytotoxicity in H292 cells. When cells were treated with 
apoptolidin at a lower cell number, a uniform reduction in cell growth rate was observed. 
With these optimized conditions, we were able to quantify the cytotoxicity of apoptolidin 
and any derivatives. Apoptolidin A was found to have an EC50 of 13 nM in this assay 
(Figure III-7). Apoptolidin H isolated from mutant Nocardiopsis sp. FU40∆G2 had an 
EC50 in this assay of 600 nM, ~46 times less potent.  
 
 
Figure III-6: Apoptolidin cell density assay 
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Figure III-7: Apoptolidin A and H H292 cell viability assay 
 
 We were intrigued by the unusual dependency of cytotoxicity on cell density. 
H292 cells are not among the cells in the NCI’s 60 cell line panel assay nor were they 
among those co-treated by the Stanford group with glycolytic inhibitors to induce 
apoptolidin sensitivity. This cell line was chosen due to its prevalent use in the Wender 
laboratory for testing of apoptolidin shunt metabolites (Apoptolidin B-F) and in SAR 
studies. Interestingly, the same effect of cell density was observed in this cell line for 
oligomycin A (Figure III-8) giving credence to reports that the two compounds share a 
common target and mechanism.  
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Figure III-8: Oligomycin cell density requirement 
 
 Based upon the previous reports for the dependency of apoptolidin cytotoxicity on 
metabolic preference for oxidative phosphorylation, we hypothesized that these cells 
were undergoing a metabolic shift as they neared confluence. We thought that within the 
experimental constraints of a 96-well plate, the cells could sense that they were unable to 
continue to rapidly proliferate when grown to confluence (proliferation contact 
inhibition) and respond by shifting glucose metabolism from aerobic glycolysis to 
oxidative phosphorylation, enhancing sensitivity to apoptolidin.50 We wondered if we 
could induce the potent cytotoxicity by creating this sort of metabolic shift at low cell 
density, in a similar way to that employed by Salomon et al. Instead of using inhibitors of 
glycolysis, we instead investigated the use of recently reported PK-M2 activators. A 
highly activated PK-M2 should, in theory, mimic the activity of the more active isoform 
PK-M1 and thereby increase metabolic flux into the mitochondria. Recent reports have 
identified potent allosteric activators of PK-M2 (Figure III-9).51 
 
A B 
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Figure III-9: PK-M2 allosteric activators 
 
 To test our hypothesis, cells were treated with each activator as well as with 
apoptolidin under the seven day, low cell density assay conditions. First, neither activator 
was shown to influence growth significantly in the absence of apoptolidin (up to 10 µM, 
data not shown). Second, a significant difference was observed in the growth inhibition 
activity of apoptolidin at 16 nM in the presence of 80 nM PK-M2 activator (Figure 
III-10). Indeed, at 16 nM, apotolidin alone only inhibited 18.6% cell growth, but when 
co-dosed with PK-M2 activator 3.2 at 80 nM, 48.9% growth inhibition was observed. 
While increased sensitivity to apoptolidin was observed in these experiments resulting in 
increased growth inhibition, we did not observe the potent cytotoxic effects observed in 
the high cell density experiments. It is possible that PK-M2 activation by these 
compounds is not sufficient to facilitate a complete switch to mitochondrial respiration 
required for cytotoxicity.  
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Figure III-10: PKM2 activator co treatment results 
 
  We have developed assay conditions to quantify the activity of apoptolidin 
natural products as well as unnatural apoptolidin congeners prepared by semisynthesis or 
mutasynthesis in H292 human lung carcinoma cells. In doing so, we observed a 
dependency of cytotoxicity on high cell density conditions. A similar result was observed 
for oligomycin, a known inhibitor of the F1FoATPase. Metabolic profiling studies on 
HepG2 cells indicate that at low cell density, glucose consumption is strongly correlated 
with lactate production but this relationship was lost at cell densities nearing 
confluence. 52  These results appear to indicate a shift from aerobic glycolysis to 
mitochondrial respiration for ATP production as cell density reaches a maximum for 
some cell lines. Such cell density based contact inhibition effects are stronger and more 
common among primary tissue cultures than in cell lines, likely contributing to the cell 
line selectivity of apoptolidin and other inhibitors of mitochondrial ATP synthesis. Future 
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work in this area will involve testing in additional cell lines reported to be sensitive or 
resistant to apoptolidin by the NCI at high and low cell densities. For example, testing in 
similar pairs such as the adenocarcinomas MCF-7 (sensitive) and MDA-MB-231 
(insensitive) would reveal if high cell density enhances sensitivity in these cell lines as 
well.  
 The Stanford group demonstrated that many cell lines gain sensitivity to 
apoptolidin by co-treatment with inhibitors of glycolysis. Allosteric activation of PKM2 
with small molecules was insufficient to induce cell death at low cell densities in H292 
cells. Inhibition of both glycolytic and mitochondrial ATP production would result in 
cellular energy crisis leading to the reported cell death. Activation of PKM2 may allow 
for sufficient ATP synthesis for survival via aerobic glycolysis when mitochondrial 
respiration is inhibited by apoptolidin but leads to the observed reduction in growth rate. 
A massive reduction in cellular ATP is implicated as a cause of both necrosis and 
apoptosis. This knowledge coupled with the lack of definitive data confirming apoptosis 
induction by apoptolidin in human cancer cell lines prompts further investigation to 
determine the mechanism of apoptolidin induced cytotoxicity. 
Toxicity Through Apoptosis or Necrosis  
 To assay for apoptosis signaling in H292 cell lines as a response to treatment with 
apoptolidin, we employed a standard Annexin V and propidium iodide (PI) staining assay 
for use in fluorescence assisted cell sorting (FACS) experiments. Annexin V selectively 
binds to lipoproteins, and is covalently bound to a fluorophore (FITC) for use in FACS. 
As Annexin V is not cell permeable, positive signal from this fluorophore can be 
attributed to external presentation of phosphatidyl serine, an early hallmark of apoptosis. 
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Propidium iodide is used as a complimentary probe to detect cell death through other 
mechanisms. PI can intercalate into DNA but only when the plasma membrane is 
sufficiently compromised. In these experiments, cells undergoing apoptosis are positive 
for Annexin V staining but negative for PI, as disruption of the plasma membrane can 
allow Annexin V to stain internal phosphatidyl serine.  
 H292 cells were plated at high cell density in 6-well plates and treated with 
apoptolidin A and H at concentrations from 1 nM to 1 µM for one to four days. The cells 
were then detached from the plates using by proteolitic digestion with trypsin and 
resuspended in media. After washing with phosphate buffered saline (PBS), cells were 
suspended in binding buffer and treated with PI and Annexin V-FITC then analyzed by 
FACS. No statistically significant difference was observed between one or two day 
treatments with either compound at any concentration and vehicle control. However, 
three and four day treatments showed no surviving cells when treated with apoptolidin A 
at 100 nM or more. Indeed, in these experiments almost no intact cells were observed 
(Figure III-11). 
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Figure III-11: Annexin V-FITC (X-axis) and propidium iodide (Y-axis) FACS results 
from 100 nM treatment with apoptolidin A and H for two and three days 
 
As cells have been reported to undergo apoptosis rapidly (as quickly as two 
hours) we next assayed at more time points. First, a 60 hour treatment gave similar results 
to a two day treatment, suggesting that apoptosis was occurring between 60 and 72 hours. 
Experiments with treatments at two hour increments between 60 and 72 h failed to show 
any significant Annexin V-FITC staining. Again treated cells were either identical to 
control or only debris was collected. We observed that in conditions where treatment 
resulted in the collection of debris alone, the cells required a significantly longer 
treatment with trypsin to detach. Attempts at manual cell lifting, however, gave PI and 
Annexin V-FITC positive cells in vehicle controls.  
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 The lack of data supporting apoptosis as a cell death pathway is insufficient to 
confirm that the cells are undergoing necrosis. Future studies should include Western blot 
experiments for caspase activation and additional cell sorting assays to sufficiently 
confirm or refute apoptosis. Additionally, these experiments should be performed on 
other cell lines known to be sensitive to apoptolidin. Both apoptolidin A and H have been 
submitted for testing by a collaborating group to determine if they are able to induce 
autophagy.  
 
Experimental Methods 
MTT Cell Viability Assay for Cell Density Requirement: Low passage (P#<25) H292 
human lung carcinoma cells (obtained from the American Type Culture Collection, 
ATCC) were plated at 5, 10, 15, 20 or 25 thousand cells per well in 96-well plates in 100 
µL of RMPI 1640 medium containing 10% fetal bovine serum and 100 IU penicillin and 
100 mg/mL streptomycin and incubated for 16 hours to attach. Apoptolidin A was 
dissolved in DMSO at1 µM, 10 µM, 100 µM and 1 mM. The resulting DMSO stock 
solutions were diluted in complete RPMI medium 1000:1 to yield medium solutions 
containing 1 nM, 10 nM, 100 nM, and 1 µM apoptolidin A or DMSO to give a final 
DMSO concentration of 0.1%. Media was removed from each well by aspiration and 
replaced with media containing DMSO vehicle or apoptolidin A for a total of n=4 wells 
per cell density and concentration. Cells were incubated for four days (96 hours). The 
media from each well was then aspirated and replaced with 100 µL of complete RPMI 
medium containing 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) at 0.5 mg/mL and returned to the incubator at 37 °C for two hours. Media from 
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each well was aspirated and replaced with 100 µL DMSO. Absorbance was measured at 
560 nM using a GloMax Multiplate reader (Promega, Madison, WI, USA). Blank 
absorbance from the average of 8 wells treated with MTT in cell-free medium was 
subtracted from each value. The percent cell viability of each well was calculated as the 
fraction of the average absorbance of DMSO control treated cells at each condition and 
data was plotted in Figure III-6.  
Standard MTT Cell Viability Assay: Low passage (P#<25) H292 human lung 
carcinoma cells were plated at 25,000 cells per well in 96-well plates in 100 µL of RMPI 
1640 medium containing 10% fetal bovine serum and 100 IU penicillin and 100 mg/mL 
streptomycin and incubated for 16 hours to attach. Compounds used for testing were 
dissolved in DMSO at various concentrations from 1 µM to 10 mM. The resulting DMSO 
stock solutions were diluted in complete RPMI medium 1000:1 to yield medium 
solutions containing 1 nM to 10 µM of the respective compound to be assayed and a 
uniform DMSO concentration of 0.1%. Media was removed from each well by aspiration 
and replaced with media containing DMSO vehicle or compound for a total of n=8 wells 
per concentration. Cells were incubated for four days (96 hours). The media from each 
well was then aspirated and replaced with 100 µL of complete RPMI medium containing 
MTT at 0.5 mg/mL and returned to the incubator at 37 °C for two hours. Media from 
each well was aspirated and replaced with 100 µL DMSO. Absorbance was measured at 
560 nM using a GloMax Multiplate reader (Promega, Madison, WI, USA). Blank 
absorbance from the average of 8 wells treated with MTT in cell-free medium was 
subtracted from each value. The percent cell viability of each well was calculated as the 
fraction of the average absorbance of DMSO control treated cells. Data was plotted 
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GraphPad Prism 5 and fitted with a non-linear regression curve. Effective concentration 
50 (EC50) was estimated graphically as the concentration at which 50 % of control 
formazan product absorbance was detected.  
Standard WST Cell Viability Assay: Low passage (P#<25) H292 human lung 
carcinoma cells were plated at 25,000 cells per well in 96-well plates in 100 µL of RMPI 
1640 medium containing 10% fetal bovine serum and 100 IU penicillin and 100 mg/mL 
streptomycin and incubated for 16 hours to attach. Compounds used for testing were 
dissolved in DMSO at various concentrations from 1 µM to 10 mM. The resulting DMSO 
stock solutions were diluted in complete RPMI medium 1000:1 to yield medium 
solutions containing 1 nM to 10 µM of the respective compound to be assayed and a 
uniform DMSO concentration of 0.1%. 90 µL of media was removed from each well by 
multichannel micropippeter and replaced with 100 µL of media containing DMSO 
vehicle or compound for a total of n=8 wells per concentration. Cells were incubated for 
four days (96 hours).Viability was measured by adding 10 µL Cell Proliferation Reagent 
WST-1 to each well then incubating for 1 hour at 37 °C. Absorbance was measured at 
450 nm less reference absorbance at 690 nm using a VERSAMax (Molecular Devices) 
96-well plate reader. Blank absorbance from the average of 8 wells treated with WST-1 
in cell-free medium was subtracted from each value. The percent cell viability of each 
well was calculated as the fraction of the average absorbance of DMSO control treated 
cells. Data was plotted GraphPad Prism 5 and fitted with a non-linear regression curve. 
Effective concentration 50 (EC50) was estimated graphically as the concentration at 
which 50 % of control formazan product absorbance was detected. 
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Annexin V/ Propidium Iodide FACS Assay: Low passage (P#>25) H292 human lung 
carcinoma cells were plated at either 700,000 cells per well (Low density) or 1,200,000 
cells per well (high density) in 6-well plates in 2.0 mL of RMPI 1640 medium containing 
10% fetal bovine serum and 100 IU penicillin and 100 mg/mL streptomycin and 
incubated for 16 hours to attach. Media was removed and replaced with complete media 
containing 1 nM, 10 nM, 100 nM, or 1 µM of apoptolidin A or H or DMSO vehicle 
control give a uniform DMSO concentration of 0.1%. Treatment with compounds was 
continued for 2, 3, or 4 days by staggering plating and treatment times such that all 
treatment conditions could be assayed at once. Subsequent experiments also investigated 
2.5 day (60 hour) treatments as well as treatment every 2 hours between 60 and 72 hours. 
After the desired treatment time, media was removed from each well by aspiration. Cells 
were treated with 0.05% trypsin-EDTA and returned to the incubator for 3-15 minutes or 
until detached. Detached cells from each well were suspended in 5 mL phosphate 
buffered saline (PBS) and centrifuged at 1500 RPM for 5 minutes to pellet cells in 15 mL 
Falcon tubes. Media was aspirated and cells were resuspended in 2 mL PBS and pelleted 
again (this PBS was repeated 2x to remove EDTA from trypsin digestion). Cells were 
resuspended in 1 mL of PBS and transferred to 1.5 mL Eppendorf tubes and repelleted. 
Media was aspirated again and cells were resuspended in 100 µL 1 x binding buffer (BD 
Biosciences Annexin V:FITC Apoptosis Detection Kit). Vehicle treated well was 
suspended in 400 µL of binding buffer instead and split between 4 tubes. 5 µL of PI and 
Annexin V:FITC solutions were added to each cell suspension with the exception of 3 of 
the suspensions of the vehicle treated cells. One of these was left unstained, and one was 
treated with only PI and one only Annexin V: FITC. After 15 minutes incubation at room 
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temperature, each suspension was diluted to 500 µL with 1x binding buffer and cells 
were sorted using a BD LRSIFortessa cell analyzer (BD Biosciences).  
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CHAPTER IV  
 
 
Probing the Role of Apoptolidin Deoxy Sugars 
 
 
 Fluorescent Apoptolidin Probe Syntheses 
 Many bioactive natural products contain sugar moieties that are critical for 
activity, however the specific reason(s) for this is often unstudied. It is typically expected 
that such essential sugars are either involved in critical interactions with a cellular target 
or associated with transport of the natural product into the cell or into specific subcellular 
compartments to allow for target binding. For apoptolidin A, the C9 and C27 deoxy 
sugars have different effects on biological activity. The sugar at C9 can be removed or 
modified with minimal effect on activity but removal of the C27 disaccharide moiety 
greatly reduces cytotoxicity (46 fold less potent). While the F1FoATPase inhibition SAR 
data is incomplete, the data available suggest that the resulting loss in enzyme activity is 
much less significant (Table III-1). We therefore hypothesize that removal of the C27 
disaccharide moiety does not significantly affect the binding to its biological target, 
assuming F1FoATPase,1 but instead inhibits the transport of the compound to its target 
within the mitochondria. To test this, we have developed a strategy for the site selective 
modification of both apoptolidin A and apoptolidin H with fluorescent tags and designed 
experiments using the derived fluorescent probes to compare both subcellular localization 
and any significant differences in compound uptake rates. 
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Mitochondrial Co-localization and Transport Experiment Plan  
 We planned to implement several confocal microscopy experiments to test our 
hypothesis. First, we needed to identify a method for the site selective modification of 
both apoptolidin A and H with a fluorescent moiety in a position that would have a 
minimal effect on activity in our H292 cell viability assay. Second, we would employ 
fluorescence confocal microscopy to image H292 cells that were treated with fluorescent 
apoptolidin A and organelle specific dyes to determine if localized in the mitochondria.1,2 
Next, we could perform identical experiments with a fluorescent probe of apoptolidin H. 
We expect that if apoptolidin H transport to the mitochondria is significantly slower than 
that of apoptolidin A, the target staining with this compound would be greatly reduced in 
a short treatment time. Finally, we could measure the rate of mitochondrial staining in 
real time after treatment to attempt to quantify any differences in transport.  
 To realize our first goal, we desired a method to couple apoptolidin to diverse 
fluorophores in a site selective manner. Recognizing the large number of reactive 
functional groups, the tendency towards isomerization and instability of apoptolidin, we 
chose to pursue a synthetic strategy implementing the Huisgen [3+2] cycloaddition or 
“click” reaction.3 In this reaction, two bioorthogonal functional groups, an alkyne and an 
azide, react selectively under mild reaction conditions (copper(I) catalyzed or strain 
promoted) to produce a coupled triazole. For this strategy, we sought to prepare azido-
modified analogues of apoptolidin A and H and alkyne-modified fluorophores. The 
fluorophore would be tethered to the alkyne by a linker to minimize steric interactions 
between the fluorescent moiety and the biological target. This convergent strategy limits 
the number of synthetic transformations to be carried out on apoptolidin and allows for 
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simple optimization of both the fluorophore moiety and the linker to maintain biological 
activity.  
Synthesis and Biological Evaluation of Azido Apoptolidin A and H 
 To maintain structural similarity of apoptolidins A and H probes we required the 
azido group to be introduced at the same position. Previous studies by Wender et al 
revealed some selectivity for the acylation of apoptolidin A at the C2’ hydroxyl group of 
the C9 sugar which resulted in a negligible change in activity in both cell viability assays 
and F1FoATPase inhibition assays.4 Optimal regioselectivity was reported with the use of 
either a peptide catalyst5 or by treatment of a preformed C2’-C3’ apoptolidin stanylidine 
acetal with an acyl chloride.6 The stanylidine acetal conditions were applied for the 
acylation of apoptolidin A and H with δ-azidopentanoyl chloride to produce azido 
apoptolidin A 4.1 and azido apoptolidin H 4.2. However, preparative RP-HPLC 
purification of the resultant mixture revealed a lower isolated yield than reported for the 
benzoylation by Wender et al, likely due to an observed second, isomeric product not 
separated by flash chromatography. Ultimately, investigations with various coupling 
reagents identified the use of PyBrop produced superior yields under mild conditions 
(Scheme IV-1). The desired regioselectivity in the acylation was confirmed by 1H–13C 
couplings from CIGAR-HMBC experiments. Similar results for both apoptolidin A and 
H were observed for both sets of reaction conditions. 
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Scheme IV-1: Synthesis of azido apoptolidin A 4.1 and H 4.2 
 
 Next, azido apoptolidin A and H were tested in our H292 cell viability assay 
(Figure IV-1). Both compounds retained cytotoxicity with EC50’s comparable to the 
parent compounds apoptolidin A and H (EC50 = 12 and 600 nM respectively). With these 
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compounds in hand we began to investigate the synthesis of an optimal alkyne 
fluorophore conjugate for preparation of the desired fluorescent probes.  
 
 
Figure IV-1: Azido apoptolidin A and H H292 cell viability assay 
 
 First Generation “Click” Fluorophore: Terminal Alkyne  
 Our initial investigations into the preparation of fluorescent alkyne conjugates 
focused on the use of the standard copper(I) catalyzed Hüisgen [3+2] cycloaddition 
reaction. For this “click” reaction a terminal alkyne is required. Because of its ready 
availability from collaborators 7  and good spectral properties for use in confocal 
microscopy, Rhodamine X (Rhox) was chosen as a fluorophore to begin investigation. A 
(9 methylene) alkyl chain was used as a linker between the alkyne and Rhox for this first 
generation probe. Specifically, undecynol 4.3 was converted to amine 4.4 by a Gabriel 
synthesis sequence. This amine was treated with the N-Hydroxy succinimidal ester of 
Rhox 4.5 to produce Rhox alkyne conjugate 4.6.  
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Scheme IV-2: Synthesis of Rhox-alkyne 4.6 
 
 In an initial experiment, treatment of azido apoptolidin A 4.1 with Rhox alkyne 
conjugate 4.6 in the presence of copper(I) produced a brightly fluorescent product, by 
TLC (Scheme IV-1). While attempts at purification of this product by flash column 
chromatography failed to produce spectral data confidently indicating the structure of the 
desired product, the compound was assumed to be the triazole 4.7. Furthermore, in the 
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standard H292 cell viability assays, this material gave an estimated EC50 of 18 nM, 
further suggesting the success of the cycloaddition reaction in coupling the fluorophore to 
azido apoptolidin A 4.1. 
 
 
Scheme IV-3: First generation fluorescent apoptolidin synthesis 
 
 While we were less than confident of the structure of the compound and 
dissatisfied with the low level of purity, we performed initial assays to attempt to 
measure any co-localization of the new probe with the mitochondria specific dye 
Mitotracker Green FM. H292 cells were treated with conjugate 4.7 for 45 minutes, then 
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with mitotracker for 30 minutes followed by a washout period to eliminate non-
specifically bound fluorophore. The cells were then imaged by confocal fluorescence 
microscopy and an example of the resulting images is shown (Figure IV-1). 
Fluorescence from conjugate 4.7 shown in panel A in red, mitotracker in B in green and 
the images are overlayed in panel C revealing areas of significant co-localization in 
yellow. Co-localization analysis of these images using the Costes method8 gave a 
Pearson’s coefficient of Pc = 0.7 indicating a significant amount of overlap between the 
two signals. A control treatment with Rhox acid showed no staining (data not shown).  
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Figure IV-2: Initial confocal microscopy results with compound 4.7 
 
 While these initial results were somewhat promising, neither NMR nor MS 
analysis confirmed the structural assignment. Furthermore, the compound mixture had 
particularly weak fluorescence, requiring high loading concentration (2 µM) to give good 
signal in confocal microscopy experiments. Finally, multiple attempts at repeating the 
reaction gave rise only to products containing the Rhox chromophore that were separable 
from any peaks containing the apoptolidin chromophore by RP-HPLC. We suspected that 
A  B 
C 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the copper catalyzed “click” reaction was somehow incompatible with our coupling 
partners and instead turned our attention to copper-free click reactions. 
 
Second Generation “Click” Fluorophore: Cyclooctyne 
 
Scheme IV-4: Synthesis of cyclooctyne amine 4.11 
 
 Bertozzi et al developed a copper free variant of the Hüisgen cycloaddition that 
utilizes ring strain to activate the alkyne for cyclization rather than copper catalysis.9 To 
investigate this method, we prepared a cylooctyne amine as reported in the literature 
(Scheme IV-4). 10  Briefly, carbene addition to cycloheptene provided dibromo-
bicyclo[5.1.0]octane 4.8. Treatment of 4.8 with silver triflate in the presence of 
trifluoroacetate protected ethanolamine 4.9 yielded vinyl bromide 4.10. Hydrolysis to the 
amine followed by dehydrobromination yields cyclooctyne 4.11. This amine was then 
coupled to the N-hydroxysuccinimide ester of Rhox to give cyclooctyne fluorophore 4.12 
(Scheme IV-5). 11  Treatment of azidoapoptolidin A with this compound, however, 
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resulted only in the recovery of starting material (Scheme IV-6). The strain promoted 
azide alkyne cycloaddition reaction with simple cyclooctynes such as 4.12 often requires 
significant heating to temperatures likely to decompose apoptolidin in order to observe 
fast reaction rates.  
 
 
Scheme IV-5: Cyclooctne Rhox conjugate 4.12 
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Scheme IV-6: Unsuccessful cyclooctyne “click” reaction 
 
Third Generation “Click” Fluorophore: Bicyclononyne  
 Since the initial use of the copper-free click reaction was reported by Bertozzi 
utilizing cyclooctyne, several more reactive cyclic alkynes have been developed that take 
advantage of altered electronics and increased ring strain to greatly increase [3+2] 
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cycloaddition rates.12 In order to ensure rapid and selective reactivity with the azido 
apoptolidin conjugates, we selected from among the most reactive of these compounds as 
candidates for our probe synthesis (Figure IV-3). A significant improvement in 
cyclooctyne reactivity is observed by placing electron withdrawing groups (e.g. 
difluoromethylene) adjacent to the alkyne as in 4.14. Increasing strain energy by fusing 
the cyclooctyne to two aryl groups also significantly enhances reaction rates as reported 
for compounds such as 4.15. A similar rate enhancement is also observed for 
bicyclononyne deriviatives 4.16 by the fusion of the octyne to a cyclopropane. While 
reaction rates for each of these cyclooctynes are comparable, the synthesis of 4.14 and 
4.15 require eight and nine steps respectively and are relatively poor yielding. In 4.15, the 
addition of the biaryl groups significantly increases lipophilicity, enhancing nonspecific 
protein binding in biological systems. Finally, due to the asymmetry of 4.14 and 4.15, 
“click” reactions with azides will produce regioisomeric mixtures. Bicyclononyne (4.16, 
BCN) was chosen to investigate next as it can be assembled in good yield over four 
simple steps from cyclooctadiene, requires a minimal addition of hydrophobic groups and 
is symmetric. 13 
 
 
Figure IV-3: Highly reactive cyclooctynes for “click” chemistry 
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 A bicyclononyne amine was prepared as previously described from 
cyclooctadiene (Scheme IV-7).13 Cyclopropanation of cyclooctadiene with ethyl 
diazoacetate in the presence of catalytic rhodium acetate afforded bicyclononene 4.17 as 
a seperable mixture of diastereomers. The minor, but more strained endo product was 
taken forward to provide the most reactive bicyclononyne. Reduction of ester 4.17 with 
lithium aluminum hydride provided alcohol 4.18. Bromination of the alkene followed by 
double dehydrobromination produced the desired bicyclononyne 4.19. At this stage, a 
short PEG linker was introduced to balance lipophilicity and hydrophilicity while 
providing distance between the fluorophore and apoptolidin moieties. To that end, 
alcohol 4.19 was coupled to p-nitrochloroformate to give carbonate 4.20. Treatment of 
4.20 with diamine 4.21 provided amino bicyclononyne 4.22 in good yield.  
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Scheme IV-7: Synthesis of bicyclononyne amine 4.22 
 
 Having had poor success with Rhox based probes in our previous “click” reations; 
we decided to investigate alternative fluorophores. The cyanine dye Cy3, was selected 
first due to its optical properties (excitation/emission spectra), photostability, relatively 
low molecular weight and commercial availability. 14  Treatment of the N-
hydroxysuccinimide ester of Cy3 4.23 with amino bicyclononyne 4.22 afforded the Cy3 
bicyclononyne (4.24, Cy3–BCN). 
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Scheme IV-8: Preparation of Cy3 bicyclononyne conjugate 4.24 
 
 Treatment of azido apoptolidin A 4.1 with Cy3–BCN 4.24 in methanol at 37°C 
for 4 h resulted in complete consumption of 4.1 and the formation of a new product with 
the signature chromophore of both apoptolidin and Cy3 as indicated by HPLC. Isolation 
and spectral characterization of this product indicated that it was the desired Cy3 
apoptolidin A conjugate 4.25. Analogous results were obtained from the reaction of Cy3–
BCN 4.24 with azido apoptolidin H 4.2 to produce the Cy3 apoptolidin H conjugate 4.26 
(Scheme IV-9). Finally, Cy3 conjugates 4.25 and 4.26 were tested for activity in the 
H292 cell viability assay. Gratifyingly both compounds showed comparable activity to 
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apoptolidin A and H, respectively (Figure IV-4). Having prepared these fluorescent 
probes of both apoptolidin A and H and confirmed the retention of their biological 
activity in H292 cells, we next began to investigate their subcellular localization using 
confocal microscopy.  
 
 
Figure IV-4: Cy3 apoptolidin A and H H292 cell viability assay 
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Scheme IV-9: Preparation of Cy3 Apoptolidin A and H Conjugates 
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 Cyanine Apoptolidin Conjugate Microscopy Studies 
Cy3 Conjugate Treatment Conditions 
 To determine the necessary treatment conditions to observe an ideal level of 
cellular staining in H292 cells with Cy3 apoptolidin conjugates 4.25 and 4.6, 
optimization experiments were performed using a standard fluorescence microscope. 
H292 cells were treated with 200 nM of each compound for 15–90 minutes. The culture 
media was then replaced with new media to allow for any nonspecific staining to diffuse 
for either 40 or 105 minutes. After only 15 minutes, a significant amount of staining was 
observed for both compounds (Figure IV-5). After washout, most diffuse staining, 
apparently in the cytosol and intercellular space, was eliminated. Increased treatment 
time significantly increased the brightness of the staining but also increased diffuse, 
nonspecific signal. Based upon these results, we chose to use a 15 minute treatment at 
200 nM of each Cy3 conjugate, followed by a 60 minute washout to remove nonspecific 
binding for use in our confocal microscopy experiments. These results showed lower 
fluorescence signal for staining with Cy3 apoptolidin H conjugate 4.26 at treatment times 
up to 60 minutes. However, 90 minute treatments with either compound were similarly 
saturated. While this indicated a minor reduction in cell permeability of apoptolidin H 
compared to apoptolidin A, this difference would be inconsequential in the course of a 
four day treatment in cell viability testing.  
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Figure IV-5: Treatment of H292 cells for 15 or 60 minutes with 200 nM Cy3 
Apoptolidin A or H with or without washout as indicated. 
200 nM Cy3 Apo A 
15 min treatment
No washout
200 nM Cy3 Apo H 
15 min treatment
 No washout
200 nM Cy3 Apo A
15 min treatment
105 minute  washout
200 nM Cy3 Apo H 
15 min treatment
105 min washout
200 nM Cy3 Apo A 
60 min treatment
No washout
200 nM Cy3 Apo A 
60 min treatment
40 min washout
200 nM Cy3 ApoH 
60 min treatment
40 min washout
200 nM Cy3 Apo H 
60 min treatment
No washout
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Cy3 Confocal Microscopy: Subcellular Localization  
 Our first confocal microscopy experiments with these probes examined co-
localization of either Cy3 carboxylic acid 4.27, Cy3 apoptolin A 4.25 or Cy3 apoptolidin 
H 4.26 with Mitotracker Green FM to determine if the compounds bound to a target in 
the mitochondria. Mitotracker Green FM was added into the washout media of the Cy3 
treatment conditions for the final 30 minutes. For each compound, 3 dishes of cells were 
treated and 10 random fields were captured for each dish (Figure IV-6). Treatment with 
Cy3 carboxylic acid 4.27 showed no Cy3 specific staining. Both of the cy3 apoptolidin 
conjugates, however, showed a high degree of staining that appeared to significantly 
overlap with staining from Mitotracker Green FM. Indeed, Costes’s analysis of this data 
revealed excellent overlap for both compounds providing Pearson’s coefficients (Pc) of 
0.89 and 0.88 for Cy3 apoptolidin A and H conjugates, respectively. However, it seemed 
arguable that the Cy3 carboxylic acid might not be a sufficient negative control in these 
experiments for localization contribution of the fluorophore and linker portion of the 
molecule. H292 cells were treated with Cy3–BCN 4.24. A high amount of mitochondrial 
specific staining was observed for this compound as well. While the overlap of Cy3–
BCN 4.24 (Pc=0.80) was less than that of the Cy3 apoptolidin conjugates, it was still 
significant enough to cause us to question the validity of these results.  
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Figure IV-6: H292 cells stained with 4.25 (top left), 4.26 (top right), 4.27 (bottom left) 
and 4.24 (bottom right) and with Mitotracker Green FM. Cy3 fluoresence is shown in red, 
Mitotracker in green. 
 
 The mitochondrial staining of the Cy3–BCN 4.24, while unanticipated, should not 
be surprising. One explanation is that the hydrophobicity of the linker and the 
bicyclononyne moiety cause the probe to be nonspecifically bound to lipid bilayers in the 
plasma membrane as well as the membrane of organelles, including mitochondria. 
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However, the high Pearson’s coefficient with the mitochondria and the lack of obvious 
staining of the plasma membrane in these experiments suggest that this is likely an 
insufficient explanation. Given the previous reports of the bioorthogonal nature of the 
alkyne moiety and the lack of other reactive functional groups within 4.24, it is not 
expected that the compound is specifically reacting with any biomolecules to cause the 
staining. A survey of the literature on uses of cyanine dyes found examples of where 
certain aliphatic cyanine esters had been used as a means of measuring the mitochondrial 
membrane potential.15 The use of cationic fluorophores, for example Rhodamine 123, for 
the quantification of the mitochondrial membrane potential is well precedented.16,17 The 
equilibrium of fluorophore concentration between the mitochondria and the cytosol is 
highly predictable by the positive charge of the fluorophore and ∆Ψm by the Nernst 
equation. Under biological conditions, the carboxylic acid of Cy3 would be deprotonated, 
resulting in a net neutral charge for the molecule and thus no staining of the mitochondria 
was observed with this compound (Scheme IV-10). However, when coupled to non-
acidic moieties, as in 4.24, 4.25 and 4.26, the net charge is positive at physiological pH, 
resulting in a high degree of mitochondrial staining as observed in our experiments.  
 
 
Scheme IV-10: Cy3 acid 4.27 at physiological pH 
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 While this control calls to question the significance of the co-localization results, 
there are still positive indications from these studies. First, any increase in localization at 
the mitochondria due to the incorporation of the fluorophore moiety neither significantly 
disrupts nor enhances the cytotoxicity of either apoptolidin A or H, suggesting that the 
important biological target of these compounds may indeed lie in the mitochondria. 
Furthermore, no significant differences were observed between Cy3 apoptolidin A and H 
conjugates with respect to cellular and mitochondrial uptake rates. While the rapid 
transport to the mitochondria could easily be attributed to the cationic cyanine moiety, if 
differential transport rates were responsible for the reduced potency of Cy3 apoptolidin H 
conjugate 4.26 this compound would likely have activity more comparable to apoptolidin 
A. This data, therefore, suggests that the disaccharide moiety is likely important for target 
affinity and not cellular or subcellular transport, as previously hypothesized. 
 
Current Studies: Depolarization and Non-cationic Fluorophores  
 With possible reasons attributed for the unacceptable staining by Cy3–BCN 4.24 
in our experiments, we have identified two strategies circumvent the problem. First, the 
conditions of our treatment protocol could be modified in a way that eliminates Cy3 
specific staining of the mitochondria with control compound 4.24. Second, additional, 
noncationic fluorescent conjugates of apoptolidins could be prepared for these studies. 
We are currently pursuing both of these strategies.  
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Mitochondrial Decoupling Strategy 
 
 
Figure IV-7: Protonophore mitochondrial decouplers 
 
 Assuming that Cy3–BCN 4.24 staining is caused by the cationic nature of the 
fluorophore and the mitochondrial membrane potential, dissipation of the membrane 
potential should result in the elimination of the undesired staining.18 Several compounds 
are known to cause changes in ∆Ψm either by inhibition of the mitochondrial respiratory 
chain or by transferring protons into the mitochondria from the cytosol. Protonophores 
such as FCCP and CCCP can be used to rapidly dissipate ∆Ψm. These compounds are 
easily protonated in the cytosol, causing them to rapidly diffuse into the mitochondria and 
be deprotonated. The resultant rapid catalytic influx of protons into the mitochondria 
eliminates ∆Ψm. If conditions can be found to eliminate mitochondrial staining by Cy3–
BCN 4.24 by dissipaion of ∆Ψm, these conditions could be applied to assays with Cy3 
conjugates 4.25 and 4.26 to measure apoptolidin specific staining only. Preliminary 
confocal microscopy experiments with treatment of H292 cells with 200 nM 4.24, 
followed by treatment with 5 µM CCCP and immediate imaging showed only a small 
decrease in mitochondrial staining (results not shown). Further experimentation is 
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underway to determine the optimal order and duration of treatment with each compound 
to effectively eliminate ∆Ψm. 
Fourth Generation “Click” Fluorphores: Non-cationic Fluorophores 
  The synthesis of our Cy3 fluorescent probes was designed in a way that would 
allow for facile alteration of the fluorophore moiety. Amine 4.22 can be easily coupled to 
the commercially available N-hydroxysuccinimdyl ester of many fluorophores to provide 
clickable intermediates. Two new fluorphores were selected for investigation that would 
not be cationic under physiological conditions. Aminomethylcoumarin acetate (AMCA) 
was selected for its relatively small molecular weight, neutral charge and affordability but 
suffers from poor optical characteristics (namely a short excitation wavelength). 
Alternatively, Alexafluor 568 (Af568) was selected due to superior optical qualities 
despite its larger molecular weight, high cost and the fact that it is sold as a mixture of 
isomers, significantly complicating spectral characterization of probes incorporating this 
fluorophore.  
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Scheme IV-11: Preparation of AMCA bicyclononyne conjugate 4.29 
 
 The synthesis of AMCA apoptolidin A and H conjugates proceeded without 
significant complications using conditions previously developed for Cy3 conjugate 
synthesis (Scheme IV-11, Scheme IV-12). Evaluation of these compounds in cell 
viability assays gave EC50’s of 99 (4.30) and 540 (4.31) nM, showing a retention of 
activity to apoptolidin A and H. Initial treatment of H292 cells with 200 nM AMCA BCN 
conjugate 4.29 resulted in no staining compared to untreated cells. The short excitation 
wavelength of the ACMA derivatives requires the use of two photon excitation methods 
by a long wavelength IR laser in confocal microscopy experiments. Unfortunately, the 
excitation of NADH autofluorescence overlaps significantly with that of AMCA, causing 
signal to be observed in the absence of AMCA treatment. However, the level of NADH 
can be significantly knocked down by glucose deprivation immediately prior to treatment. 
Studies utilizing this technique and the AMCA fluorescent conjugates 4.30 and 4.31 are 
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currently in progress to determine apoptolidin subcellular localization and evaluate the 
effect of the C27 disaccharide on cellular transport rates.  
 
 
Figure IV-8: AMCA apoptolidin A and H H292 cell viability assay 
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Scheme IV-12: Preparation of AMCA apoptolidin A and H conjugates 4.30 and 4.31. 
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 Due to the exceptional cost of Alexafluor 568 NHS, only the Alexafluor 568 BCN 
derivative (Scheme IV-13) has been prepared while confocal experiments with AMCA 
derivatives are investigated. The presence of multiple isomeric forms of Alexafluor 568 
either greatly reduces the yield (if separated) or prohibits NMR spectral characterization 
of the products.  
 
 
Scheme IV-13: Alexafluor 568 BCN Synthesis 
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Conclusions and Future Studies 
 A simple and versatile method has been developed for the site-selective 
modification of apoptolidin with a variety compounds at a position that has a negligible 
impact on cytotoxicity in H292 cells. While in these examples, only fluorescent moieties 
have been attached to apoptolidin, the chemistry is easily modified to incorporate a 
variety of structures. Furthermore, the bioorthogonaility of the click reaction and the 
apparent cell permeability of conjugates such as 4.24 and 4.29 suggest that these reagents 
could be used for the in vitro labeling of azides attached to small molecules, natural 
products or biomolecules within cells.  
 Experiments utilizing fluorescent apoptolidin A and H conjugates are 
inconclusive to date, but multiple tools have been prepared yielding two strategies to 
eliminate non-apoptolidin specific staining observed in control experiments. The use of 
decoupling agents in addition to Cy3 Apoptolidin A and H conjugates 4.25 and 4.26 may 
yet allow us to judge the effects of the C27 disaccharide on the cellular transport of 
apoptolidin A utilizing these compounds. Alternative fluorophores that do not include a 
cationic moiety have also been prepared that should also eliminate fluorophore specific 
binding. Finally, should both of these strategies fail, Alexafluor deriviative 4.33 could be 
used to either prepare new fluorescent conjugates of apoptolidin A and H or potentially 
for in vivo labeling of azido apoptolidins. Results from these experiments will provide 
novel insight into the importance of sugar moieties in the biological activity of 
apoptolidin.  
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 Experimental Methods 
General Synthetic procedures: All non-aqueous reactions were performed in flame-
dried or oven dried round-bottomed flasks under an atmosphere of argon. Where 
necessary (so noted) solutions were deoxygenated by alternate freeze (liquid 
nitrogen)/evacuation/argon-flush/thaw cycles (FPT, three iterations) or degassed by 
purging with argon for several minutes. Stainless steel syringes or cannulae were used to 
transfer air- and moisture-sensitive liquids. Reaction temperatures were controlled using 
a thermocouple thermometer and analog hotplate stirrer. Reactions were conducted at 
room temperature (rt, approximately 23 °C) unless otherwise noted. Flash column 
chromatography was conducted as described Still et. al. using silica gel 230-400 mesh.19 
Where necessary, silica gel was neutralized by treatment of the silica gel prior to 
chromatography with the eluent containing 1% triethylamine. Analytical thin-layer 
chromatography (TLC) was performed on E. Merck silica gel 60 F254 plates and 
visualized using UV, ceric ammonium molybdate, potassium permanganate, and 
anisaldehyde stains. Yields were reported as isolated, spectroscopically pure compounds.  
Materials. Solvents were obtained from either a MBraun MB-SPS solvent system or 
freshly distilled (tetrahydrofuran was distilled from sodium-benzophenone; toluene was 
distilled from calcium hydride and used immediately; dimethyl sulfoxide was distilled 
from calcium hydride and stored over 4Å molecular sieves). Commercial reagents were 
used as received with the following exceptions.  
Instrumentation. Semi-preperative reverse phase HPLC was conducted on a Waters 
HPLC system using a Phenomenex Luna 5 µm C18(2) 100A Axia 250 x 10.00 mm 
column or preperative reverse phase HPLC (Gilson) using a Phenomenex Luna column 
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(100 Å, 50 x 21.20 mm, 5 µm C18) with UV/Vis detection. Infrared spectra were 
obtained as thin films on NaCl plates using a Thermo Electron IR100 series instrument 
and are reported in terms of frequency of absorption (cm-1). 1H NMR spectra were 
recorded on Bruker 300, 400, 500, or 600 MHz spectrometers and are reported relative to 
deuterated solvent signals. Data for 1H NMR spectra are reported as follows: chemical 
shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = 
multiplet, br = broad, app = apparent), coupling constants (Hz), and integration. 13C 
NMR spectra were recorded on Bruker 75, 100, 125, or 150 MHz spectrometers and are 
reported relative to deuterated solvent signals. LC/MS was conducted and recorded on an 
Agilent Technologies 6130 Quadrupole instrument. High-resolution mass spectra were 
obtained from the Department of Chemistry and Biochemistry, University of Notre Dame 
using either a JEOL AX505HA or JEOL LMS-GCmate mass spectrometer or by the 
Vanderbilt University Center for Neuroscience Drug Discovery (VCNDD) on a 
Micromass –Q-Tof API-US mass spectrometer. 
Azido Apoptolidin 
A 4.1 To a solution 
of azido pentanoic 
acid (7.6 mg, 0.053 
mmol) in 
dichloromethane 
(4.0 mL) at 0°C was 
added bromo-tris-pyrrolidino phosphoniumhexafluorophosphate (PyBrop, 25 mg, 0.053 
mmol) and diisopropylethyl amine (31 µL, 0.177 mmol) the resulting solution was stirred 
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at 0 °C for 10 min. Apoptolidin A 2.1 (20 mg, 0.018 mmol) was added to the resulting 
solution followed by one small crystal of 4-dimethylaminopyridine (DMAP). The 
resulting solution was warmed to rt and maintained at that temperature for 16 h. 
Methanol (100 µL) was added to the reaction mixture and then concentrated. The 
resulting residue was diluted in EtOAc (20 mL) and washed with 1 N HCl (5 mL). The 
aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic extracts 
were washed with NaHCO3 (1x 5mL) and brine (1 x 5 mL) and dried (Na2SO4) and 
concentrated in vacuo. The resulting residue was dissolved in 1.2 mL of DMSO, filtered 
through a 0.2 µm polytetrafluoroethylene PTFE syringe tip filter and purified by 
preparative reversed phase HPLC with a 4 minute gradient from 45% to 75% MeCN in 
H2O in four 300 µL injections. Fractions containing desired product (r.t. 2.68 min) were 
combined and concentrated to remove acetonitrile only (T < 31°C) and the resulting 
aqueous solutions were frozen at -80°C. Water was removed by lyophilization to afford 
7.0 mg (31%) of 4.1 as a white solid: IR (neat) 3436, 2930, 2098, 1668, 1381, 1256 cm-1; 
1H NMR (600 MHz, CD3OD) δ 7.38 (s, 1H), 6.19 (s, 1H), 6.15 (d, J = 15.7 Hz, 1H), 5.65 
(dd, J = 7.9, 8.0 Hz, 1H), 5.29 (d, J = 11.4 Hz, 1H), 5.21 (d, J = 10.0 Hz, 1H), 5.05 (dd, J 
= 8.9, 15.8 Hz, 1H), 4.98 (d, J = 3.8 Hz, 1H), 4.94 (d, J = 4.1 Hz, 1H), 4.82 (d, J = 1.7 Hz, 
1H), 4.56 (dd, J= 3.9, 10.1 Hz, 1H), 3.95 (m, 1H), 3.91 (dd, J= 9.1, 9.9 Hz, 1H), 3.83 (dd, 
J = 8.9, 8.9 Hz, 1H), 3.78 (dd, J = 6.3, 9.5 Hz, 1H), 3.71 (dd, J = 4.6, 11.1 Hz, 1H), 3.67 
(dd, J = 6.2, 9.7 Hz, 1H), 3.60 (s, 3H), 3.53 (d, J = 1.3 H z, 1H), 3.45 (m, 1H), 3.43 (s, 
3H), 3.41 (m, 1H), 3.37 (s, 3H), 3.34 (m, 1H), 3.33 (m, 5H), 3.27 (s, 3H), 3.21 (dd, J = 
6.2, 9.2 Hz, 1H), 3.17 (m, 1H), 2.97 (dd, J = 8.9, 9.0 Hz, 1H), 2.82 (dd, J = 9.2, 9.2 Hz, 
1H), 2.72 (dd, J = 4.6, 9.8 Hz, 1H), 2.67 (m, 1H), 2.40-2.48 (m, 4H), 2.19 (s, 3H), 2.16 
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(m, 1H), 2.11 (s, 3H), 2.08 (m, 1H), 2.05 (m, 1H), 1.95 (s, 3H), 1.92 (d, J= 12.7 Hz, 1H), 
1.80 (dd, J = 4.4, 13.5 Hz, 1H), 1.74 (m, 1H), 1.73 (m, 1H), 1.69 (m, 2H), 1.66 (s, 3H), 
1.65 (m, 2H), 1.57 (m, 1H), 1.48 (m, 2H), 1.32 (s, 3H), 1.30 (m, 2H), 1.29 (m, 1H), 1.25-
1.30 (m, 12H), 1.22 (d, J = 6.2 Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H), 1.02 (d, J= 6.7 Hz, 3H), 
0.89 (d, J= 6.9 Hz, 3H); 13C NMR (150 MHz, CD3OD) δ; 174.5, 172.7, 149.3, 146.9, 
142.7, 141.3, 134.6, 133.9, 133.7, 133.1, 125.5, 123.8, 101.9, 101.3, 99.5, 93.6, 87.4, 87.4, 
85.9, 84.4, 83.9, 82.0, 77.1, 76.9, 76.8, 75.4, 75.1, 74.6, 73.9, 73.2, 73.0, 72.5, 72.3, 69.4, 
68.2, 67.4, 61.3, 61.3, 59.5, 57.3, 52.2, 45.5, 40.6, 39.1, 38.4, 37.2, 36.4, 34.4, 33.1, 30.8, 
29.4, 24.7, 23.3, 22.8, 18.9, 18.3, 18.2, 18.1, 17.9, 16.5, 14.2, 12.2, 12.1, 5.2; HRMS 
(ESI-TOF MS) m/z  1276.6925 (M+Na)+ calculated for C63H103 N3NaO22, measured 
1276.6940.  
Azido Apoptolidin H 4.2 To a 
solution of azido pentanoic 
acid (10 mg, 0.071 mmol) in 
dichloromethane (5.0 mL) at 
0°C was added PyBrop (33 mg, 
0.071 mmol) and 
diisopropylethyl amine (41 µL, 
0.238 mmol) the resulting 
solution was stirred at 0 °C for 10 min. Apoptolidin H 2.11 (20 mg, 0.024 mmol) was 
added to the resulting solution followed by one small crystal of DMAP. The resulting 
solution was warmed to rt and maintained at that temperature for 16 h. Methanol (100 
µL) was added to the reaction mixture and then concentrated. The resulting residue was 
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diluted in EtOAc (20 mL) and washed with 1 N HCl (5 mL). The aqueous layer was 
extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with 
NaHCO3 (1x 5mL) and brine (1 x 5 mL) and dried (Na2SO4) and concentrated in vacuo. 
The resulting residue was dissolved in 1.2 mL of DMSO, filtered through a 0.2 µm 
polytetrafluoroethylene PTFE syringe tip filter and purified by preparative reversed phase 
HPLC with a 4 minute gradient from 35% to 75% MeCN in H2O (r.t. of desired product 
3.23 min) in four 300 µL injections. Fractions containing desired product were combined 
and concentrated to remove acetonitrile only (T < 31°C) and the resulting aqueous 
solution was frozen at -80°C. Water was removed by lyophilization to afford 5.5 mg 
(24%) of 4.2 as a white solid.: IR (neat) 3425, 2928, 2098, 1669, 1385, 1257 cm-1; 1H 
NMR (600 MHz, CDCl3) δ 7.28 (s, 1H), 6.15 (s, 1H), 6.11 (d, J = 15.7 Hz, 1H), 5.61 (dd, 
J = 6.3, 9.8 Hz, 1H), 5.25 (d, J = 5.25 Hz, 1H), 5.16 (d, J = 10.0 Hz, 1H), 5.00 (d, J = 3.5 
Hz, 1H), 4.99 (dd, J = 9.6, 15.2 Hz, 1H), 4.71 (dd. J = 3.8, 10.2 Hz, 1H), 4.19 (d, J = 8.5 
Hz, 1H), 4.00 (dd, J = 9.5, 9.5 Hz, 1H), 3.86 (dd, J = 4.7, 10.7 Hz, 1H), 3.79 (m, 1H), 
3.77 (m, 1H), 3.61 (s, 3H), 3.56 (m, 1H), 3.51 (m, 1H), 3.47 (m, 1H), 3.37 (s, 3H), 3.31 (s, 
3H), 3.30 (m, 2H), 3.22 (dd, J = 3.3, 9.3 Hz, 1H), 3.11 (dd, J = 7.7, 9.1 Hz, 1H), 2.86 (dd, 
J = 9.3, 9.3 Hz, 1H), 2.74 (dd, J = 5.8, 9.6 Hz, 1H), 2.62 (m, 1H), 2.41 (m, 2H), 2.15 (s, 
3H), 2.10 (s, 3H), 2.01 (m, 1H) 1.90 (s, 3H), 1.82 (m, 1H), 1.72 (m, 2H), 1.64 (m, 3H), 
1.63 (s, 3H), 1.43 (m, 2H), 1.32 (d, J = 6.24 Hz, 3H), 1.25 (m, 2H) 1.12 (d, J = 6.4 Hz, 
3H), 1.05 (d, J = 6.4 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H); 13C NMR (150 MHz, CDCl3) 
δ;172.8, 171.7, 148.1, 146.6, 141.6, 140.1, 133.3, 133.2, 132.3, 132.2, 124.7, 122.7, 99.9, 
92.8, 86.2, 83.9, 82.4, 73.6, 71.4, 67.5, 67.1, 61.2, 61.0, 59.2, 51.2, 38.9, 37.9, 37.0, 36.4, 
35.9, 34.7, 33.7, 33.6, 32.1, 29.8, 29.7, 29.5, 28.3, 24.6, 22.8, 22.3, 18.2, 18.0, 17.4, 16.3, 
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14.3, 13.7, 12.1, 5.0; HRMS (ESI-TOF MS) m/z  988.5353 (M+Na)+ calculated for 
C49H79 N3NaO16, measured 988.5381.  
Bicyclononyne Amine 4.22 Carbonate 4.20 (36 
mg, 0.114 mmol) was dissolved in DMF (1.0 
mL). Triethylamine (48 µL, 0.685 mmol) was added to the resulting solution. Diamine 
4.21 was added at once resulting in an immediate color change of the solution to bright 
yellow. After 45 minutes, the DMF was removed on high vacuum overnight. The 
resulting yellow residue was dissolved in 30 mL DCM and washed with 1 N NaOH (2 x 
5 mL) and H2O (1 x 5 mL). The combined aqueous layers were back extracted with DCM 
(1 x 10 mL). Combined organics were washed again with H2O (1 x 5 mL), dried 
(Na2SO4) and concentrated to yield a colorless oil. Flash column chromatography (30 % 
80:18:220 in DMC) yielded 34.6 mg (94%) of amine 4.22 as a colorless oil. Spectral data 
for this compound was identical to that reported in the literature.13 
Bicyclononyne Cy3 
Conjugate 4.24 To a 
solution of amine 4.22 
(24.0 mg, 0.074 mmol) 
in DMF (1.0 mL) was added Cy3 NHS 2.23 as a solution in DMF (0.5 mL). After six 
hours, the DMF was removed on high vacuum overnight. The resulting purple residue 
was dissolved in methanol (1.0 mL) and purified on semipreperative reverse phase HPLC 
(30 minute gradient from 35% strong to 100% strong buffer in weak buffer where strong 
is 95% MeCN in H2O + 10 mM NH4OAc and weak buffer is 5% MeCN in H2O + 10 mM 
NH4OAc). The conical reaction flask was rinsed with an additional 0.5 mL of methanol 
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and this solution was purified as well. Fractions containing the desired product (r.t. 22.50 
min) were combined and concentrated to remove acetonitrile only (T<31°C). The 
resulting aqueous solution was frozen at -80°C. Water was removed by lyophilization to 
yield 4.29 mg (63%) of bicyclononyne Cy3 conjugate 4.24 as a deep red solid. 1H NMR 
(600 MHz, CD3OD) δ 8.55 (t, J = 13.5, 1H) 7.55 (d, J = 7.5, 2H), 7.45 (m, 2H), 7.36 (dd, 
J = 4.1, 8.0, 2H), 7.32 (m, 2H), 6.45 (dd, J = 8.4, 13.5 Hz, 2H), 4.15 (dd, J = 7.5, 7.5 Hz, 
2H), 4.11 (d, J = 8.1 Hz, 2H), 3.69 (s, 3H), 3.59 (s, 4H), 3.52 (t, J = 5.6 Hz, 4H), 3.34 (t, 
J = 5.6 Hz, 2H), 3.26 (t, J = 3.3 Hz, 2H), 2.23 (t, J = 7.3 Hz, 2H), 2.1-2.25 (m, 4H), 1.85 
(m, 2H), 1.77 (s, 12 H), 1.71 (m, 2H) 1.58 (m, 2H), 1.51 (m, 2H), 1.33 (m, 1H), 1.29 (s, 
4H) 0.91 (m, 2H); 13C NMR (150 MHz, CD3OD) δ 179.2, 176.7, 176.0, 175.9, 159.2, 
152.1, 144.1, 143.4, 142.2, 142.1, 130.0, 129.9, 126.8, 126.8, 123.5, 123.4, 112.5, 112.3, 
103.8, 103.6, 99.5, 71.3, 71.3, 71.0, 70.6, 63.7, 50.7, 50.6, 45.1, 41.6, 40.3, 36.6, 31.8, 
30.1, 28.3, 28.2, 28.1, 27.3, 26.5, 23.4, 21.9, 21.4, 18.9; HRMS (ESI-TOF MS) m/z 
763.4798 (M-Cl)+ calculated for C47H63N4O5, measured 763.4794. 
 
Cy3 Apoptolidin 
A Conjugate 4.25 
To a solution of 
Cy3 BCN 
conjugate 4.24 
(2.6 mg, 0.0033 mmol) in methanol (0.5 mL) was added azido apoptolidin A 4.1 (2.05 
mg, 0.0016 mmol) as a solution in 0.5 mL methanol. The resulting solution was stirred at 
37 °C for 4 hours, removed from the bath and concentrated. The resulting residue was 
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dissolved in methanol (0.5 mL) and purified on semipreperative reverse phase HPLC (30 
minute gradient from 35% strong to 100% strong buffer in weak buffer where strong is 
95% MeCN in H2O + 10 mM NH4OAc and weak buffer is 5% MeCN in H2O + 10 mM 
NH4OAc). The conical reaction flask was rinsed with an additional 0.5 mL of methanol 
and this solution was purified as well. Fractions containing the desired product (r.t. 28.10 
min) were combined and concentrated to remove acetonitrile only (T<31°C). The 
resulting aqueous solution was frozen at -80°C. Water was removed by lyophilization to 
yield 1.29 mg (39%) of Cy3 apoptolidin A conjugate 4.25 as a deep red solid. (600 MHz, 
CD3OD) δ 8.55 (t, J = 13.5, 1H) 7.55 (d, J = 7.5, 2H), 7.45 (m, 2H), 7.36 (dd, J = 3.6, 8.0, 
2H), 7.32 (m, 3H), 6.44 (dd, J = 8.7, 13.4 Hz, 2H), 6.17 (s, 1H), 6.12 (d, J = 15.7 Hz, 1H), 
5.62 (m, 1H), 5.4 (m, 1H), 5.34 (m, 1H), 5.29 (d, J = 11.3 Hz, 1H), 5.19 (d, J = 10.0 Hz, 
1H), 5.00 (m, 1H), 4.9 (m, 2H), 4.82 (m, 1H), 4.54 (m, 1H), 4.30 (dd, J = 7.1, 7.1 Hz, 
2H), 4.15 (dd, J = 7.5, 7.5 Hz, 2H), 4.11 (m, 2H), 3.95 (m, 2H), 3.89 (m, 1H), 3.80 (m, 
2H), 3.69 (s, 3H), 3.65 (m, 2H), 3.60 (s(br), 4H), 3.58 (m, 3H), 2.52 (dd, J = 5.5, 5.5 Hz, 
4H), 3.42 (s, 3H), 3.41 (m, 2H), 3.35 (m, 4H), 3.26 (m, 2H), 3.14-3.21 (m, 3H), 2.97 (dd, 
J = 9.0, 9.0 Hz, 1H), 2.67-2.88 (m, 5H), 2.63 (m, 1H), 2.29-2.49 (m, 7H), 2.23 (t, J = 7.3 
Hz, 2H), 2.11-2.27 (m, 8H), 2.00-2.11 (m, 8H), 1.9-1.98 (m, 5H), 1.85 (m, 6H), 1.77 (s, 
12H), 1.71 (m, 2H), 1.54-1.67 (m, 6H) 1.51 (m, 4H), 1.19-1.36 (m, 13 H), 1.11 (d, J = 6.6 
Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H), 0.97-1.07 (m, 2H), 0.90 (d, J = 7.2 Hz 3H), 0.83-0.93 
(m, 1H). HRMS (ESI-TOF MS) m/z 2017.1832 (M-Cl)+ calculated for C110H166N7O27, 
measured 2017.1821. 
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Cy3 Apoptolidin H 
Conjugate 4.26 To a 
solution of Cy3 BCN 
conjugate 4.24 (2.03 mg, 
0.0025 mmol) in methanol 
(0.5 mL) was added azido apoptolidin H 4.2 (2.45 mg, 0.0025 mmol) as a solution in 0.5 
mL methanol. The resulting solution was stirred at 37 °C for 4 hours, removed from the 
bath and concentrated. The resulting residue was dissolved in methanol (0.5 mL) and 
purified on semipreperative reverse phase HPLC (30 minute gradient from 35% strong to 
100% strong buffer in weak buffer where strong is 95% MeCN in H2O + 10 mM 
NH4OAc and weak buffer is 5% MeCN in H2O + 10 mM NH4OAc). The conical reaction 
flask was rinsed with an additional 0.5 mL of methanol and this solution was purified as 
well. Fractions containing the desired product (r.t. 27.35 min) were combined and 
concentrated to remove acetonitrile only (T<31°C). The resulting aqueous solution was 
frozen at -80°C. Water was removed by lyophilization to yield 1.38 mg (32%) of Cy3 
apoptolidin H conjugate 4.26 as a deep red solid. (600 MHz, CD3OD) δ 8.55 (t, J = 13.5, 
1H) 7.55 (d, J = 7.4, 2H), 7.45 (m, 2H), 7.36 (dd, J = 3.5, 8.0, 2H), 7.32 (m, 3H), 6.44 
(dd, J = 8.6, 13.5 Hz, 2H), 6.17 (s, 1H), 6.12 (d, J = 15.7 Hz, 1H), 5.64 (m, 1H), 5.57 (m, 
1H), 5.40 (m, 1H), 5.30 (d, J = 11.2 Hz, 1H), 5.19 (d, J = 10.0 Hz, 1H), 5.00 (ddd, J = 8.2, 
8.2, 16.0 Hz, 1H), 4.95 (m, 1H), 4.54 (ddd, J = 2.0, 3.8, 10.2 Hz, 1H), 4.51 (m, 1H), 4.30 
(dd, J = 7.2, 7.2 Hz, 2H), 4.15 (dd, J = 7.5, 7.5 Hz, 2H) 4.00-4.10 (m, 3H), 3.96 (dd, J = 
9.5, 9.5 Hz, 1H), 3.98 (m, 1H), 3.81 (dd, J = 8.9, 8.9 Hz, 1H), 3.72-3.78 (m, 2H), 3.69 (s, 
3H), 3.65 (m, 1H), 3.60 (m, 4H), 3.54 (m, 1H), 3.52 (t, J = 5.6 Hz, 4H), 3.42 (m, 2H), 
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3.25-3.72 (m, 2H), 3.24-3.29 (m, 2H), 3.14-3.22 (m, 3H), 3.02 (m, 2H), 3.69-3.87 (m, 
3H), 2.63 (m, 1H), 2.29-2.50 (m, 4H), 2.24 (t, J = 7.3 Hz, 4H), 2.12-2.20 (m, 4H), 1.97-
2.08 (m, 4H), 1.89-1.95 (m, 2H), 1.86 (m, 4H), 1.74 (s, 12H), 1.71 (m, 4H), 1.55-1.68 (m, 
6H), 1.50 (m, 5H), 1.22-1.35 (m, 10H), 1.11 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H), 
0.97-1.07 (m, 2H),0.83-0.93 (m, 4H). HRMS (ESI-TOF MS) m/z 1729.0259 (M-Cl)+ 
calculated for C96H142N7O21, measured 1729.0250. 
Bicyclononyne AMCA 
Conjugate 4.29 To a solution of 
amine 4.22 (10.0 mg, 0.031 mmol) in DMF (0.25 mL) was added AMCA NHS 2.28 (5.0 
mg, 0.015 mmol) as a solution in DMF (0.5 mL). After two hours, the DMF was removed 
on high vacuum. The resulting residue was dissolved in methanol (0.3 mL) and purified 
on semipreperative reverse phase HPLC (30 minute gradient from 35% strong to 100% 
strong buffer in weak buffer where strong buffer was 95% MeCN in H2O + 10 mM 
NH4OAc and weak buffer was 5% MeCN in H2O + 10 mM NH4OAc). The conical 
reaction flask was rinsed with an additional 0.3 mL of methanol and this solution was 
purified as well. Fractions containing the desired product (r.t. 10.5 min) were combined 
and concentrated to remove acetonitrile only (T<31°C). The resulting aqueous solution 
was frozen at -80°C. Water was removed by lyophilization to yield 2.83 mg (35%) of 
bicyclononyne AMCA conjugate 4.29 as a deep white solid. 1H NMR (600 MHz, CDCl3) 
δ 7.41 (d, J = 8.6 Hz, 1H), 6.76 (s (br), 1H) 6.59 (dd, J = 2.2, 8.5 Hz, 1H), 6.54 (d, J = 2.2 
Hz, 1H), 5.46 (s (br), 1H), 4.19 (s (br), 2H), 4.14 (d, J = 8.0 Hz,, 2H), 3.5-3.6 (m, 10H), 
3.35-3.43 (m, 4H), 2.49 (s, 3H), 2.23 (m, 4H), 1.56 (m, 2H), 1.32 (ddd, J = 8.4, 8.4, 17.1 
Hz, 2H), 1.18 (dd, J = 7.0, 7.0 Hz, 1H), 0.89 (m, 2H); 13C NMR (150 MHz, CDCl3) δ 
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170.3, 163.3, 157.1, 154.3, 150.5, 150.1, 126.4, 112.3, 100.9, 99.0, 70.5, 70.4, 70.3, 69.8, 
62.8, 41.0, 39.5, 35.8, 29.8, 29.2, 21.6, 20.2, 17.9, 15.6; HRMS (ESI-TOF MS) m/z 
540.2710 (M+H)+ calculated for C29H38N3O7, measured 540.2708. 
AMCA 
Apoptolidin A 
Conjugate 4.30 To 
a solution of 
AMCA BCN 
conjugate 4.29 (1.05 mg, 0.0029 mmol) in methanol (0.5 mL) was added azido 
apoptolidin A 4.1 (7.0 mg, 0.0056 mmol) as a solution in 0.5 mL methanol. The resulting 
solution was stirred at 37 °C for 4 hours, removed from the bath and concentrated. The 
resulting residue was dissolved in methanol (0.3 mL) and purified on semipreperative 
reverse phase HPLC (30 minute gradient from 35% strong to 100% strong buffer in weak 
buffer where strong is 95% MeCN in H2O + 10 mM NH4OAc and weak buffer is 5% 
MeCN in H2O + 10 mM NH4OAc). The conical reaction flask was rinsed with an 
additional 0.3 mL of methanol and this solution was purified as well. Fractions 
containing the desired product (r.t. 13.0 min) were combined and concentrated to remove 
acetonitrile only (T < 31°C). The resulting aqueous solution was frozen at -80°C. Water 
was removed by lyophilization to yield 3.6 mg (71%) of AMCA apoptolidin A conjugate 
4.30 as a white solid. (600 MHz, CD3OD) δ 7.50 (d, J = 8.7 Hz, 1H), 7.37 (s, 1H), 6.66 
(dd, J = 2.2, 8.7 Hz, 1H), 6.50 (d, J =2.2 Hz, 1H), 6.16 (s, 1H), 6.12 (d, J = 15.7 Hz, 1H), 
5.63 (dd, J = 7.7, 8.1 Hz, 1H), 5.29 (d, J = 11.4 Hz, 1H), 5.19 (d, J =10.0 Hz, 1H), 5.00 
(ddd, J = 6.7, 8.9, 15.7 Hz, 1H), 4.95 (m, 2H), 4.82 (d, J = 1.7 Hz, 1H), 4.58 (s (br), 2H), 
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4.55 (ddd, J = 1.3, 3.8, 10.2 Hz, 2H), 4.29 (dd, J = 7.0, 7.0, 2H), 4.13 (m, 3H), 3.95 (m, 
1H), 3.89 (m, 1H), 3.80 (dd, J = 8.9, 8.9 Hz, 1H), 3.78 (dd, J = 6.2, 9.5 Hz, 1H), 3.71 (dd, 
J = 4.7, 11.0 Hz, 1H), 3.67 (dd, J = 6.3, 9.8 Hz, 1H), 3.66 (m, 1H), 3.61 (s, 4H), 3.59 (s, 
2H), 3.58 (s, 2H), 3.51-3.56 (m, 5H), 3.42 (s, 3H), 3.38 (dd, J = 5.5, 5.5 Hz, 1H), 3.36 (s, 
2H), 3.34 (m, 2H), 3.29 (m, 2H), 2.36 (m, 2H), 3.21 (dd, J = 6.2, 9.3 Hz, 1H), 3.17 (m, 
1H), 2.97 (dd, J = 9.0, 9.0 Hz, 1H), 2.82 (m, 1H), 2.81 (dd, J = 9.2, 9.2 Hz, 1H), 2.74 (m, 
1H), 2.71 (dd, J = 4.8, 9.9 Hz, 1H), 2.63 (m, 1H), 2.39 (s, 3H), 2.34-2.50 (m, 4H), 2.22 
(m, 2H), 2.17 (s, 2H), 2.14 (m, 1H), 2.09 (s, 2H), 2.06 (m, 3H), 1.93 (s, 1H), 1.91 (s (br), 
5H), 1.86 (m, 3H), 1.80 (m, 2H), 1.74 (m, 2H), 1.53-1.78 (m, 8H), 1.44-1.52 (m, 2H), 
1.36-144 (m, 2H), 1.31 (d, J = 6.1 Hz, 3H), 1.22 (d, J = 6.1 Hz, 3H), 1.20-1.36 (m, 9H), 
1.17 (dd, J = 7.0, 7.0 Hz, 1H), 1.11 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 0.89 (d, 
J = 6.9 Hz, 1H) 0.81-0.94 (m, 2H). HRMS (ESI-TOF MS) m/z 1793.9743 (M+H)+ 
calculated for C92H141N6O29, measured 1793.9747.  
AMCA Apoptolidin H 
Conjugate 4.31 To a 
solution of AMCA BCN 
conjugate 4.29 (4.4 mg, 
0.0082 mmol) in methanol 
(0.5 mL) was added azido apoptolidin H 4.2 (5.5 mg, 0.0057 mmol) as a solution in 0.5 
mL methanol. The resulting solution was stirred at 37 °C for 4 hours, removed from the 
bath and concentrated. The resulting residue was dissolved in methanol (0.5 mL) and 
purified on semipreperative reverse phase HPLC (30 minute gradient from 35% strong to 
100% strong buffer in weak buffer where strong is 95% MeCN in H2O + 10 mM 
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NH4OAc and weak buffer is 5% MeCN in H2O + 10 mM NH4OAc). The conical reaction 
flask was rinsed with an additional 0.5 mL of methanol and this solution was purified as 
well. Fractions containing the desired product (r.t. 11.35 min) were combined and 
concentrated to remove acetonitrile only (T < 31°C). The resulting aqueous solution was 
frozen at -80°C. Water was removed by lyophilization to yield 2.0 mg (24%) of AMCA 
apoptolidin H conjugate 4.31 as a white solid. (600 MHz, CD3OD) δ 7.50 (d, J = 8.7 Hz, 
1H), 7.35 (s, 1H), 6.66 (dd, J = 2.2, 8.7 Hz, 1H), 6.50 (d, J =2.1 Hz, 1H), 6.16 (s, 1H), 
6.12 (d, J = 15.7 Hz, 1H), 5.64 (dd, J = 7.8, 7.8 Hz, 1H), 5.30 (d, J = 11.3 Hz, 1H), 5.18 
(d, J =10.0 Hz, 1H), 5.00 (ddd, J = 8.0, 8.0, 15.8 Hz, 1H), 4.95 (m, 1H), 4.58 (s (br), 2H), 
4.55 (ddd, J = 1.6, 3.8, 10.1 Hz, 2H), 4.29 (dd, J = 7.0, 7.0, 2H), 4.13 (m, 3H), 4.09 (m, 
1H), 3.89 (dd, J = 8.9, 10.0 Hz, 1H), 3.80 (dd, J = 9.0, 9.0 Hz, 1H), 3.77 (m, 1H), 3.75 
(dd, J = 4.8, 11.1 Hz, 1H), 3.65 (m, 1H), 3.61 (s, 4H), 3.59 (s, 2H), 3.58 (s, 2H), 3.51-
3.56 (m, 5H), 3.38 (dd, J = 5.4, 5.4 Hz, 1H), 3.36 (s, 2H), 3.34 (m, 2H), 3.29 (m, 2H), 
3.21 (dd, J = 4.7, 9.4 Hz, 1H), 3.16 (dd, J = 6.3, 9.4 Hz, 1H), 2.95-3.08 (m, 4H), 2.81 (dd, 
J = 8.2, 8.2 Hz, 1H), 2.74 (m, 1H), 2.72 (dd, J = 4.3, 9.9 Hz, 1H), 2.63 (m, 2H), 2.39 (s, 
3H), 2.34-2.50 (m, 3H), 2.22 (m, 2H), 2.18 (s, 2H), 2.14 (m, 1H), 2.10 (s, 2H), 2.03 (m, 
3H), 1.93 (s, 1H), 1.91 (s, 2H), 1.86 (m, 3H), 1.76 (m, 2H), 1.53-1.78 (m, 8H), 1.44-1.52 
(m, 2H), 1.36-144 (m, 2H), 1.27 (d, J = 6.3 Hz, 3H), 1.20-1.36 (m, 9H), 1.16 (dd, J = 7.0, 
7.0 Hz, 1H), 1.11 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.4 Hz, 3H), 0.88 (d, J = 7.0 Hz, 1H) 
0.81-0.94 (m, 2H). HRMS (ESI-TOF MS) m/z (M-H)+ 1505.8170 calculated for 
C78H117N6O23, measured 1505.8182. 
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Bicyclononyne Alexafluor 568 
Conjugate 4.33 To a solution of 
amine 4.22 (6.0 mg, 0.0189 
mmol) in DMF (0.25 mL) was 
added Alexafluor 568 NHS 2.32 (5.0 mg, 0.0063 mmol). After five hours, the DMF was 
removed on high vacuum. The resulting residue was dissolved in methanol (0.3 mL) and 
purified on semipreperative reverse phase HPLC (30 minute gradient from 0% strong to 
50% strong buffer in weak buffer where strong buffer was 95% MeCN in H2O + 10 mM 
NH4OAc and weak buffer was 5% MeCN in H2O + 10 mM NH4OAc). The conical 
reaction flask was rinsed with an additional 0.3 mL of methanol and this solution was 
purified as well. Fractions containing the desired product (r.t. 21.5 min) were combined 
and concentrated to remove acetonitrile only (T<31°C). The resulting aqueous solution 
was frozen at -80°C. Water was removed by lyophilization to yield bicyclononyne 
alexafluor 568 conjugate 4.33 as a purple solid.  
 Confocal Microscopy Studies: Low passage (P < 25) H292 human lung carcinoma cells 
were plated in MaTek dishes at 15% confluence in 2.0 mL of RMPI 1640 medium 
containing 10% fetal bovine serum and allowed to attach and grow for 40 hours. 200 µM 
stock solutions of carboxylic acid 4.27, Cy3 apoptolin A 4.25, Cy3 apoptolidin H 4.26 , 
or Cy3 BCN 4.24  in DMSO was prepared. Each dish was treated by the following 
protocol. Media was removed by aspiration and replaced with 2.0 mL serum free RPMI 
1640 media. 2.0 µL of the appropriate DMSO stock solution was added to the dish and 
cells were returned to the incubator for 15 min. Media containing fluorophores was 
removed by aspiration followed by a wash with serum free RPMI 1640 media (3 x 2.0 
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mL) followed by a final addition of 2.0 mL of serum free media. After incubation for 30 
min, media was removed and replaced by a freshly sonicated (important for mitotracker 
solubility) 30 nM solution of Mitotracker Green FM. After an additional incubation of 30 
min in the incubator, media was removed by aspiration, (PBS, 2 x 2.0 mL) and replaced 
with 2.0 mL PBS. Each dish was then imaged at ten random fields by confocal 
microscopy. Confocal microscopy was performed on a LSM780 (Zeiss) u sing a c-
Apochromat 40x 1.2 W Corr M27 oil immersion objective. Cy3 fluorescence was excited 
using 488 nm laser (2%) and emission was measured with a 492-542 nm bandpass. 
Mitotracker Green FM fluorescence was excited with a 488 nm laser (2%) and emission 
as measured with a bandpass of 552-683 nm. All images were acquired using 512x512, 
0.14 µm diameter pixels, a 12.6 µs pixel dwell time, 12-bit gray levels and a 2.4 µm 
optical section. Each compound was tested in 3 dishes of cells. Pearson’s coefficients 
were calculated using the JACoP plugin8 for ImageJ21 1.46r software for each field from 
each dishes and are reported as the average of the 30 calculations. 
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 Spectra Relevant to Chapter Four 
 
Spectra IV-1: The 600 MHz 1H and 150 MHz 13C NMR spectra of 2.1 in CD3OD. 
  211 
 
Spectra IV-2: The 500 MHz HSQC NMR spectrum of 4.1 in CD3OD. 
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Spectra IV-3: The 500 MHz CIGAR HMBC NMR spectrum of 4.1 in CD3OD. 
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Spectra IV-4: The 600 MHz 1H and 150 MHz 13C NMR spectra of 4.2 in CDCl3. 
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Spectra IV-5: The 600 MHz COSY NMR spectrum of 4.2 in CDCl3. 
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Spectra IV-6: The 600 MHz HSQC NMR spectrum of 4.2 in CDCl3. 
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Spectra IV-7: The 600 MHz HMBC NMR spectrum of 4.2 in CDCl3. 
  217 
 
Spectra IV-8: The 600 MHz CIGAR HMBC NMR spectrum of 4.2 in CDCl3. 
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Spectra IV-9: The 600 MHz 1H and 150 MHz 13C NMR spectra of 4.24 in CD3OD. 
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Spectra IV-10: The 600 MHz COSY NMR spectrum of 4.24 in CD3OD. 
  220 
 
 
 
 
 
 
 
 
Spectra IV-11: The 600 MHz 1H NMR spectrum of 4.25 in CD3OD. 
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Spectra IV-12: The 600 MHz 1H and 150 MHz 13C NMR spectra of 4.26 in CD3OD. 
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Spectra IV-13: The 600 MHz 1H and 150 MHz 13C NMR spectra of 4.29 in CDCl3. 
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Spectra IV-14: The 600 MHz 1H NMR spectrum of 4.30 in CD3OD. 
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Spectra IV-15: The 600 MHz 1H NMR spectrum of 4.31 in CD3OD. 
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CHAPTER V  
 
 
Conclusions and Future Directions for Apoptolidin Biological Target Studies 
 
Ongoing Investigations of the Biological Target of Apoptolidin 
 The cancer cell line selective cytotoxicity of apoptolidin was attributed to 
inhibition of the F1FoATPase in cancer cell lines that rely heavily on mitochondrial 
respiration for ATP synthesis, but no rationale exists to describe selectivity for cancer 
cells over “normal” cells that also primarily utilize oxidative phosphorylation for ATP 
production. The nearly two orders of magnitude difference between the phenotypic EC50 
for cytotoxicity (~13 nM) and the concentration required for inhibition of this enzyme in 
solution (~1 µM) further casts doubt on the identification of F1FoATPase as the 
significant biological target of apoptolidin. Given the diverse mechanisms by which 
apoptotic and necrotic cell death can be initiated, it is possible that a different target is 
responsible for the observed cytotoxicity. In order to fully understand the activity of this 
natural product, we are currently working to measure the inhibition of the F1FoATPase 
and identify novel targets of apoptolidin.  
Measuring Inhibition of F1FoATPase 
 In order to complete the biological activity characterization of newly isolated 
apoptolidin congeners from mutasynthesis and apoptolidin analogues prepared through 
chemical synthesis, we are currently working on the measurement of F1FoATPase. 
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ATPase inhibition is easily measured through a pyruvate kinase (PK) coupled assay 
(Scheme V-1). 1 
 
 
Scheme V-1: The pyruvate kinase coupled ATPase assay 
 
 Previous measurements of F1FoATPase inhibition by apoptolidin have used yeast 
mitochondrial preparations or solubilized F1FoATPase derived from yeast. Structural 
differences between yeast and mammalian F1FoATPase have been cited as a possible 
explanation for the large difference between the concentrations required for cytotoxicity 
and that required for enzyme inhibition.2 To investigate this, we have attempted to isolate 
mitochondria from H292 cells using a method designed to isolate mitochondria from 
eukaryotic cells. Unfortunately, mitochondria isolated using this method were inactive in 
the ATPase assay. Currently, we are attempting to isolate active mitochondrial 
preparations from yeast to minimally allow for the characterization of apoptolidin 
derivatives in the same assay as used by the Stanford group. Future work in 
understanding the significance of F1FoATPase inhibition in apoptolidin cytotoxicity 
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should involve the isolation of active mitochondrial preparations or sub-mitochondrial 
particles from mammalian cells for the use in ATPase assays.  
Identifying Novel Targets of Apoptolidin  
 The ultimate goal of our investigations into the biological activity of apoptolidin 
is the identification of a novel biological target that can fully explain the potent and 
selective nature of the observed cytotoxicity of this compound. To that end, we have 
prepared affinity purification probes that allow access to multiple strategies for target 
identification.  
 
 
Scheme V-2: Preparation of biotinyl bicyclononyne conjugate\ 
 
 To prepare affinity probes of apoptolidin, we utilized the strategy developed for 
the preparation of fluorescent conjugates. Treatment of the N-hydroxysuccinimide ester 
of D-biotin 5.1 with bicyclononyne amine 4.22 affords the bicyclononyne biotin 
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conjugate 5.2 in modest yield. Furthermore, we have been able to successfully couple this 
compound to azido apoptolidins to provide biotinyl apoptolidin A 5.3 (Scheme V-3). 
Testing of this compound in our H292 cell viability (Figure V-1) showed an approximate 
10 fold loss in activity compared with apoptolidin A 2.1 or azido apoptolidin A 4.1. 
 
 
Figure V-1: Biotinyl apoptolidin A H292 cell viability assay 
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Scheme V-3: Preparation of biotinyl apoptolidin A 5.3 
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 With these compounds in hand, multiple strategies can be investigated to identify 
biological targets of apoptolidin.3 Whole cells or cell lysates could be treated with 5.3 
followed by affinity purification using streptavidin coated beads. Due to the reduced 
potency of 5.3 compared to apoptolidin A 2.1, a competitive target binding strategy could 
also be implemented in quantitative proteomics experiments to aid in the identification of 
bona fide biological targets. Alternatively, biotin BCN conjugate 5.2 could be used with 
azido apoptolidin 4.1 by either in vivo “click” reactions or used to extract protein targets 
from cell lysates by pre-conjugation onto streptavidin coated beads. Validation of 
candidate biological targets of apoptolidin identified in such studies through biochemical 
or genetic strategies will either confirm inhibition of the F1FoATPase as the mechanism 
of action or provide an alternative mechanism.  
 Overview of Apoptolidin Project Results  
 Utilizing a high yielding production fermentation protocol of Nocardiopsis sp. 
FU40, apoptolidin A based chemical probes have been designed and synthesized for use 
in experiments to gain insight on the mechanism of the potent, cell-line selective 
cytotoxicity of this natural product. Furthermore, utilizing a productive mutant producer 
resulting from selective genetic disruption,4 analogous probes of apoptolidin H have been 
prepared to shed light on the biological role of the C27 disaccharide moiety of 
apoptolidin A in cytotoxicity assays. Conditions required to observe the reported potent 
cytotoxicity in H292 human lung carcinoma cells were determined that indicate a cell 
density dependent shift in glucose metabolism resulting in sensitization to apoptolidin at 
confluence. Experiments aimed at determining the mechanism of cytotoxicity induced by 
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apoptolidin in H292 cells were unable to confirm an apoptotic mechanism as reported in 
non-human models.  
The prepared apoptolidin derivatives were tested in the H292 cell viability assay 
and determined to each retain similar biological activity to apoptolidin A or H despite 
significant and variable structural modifications. While initial experiments utilizing 
fluorescent apoptolidin probes to determine sub-cellular localization were inconclusive 
due to unanticipated results in a control experiment, multiple approaches to overcome 
this complication are currently being pursued. Current results indicate but do not confirm 
that the C27 disaccharide of apoptolidin A is important for target binding and not for 
cellular transport as previously hypothesized. Ongoing microscopy studies will either 
confirm or refute this initial interpretation. Finally, future target identification studies 
have been made possible by the synthesis of several tools to be used in protein affinity 
purification experiments. Experiments utilizing tools developed in these studies and 
building upon results from biological assays described herein may allow for the 
understanding of the mechanism of action of this highly selective cytotoxin and the 
advantageous application of this knowledge in new therapeutic strategies.  
 
Experimental Methods 
General procedure: All non-aqueous reactions were performed in flame-dried or oven 
dried round-bottomed flasks under an atmosphere of argon. Where necessary (so noted) 
solutions were deoxygenated by alternate freeze (liquid nitrogen)/evacuation/argon-
flush/thaw cycles (FPT, three iterations) or degassed by purging with argon for several 
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minutes. Stainless steel syringes or cannulae were used to transfer air- and moisture-
sensitive liquids. Reaction temperatures were controlled using a thermocouple 
thermometer and analog hotplate stirrer. Reactions were conducted at room temperature 
(rt, approximately 23 °C) unless otherwise noted. Flash column chromatography was 
conducted as described Still et. al. using silica gel 230-400 mesh.5 Where necessary, 
silica gel was neutralized by treatment of the silica gel prior to chromatography with the 
eluent containing 1% triethylamine. Analytical thin-layer chromatography (TLC) was 
performed on E. Merck silica gel 60 F254 plates and visualized using UV, ceric 
ammonium molybdate, potassium permanganate, and anisaldehyde stains. Yields were 
reported as isolated, spectroscopically pure compounds.  
Materials. Solvents were obtained from either a MBraun MB-SPS solvent system or 
freshly distilled (tetrahydrofuran was distilled from sodium-benzophenone; toluene was 
distilled from calcium hydride and used immediately; dimethyl sulfoxide was distilled 
from calcium hydride and stored over 4Å molecular sieves). Commercial reagents were 
used as received with the following exceptions.  
Instrumentation. Semi-preperative reverse phase HPLC was conducted on a Waters 
HPLC system using a Phenomenex Luna (5 µm C18(2) 100A Axia 250 x 10.00 mm) 
column or preperative reverse phase HPLC (Gilson) using a Phenomenex Luna column 
(100 Å, 50 x 21.20 mm, 5 µm C18) with UV/Vis detection. Infrared spectra were 
obtained as thin films on NaCl plates using a Thermo Electron IR100 series instrument 
and are reported in terms of frequency of absorption (cm-1). 1H NMR spectra were 
recorded on Bruker 300, 400, 500, or 600 MHz spectrometers and are reported relative to 
deuterated solvent signals. Data for 1H NMR spectra are reported as follows: chemical 
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shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = 
multiplet, br = broad, app = apparent), coupling constants (Hz), and integration. 13C 
NMR spectra were recorded on Bruker 75, 100, 125, or 150 MHz spectrometers and are 
reported relative to deuterated solvent signals. LC/MS was conducted and recorded on an 
Agilent Technologies 6130 Quadrupole instrument. High-resolution mass spectra were 
obtained from the Vanderbilt University Center for Neuroscience Drug Discovery 
(VCNDD) on a Micromass Q-Tof API-US mass spectrometer. 
Bicyclononyne Biotin 
Conjugate 5.2 To a solution of 
amine 4.22 (34.0 mg, 0.105 
mmol) in DMF (1.0 mL) was added Biotin NHS 5.1 (71 mg, 0.210 mmol). After 16 hours, 
the DMF was removed on high vacuum. Flash column chromatography (30 % 80:18:26 in 
DMC) yielded 35.0 mg (61%) of bicyclononyne biotin conjugate 5.2 as a pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 6.66 (s (br), 2H), 5.77 (s(br), 1H), 5.40 (s (br), 1H), 4.48 (t, 
J = 6.0 Hz, 1H), 4.29 (t, J = 5.9 Hz, 1H), 4.13 (d, J = 7.8 Hz, 2H) 3.59 (s (br), 4H), 3.55 
(m, 4H), 3.43 (m, 3H), 3.35 (m, 2H), 3.12 (dd, J = 6.9, 11.6 Hz, 1H), 2.88 (dd, J = 4.7, 
12.7 Hz, 1H), 2.72 (d, J = 12.8 Hz, 1H), 2.11-2.34 (m, 6H), 1.48-1.76 (m, 6H), 1.28-1.48 
(m, 4H), 1.23 (s, 1H), 0.92 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 173.3, 164.1, 156.8, 
98.7, 70.0, 62.7, 61.7, 60.1, 55.6, 40.7, 40.1, 39.0, 35.9, 33.2, 29.6, 29.0, 28.2, 28.0, 25.5, 
22.8, 21.3, 20.0, 17.7; HRMS (ESI-TOF MS) m/z 551.2903 (M+H)+ calculated for 
C27H43N4O6, measured 551.2900. 
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Biotin Apoptolidin 
A Conjugate 5.3 
To a solution of 
Biotin BCN 
conjugate 5.2 (2.6 
mg, 0.0033 mmol) 
in methanol (0.5 mL) was added azido apoptolidin A 4.1 (2.05 mg, 0.0016 mmol) as a 
solution in 0.5 mL methanol. The resulting solution was stirred at 37 °C for 14 hours, 
removed from the bath and concentrated. The resulting residue was dissolved in methanol 
(0.5 mL) and purified on semipreparative reverse phase HPLC (30 minute gradient from 
35% strong to 100% strong buffer in weak buffer where strong is 95% MeCN in H2O + 
10 mM NH4OAc and weak buffer is 5% MeCN in H2O + 10 mM NH4OAc). The conical 
reaction flask was rinsed with an additional 0.5 mL of methanol and this solution was 
purified as well. Fractions containing the desired product (r.t. 10.5 min) were combined 
and concentrated to remove acetonitrile only (T<31°C). The resulting aqueous solution 
was frozen at -80°C. Water was removed by lyophilization to yield 2.63 mg (29%) of 
biotin apoptolidin A conjugate 5.3 as a white solid. (600 MHz, CD3OD) δ 3.73 (s, 1H), 
6.18 (s, 1H), 6.13 (d, J = 15.8 Hz, 1H), 5.64 (dd, J = 7.9, 7.9 Hz, 1H) 5.29 (d, J = 11.3 Hz, 
1H), 5.20 (d, J = 10.1 Hz, 1H), 5.00 (m, 1H), 4.94 (m, 3H), 4.83 (dd, J = 1.8, 9.9 Hz, 1H), 
4.54 (m, 2H), 4.49 (dd, J = 4.9, 7.8 Hz, 1H), 4.31 (m, 5H), 4.17 (m, 3H), 3.95 (m, 1H), 
3.90 (m, 3H), 3.81 (dd, J = 8.8, 8.8 Hz, 1H), 3.78 (dd, J = 6.3, 9.4 Hz, 1H), 3.71 (dd, J = 
4.6, 11.0 Hz, 1H), 3.67 (dd, J = 6.3, 9.7 Hz, 1H), 3.65-3.86 (m, 3H), 3.62 (s(br), 4H), 
3.59 (s, 3H), 3.58 (m, 1H), 3.52-3.57 (m, 5H), 3.42 (s, 3H), 3.41 (m, 3H), 3.37 (m, 3H), 
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3.36 (s, 3H), 3.32 (m, 1H), 3.27 (s, 3H), 3.21 (dd, J = 6.0, 9.2 Hz, 1H), 3.17 (m, 2H), 3.06 
(m, 1H), 2.97 (dd, J = 9.0, 9.0 Hz, 1H), 2.92 (dd, J = 5.0, 12.8 Hz, 1H), 2.81 (dd, J = 9.3, 
9.3 Hz, 1H), 2.71 (m, 2H), 2.64 (m, 1H), 2.43 (m, 4H), 2.21 (m, 6H), 2.18 (s, 3H), 2.14 
(m, 1H), 2.10 (s, 3H), 1.97-2.08 (m, 4H), 1.92 (m, 1H), 1.89 (s, 3H), 1.50-1.82 (m, 18H), 
1.32 (s, 3H), 1.28-1.48 (m, 9 H), 1.25-128 (m, 13H), 1.22 (d, J = 6.3 Hz, 3H), 1.12 (d, J = 
6.5 Hz, 3H), 1,02 (d, J = 6.7 Hz, 3H), 0.90 (m, 2H), 0.89 (d, J = 6.9 Hz, 3H); HRMS 
(ESI-TOF MS) m/z 1804.9937 (M+H)+ calculated for C90H146N7O28S, measured 
1804.9946. 
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Spectral Data Relevant to Chapter 5 
 
 
Spectra V-1: The 400 MHz 1H and 100 MHz 13C NMR spectra of 5.2 in CDCl3. 
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Spectra V-2: The 600 MHz 1H NMR spectrum of 5.3 in CD3OD 
